2. Anti-infection
  3. HCV RSV Orthopoxvirus Antibiotic
  4. Ribavirin

Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV. Ribavirin also has anti-orthopoxvirus and anti-variola activities.

For research use only. We do not sell to patients.

CAS No. : 36791-04-5

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
100 mg In-stock
200 mg In-stock
500 mg In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 56 publication(s) in Google Scholar

Other Forms of Ribavirin:

Ribavirin Related Antibodies

Top Publications Citing Use of Products

56 Publications Citing Use of MCE Ribavirin

Cell Proliferation/Viability Assay
IF
WB
IHC
RT-PCR

    Ribavirin purchased from MedChemExpress. Usage Cited in: J Pharm Anal. 2025 Apr 12.

    Viability of A549 cells following treatment with 10 μM Ribavirin or the control for 1–5 days.

    Ribavirin purchased from MedChemExpress. Usage Cited in: J Pharm Anal. 2025 Apr 12.

    Ribavirin (10 μg/mL; 0-24 h). Immunoblotting of phosphorylated AMPK (p-AMPK) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in the lysates of mouse Lewis lung carcinoma (LLC) cells in the presence of Ribavirin.

    Ribavirin purchased from MedChemExpress. Usage Cited in: J Pharm Anal. 2025 Apr 12.

    Ribavirin (10 μM; 0-24 h). Quantitative real-time polymerase chain reaction (qRT-PCR) measurement of 4ebp1 transcripts in LLC cells in the presence of phosphate buffered saline (PBS) or the indicated concentrations of Ribavirin.

    Ribavirin purchased from MedChemExpress. Usage Cited in: mBio. 2023 Oct 31;14(5):e0211023.  [Abstract]

    Ribavirin (40 mg/kg; po). The RSV F protein level in the lung tissues of each group were determined using immunofluorescence assay.

    Ribavirin purchased from MedChemExpress. Usage Cited in: mBio. 2023 Oct 31;14(5):e0211023.  [Abstract]

    Ribavirin (40 mg/kg; po). Histopathological analysis of lung tissues in each group was performed using hematoxylin-eosin staining. Black arrow indicates the pulmonary infiltration of inflammatory cells.

    View All Antibiotic Isoform Specific Products:

    View All Isoforms
    Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV. Ribavirin also has anti-orthopoxvirus and anti-variola activities.

    Cellular Effect
    Cell Line Type Value Description References
    A-431 IC50
    3.18 μM
    Compound: RBV
    Antiproliferative activity against human A-431 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A-431 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 31883488]
    A549 CC50
    129.65 μM
    Compound: Ribavirin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 32882419]
    A549 CC50
    307 μM
    Compound: Ribavirin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 30612844]
    A549 CC50
    7611.1 μM
    Compound: Ribavirin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 34425312]
    A549 CC50
    > 50 μM
    Compound: Ribavirin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    		[PMID: 34273661]
    A549 CC50
    > 50 μM
    Compound: Ribavirin
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    		[PMID: 35306290]
    ACHN IC50
    > 100 μM
    Compound: Ribavirin
    Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma
    Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma
    		10.1016/0960-894X(96)00216-8
    B16-F10 IC50
    3.5 μM
    Compound: RBV
    Antiproliferative activity against mouse B16-F10 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against mouse B16-F10 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 31883488]
    BHK-21 CC50
    5.46 μM
    Compound: RBV
    Cytotoxicity against hamster BHK-21 cells incubated for 4 days by MTS assay
    Cytotoxicity against hamster BHK-21 cells incubated for 4 days by MTS assay
    		[PMID: 36764470]
    BHK-21 CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay
    Cytotoxicity against hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay
    		[PMID: 19482481]
    BHK-21 CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against mock-infected BHK21 cells after 48 to 96 hrs by MTT assay
    Cytotoxicity against mock-infected BHK21 cells after 48 to 96 hrs by MTT assay
    		[PMID: 25082514]
    BHK-21 EC50
    1.1 μM
    Compound: Ribavirin
    Inhibition of West Nile virus VLP replicon in BHK21 cell line
    Inhibition of West Nile virus VLP replicon in BHK21 cell line
    		[PMID: 16539402]
    BHK-21 EC50
    18 μM
    Compound: Ribavirin
    Inhibition of West Nile viral Rluc-Neo-Rep in BHK21 cell line
    Inhibition of West Nile viral Rluc-Neo-Rep in BHK21 cell line
    		[PMID: 16539402]
    BHK-21 EC50
    > 100 μM
    Compound: Ribavirin
    Antiviral activity against Reovirus-1 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay
    Antiviral activity against Reovirus-1 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay
    		[PMID: 19482481]
    BHK-21 EC50
    > 100 μM
    Compound: Ribavirin
    Antiviral activity against Yellow fever virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay
    Antiviral activity against Yellow fever virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay
    		[PMID: 19482481]
    BHK-21 EC50
    > 100 μM
    Compound: Ribavirin
    Antiviral activity against Reovirus type-1 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay
    Antiviral activity against Reovirus type-1 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay
    		[PMID: 25082514]
    BHK-21 EC50
    > 100 μM
    Compound: Ribavirin
    Antiviral activity against Yellow fever virus infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay
    Antiviral activity against Yellow fever virus infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay
    		[PMID: 25082514]
    BHK-21 EC50
    > 100 μM
    Compound: Ribavirin
    Antiviral activity against Reo-1 virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay
    Antiviral activity against Reo-1 virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay
    		[PMID: 26443549]
    BHK-21 EC50
    > 100 μM
    Compound: Ribavirin
    Antiviral activity against YFV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay
    Antiviral activity against YFV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay
    		[PMID: 26443549]
    BJ CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against human BJ cells assessed as reduction in cell viability after 24 hrs by CellTiter-Glo luminescent assay
    Cytotoxicity against human BJ cells assessed as reduction in cell viability after 24 hrs by CellTiter-Glo luminescent assay
    		[PMID: 28350454]
    C6 IC50
    13.51 μM
    Compound: RBV
    Antiproliferative activity against rat C6 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against rat C6 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 31883488]
    C8166 IC50
    > 100 μM
    Compound: Ribavirin
    Compound was tested for its effect on the proliferation of C8166 cells expressing the TAT gene of HTLV-1.
    Compound was tested for its effect on the proliferation of C8166 cells expressing the TAT gene of HTLV-1.
    		10.1016/0960-894X(96)00216-8
    CCRF-CEM EC50
    > 50 μM
    Compound: Ribavirin
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis
    		[PMID: 22464686]
    CCRF-CEM EC50
    > 50 μM
    Compound: Ribavirin
    Antiviral activity against Human immunodeficiency virus 2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis
    Antiviral activity against Human immunodeficiency virus 2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis
    		[PMID: 22464686]
    CCRF-CEM EC50
    > 50 μM
    Compound: Ribavirin
    Antiviral activity against HIV-1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis
    Antiviral activity against HIV-1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis
    		[PMID: 24312722]
    CCRF-CEM EC50
    > 50 μM
    Compound: Ribavirin
    Antiviral activity against HIV-2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis
    Antiviral activity against HIV-2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis
    		[PMID: 24312722]
    CCRF-CEM IC50
    1 μM
    Compound: Ribavirin
    Inhibition of IMPDH in human CEM cells assessed as formation of [2,8-3H]hypoxanthine from [2,8-3H]IMP after 20 to 60 mins
    Inhibition of IMPDH in human CEM cells assessed as formation of [2,8-3H]hypoxanthine from [2,8-3H]IMP after 20 to 60 mins
    		[PMID: 22555152]
    CCRF-CEM IC50
    19 μM
    Compound: Ribavirin
    Compound was tested for its effect on the proliferation of CCRF-CEM human lymphoblastic T-leukemia cell line
    Compound was tested for its effect on the proliferation of CCRF-CEM human lymphoblastic T-leukemia cell line
    		10.1016/0960-894X(96)00216-8
    CCRF-CEM IC50
    19 μg/mL
    Compound: ribavirin
    Tested for inhibitory effect on RNA virus cell growth in CEM cell line
    Tested for inhibitory effect on RNA virus cell growth in CEM cell line
    		[PMID: 8246242]
    CCRF-CEM IC50
    63 μM
    Compound: Ribavirin
    Cytostatic activity against human CEM/0 after 72 hrs by cell counting
    Cytostatic activity against human CEM/0 after 72 hrs by cell counting
    		[PMID: 22555152]
    CCRF-SB IC50
    > 100 μM
    Compound: Ribavirin
    Compound was tested for its effect on the proliferation of CCRF-SB human lymphoblastic B-leukemia cell line.
    Compound was tested for its effect on the proliferation of CCRF-SB human lymphoblastic B-leukemia cell line.
    		10.1016/0960-894X(96)00216-8
    CHO IC50
    622.5 μM
    Compound: ribavirin
    Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
    Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
    		[PMID: 23812503]
    CHO-K1 IC50
    50 μM
    Compound: Ribavirin
    Compound was tested for its effect on the proliferation of CHO-K1 hamster ovarian cancer cell line.
    Compound was tested for its effect on the proliferation of CHO-K1 hamster ovarian cancer cell line.
    		10.1016/0960-894X(96)00216-8
    Caco-2 IC50
    34.5 μM
    Compound: RBV
    Antiproliferative activity against human CaCo-2 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human CaCo-2 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 31883488]
    Calu-3 CC50
    160 μM
    Compound: Ribavirin
    Cytotoxicity against human Calu-3 cells assessed as cell growth inhibition incubated for 4 hrs by XTT assay
    Cytotoxicity against human Calu-3 cells assessed as cell growth inhibition incubated for 4 hrs by XTT assay
    		[PMID: 36965227]
    DU-145 IC50
    > 100 μM
    Compound: RBV
    Antiproliferative activity against human DU-145 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human DU-145 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 31883488]
    E6SM CC50
    > 400 μg/mL
    Compound: ribavirin
    Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of E6SM cells
    Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of E6SM cells
    		[PMID: 8709116]
    E6SM EC50
    0.005 μM
    Compound: Ribavirin
    Effective concentration required to inhibit Herpes simplex virus-1(HSV-1) / thymine kinase deficient (TK-)B2006 / VMW1837 induced cytopathicity by 50% in E6SM cell lines
    Effective concentration required to inhibit Herpes simplex virus-1(HSV-1) / thymine kinase deficient (TK-)B2006 / VMW1837 induced cytopathicity by 50% in E6SM cell lines
    		[PMID: 11495586]
    E6SM EC50
    128 μM
    Compound: d
    concentration required to inhibit HSV-1/TK (B2006) or VMW1837-induced cytopathicity by 50% in E6SM cells
    concentration required to inhibit HSV-1/TK (B2006) or VMW1837-induced cytopathicity by 50% in E6SM cells
    		[PMID: 9748360]
    E6SM EC50
    150 μg/mL
    Compound: ribavirin
    Antiviral activity against HSV2 G in E6SM cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against HSV2 G in E6SM cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17518459]
    E6SM EC50
    192 μM
    Compound: d
    concentration required to inhibit VSV-induced cytopathicity by 50% in E6SM cells
    concentration required to inhibit VSV-induced cytopathicity by 50% in E6SM cells
    		[PMID: 9748360]
    E6SM EC50
    192 μM
    Compound: d
    concentration required to inhibit vaccinia virus-induced cytopathicity by 50% in E6SM cells
    concentration required to inhibit vaccinia virus-induced cytopathicity by 50% in E6SM cells
    		[PMID: 9748360]
    E6SM EC50
    20 μg/mL
    Compound: ribavirin
    Antiviral activity against Vaccinia virus in E6SM cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Vaccinia virus in E6SM cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17518459]
    E6SM EC50
    20 μg/mL
    Compound: ribavirin
    Antiviral activity against thymidine kinase-deficient HSV1 B2006 in E6SM cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against thymidine kinase-deficient HSV1 B2006 in E6SM cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17518459]
    E6SM EC50
    240 μg/mL
    Compound: Ribavirin
    Inhibitory activity against HSV-1 (McIntyre) replication in E6SM cell cultures of human embryonic skin-muscle
    Inhibitory activity against HSV-1 (McIntyre) replication in E6SM cell cultures of human embryonic skin-muscle
    		[PMID: 12459010]
    E6SM EC50
    240 μg/mL
    Compound: Ribavirin
    Inhibitory activity against HSV-2 (196) replication in E6SM cell cultures of human embryonic skin-muscle
    Inhibitory activity against HSV-2 (196) replication in E6SM cell cultures of human embryonic skin-muscle
    		[PMID: 12459010]
    E6SM EC50
    240 μg/mL
    Compound: Ribavirin
    Inhibitory activity against HSV-2 (Lyons) replication in E6SM cell cultures of human embryonic skin-muscle
    Inhibitory activity against HSV-2 (Lyons) replication in E6SM cell cultures of human embryonic skin-muscle
    		[PMID: 12459010]
    E6SM EC50
    240 μg/mL
    Compound: Ribavirin
    Inhibitory activity against TK-deficient HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle
    Inhibitory activity against TK-deficient HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle
    		[PMID: 12459010]
    E6SM EC50
    240 μg/mL
    Compound: Ribavirin
    Inhibitory activity against vaccinia virus (VV) replication in E6SM cell cultures of human embryonic skin-muscle
    Inhibitory activity against vaccinia virus (VV) replication in E6SM cell cultures of human embryonic skin-muscle
    		[PMID: 12459010]
    E6SM EC50
    240 μg/mL
    Compound: ribavirin
    Antiviral activity against VSV in E6SM cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against VSV in E6SM cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 17298047]
    E6SM EC50
    320 μM
    Compound: Ribavirin
    Effective concentration required to inhibit Herpes simplex virus-1 (HSV-1) induced cytopathicity by 50% in E6SM cell lines
    Effective concentration required to inhibit Herpes simplex virus-1 (HSV-1) induced cytopathicity by 50% in E6SM cell lines
    		[PMID: 11495586]
    E6SM EC50
    320 μM
    Compound: Ribavirin
    Effective concentration required to inhibit Herpes simplex virus-2 (HSV-2) induced cytopathicity by 50% in E6SM cell lines
    Effective concentration required to inhibit Herpes simplex virus-2 (HSV-2) induced cytopathicity by 50% in E6SM cell lines
    		[PMID: 11495586]
    E6SM EC50
    40 μM
    Compound: Ribavirin
    Effective concentration required to inhibit vesicular stomatitis virus(VSV) -induced cytopathicity by 50% in E6SM cell lines
    Effective concentration required to inhibit vesicular stomatitis virus(VSV) -induced cytopathicity by 50% in E6SM cell lines
    		[PMID: 11495586]
    E6SM EC50
    48 μg/mL
    Compound: Ribavirin
    Inhibitory activity against HSV-1 (F) replication in E6SM cell cultures of human embryonic skin-muscle
    Inhibitory activity against HSV-1 (F) replication in E6SM cell cultures of human embryonic skin-muscle
    		[PMID: 12459010]
    E6SM EC50
    48 μg/mL
    Compound: Ribavirin
    Inhibitory activity against HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle
    Inhibitory activity against HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle
    		[PMID: 12459010]
    E6SM EC50
    48 μg/mL
    Compound: Ribavirin
    Antiviral activity against Vaccina virus infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Vaccina virus infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity
    		[PMID: 20377249]
    E6SM EC50
    65 μM
    Compound: Ribavirin
    Effective concentration required to inhibit Vaccinia virus-induced cytopathicity by 50% in E6SM cell lines
    Effective concentration required to inhibit Vaccinia virus-induced cytopathicity by 50% in E6SM cell lines
    		[PMID: 11495586]
    E6SM EC50
    70 μg/mL
    Compound: ribavirin
    Antiviral activity against HSV1 KOS in E6SM cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against HSV1 KOS in E6SM cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17518459]
    E6SM EC50
    70 μg/mL
    Compound: ribavirin
    Antiviral activity against thymidine kinase deficient HSV1 VMW1837 in E6SM cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against thymidine kinase deficient HSV1 VMW1837 in E6SM cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17518459]
    E6SM EC50
    80 μg/mL
    Compound: Ribavirin
    Inhibitory activity against HSV-2 (G) replication in E6SM cell cultures of human embryonic skin-muscle
    Inhibitory activity against HSV-2 (G) replication in E6SM cell cultures of human embryonic skin-muscle
    		[PMID: 12459010]
    E6SM EC50
    960 μM
    Compound: d
    concentration required to inhibit HSV-1(KOS)-induced cytopathicity by 50% in E6SM cells
    concentration required to inhibit HSV-1(KOS)-induced cytopathicity by 50% in E6SM cells
    		[PMID: 9748360]
    E6SM EC50
    960 μM
    Compound: d
    concentration required to inhibit HSV-2(G)-induced cytopathicity by 50% in E6SM cells
    concentration required to inhibit HSV-2(G)-induced cytopathicity by 50% in E6SM cells
    		[PMID: 9748360]
    E6SM EC50
    > 400 μg/mL
    Compound: Ribavirin
    Inhibitory activity against vesicular stomatitis virus (VSV) replication in E6SM cell cultures of human embryonic skin-muscle
    Inhibitory activity against vesicular stomatitis virus (VSV) replication in E6SM cell cultures of human embryonic skin-muscle
    		[PMID: 12459010]
    E6SM EC50
    > 400 μg/mL
    Compound: Ribavirin
    Antiviral activity against HSV1 KOS infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against HSV1 KOS infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity
    		[PMID: 20377249]
    E6SM EC50
    > 400 μg/mL
    Compound: Ribavirin
    Antiviral activity against HSV2 G infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against HSV2 G infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity
    		[PMID: 20377249]
    E6SM EC50
    > 400 μg/mL
    Compound: Ribavirin
    Antiviral activity against TK-deficient acyclovir-resistant HSV1 KOS infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against TK-deficient acyclovir-resistant HSV1 KOS infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity
    		[PMID: 20377249]
    E6SM EC50
    > 400 μg/mL
    Compound: Ribavirin
    Antiviral activity against VSV infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against VSV infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity
    		[PMID: 20377249]
    ESM IC50
    110 μg/mL
    Compound: ribavirin
    Tested for inhibitory effect on DNA virus TK-HSV-1(VMW 1837) in ESM cell line
    Tested for inhibitory effect on DNA virus TK-HSV-1(VMW 1837) in ESM cell line
    		[PMID: 8246242]
    ESM IC50
    45 μg/mL
    Compound: ribavirin
    Tested for inhibitory effect on DNA virus VV in ESM cell line
    Tested for inhibitory effect on DNA virus VV in ESM cell line
    		[PMID: 8246242]
    ESM IC50
    > 135 μg/mL
    Compound: ribavirin
    Tested for inhibitory effect on DNA virus TK-HSV-1 (B2006) in ESM cell line
    Tested for inhibitory effect on DNA virus TK-HSV-1 (B2006) in ESM cell line
    		[PMID: 8246242]
    ESM IC50
    > 300 μg/mL
    Compound: ribavirin
    Tested for inhibitory effect on DNA virus HSV-2 (G) in ESM cell line
    Tested for inhibitory effect on DNA virus HSV-2 (G) in ESM cell line
    		[PMID: 8246242]
    ESM IC50
    >= 350 μg/mL
    Compound: ribavirin
    Tested for inhibitory effect on DNA virus HSV-1(KOS) in ESM cell line
    Tested for inhibitory effect on DNA virus HSV-1(KOS) in ESM cell line
    		[PMID: 8246242]
    ESM IC50
    >= 400 μg/mL
    Compound: ribavirin
    Tested for inhibitory effect on RNA virus cell morphology in ESM cell line
    Tested for inhibitory effect on RNA virus cell morphology in ESM cell line
    		[PMID: 8246242]
    Epithelial cell EC50
    > 1024.6 μM
    Compound: Ribavirin
    Antiviral activity against influenza B (Hong kong/5/72) in human epithelial cells
    Antiviral activity against influenza B (Hong kong/5/72) in human epithelial cells
    		[PMID: 12729645]
    FM3A IC50
    3.9 μg/mL
    Compound: ribavirin
    Tested for inhibitory effect on RNA virus cell growth in FM3A cell line
    Tested for inhibitory effect on RNA virus cell growth in FM3A cell line
    		[PMID: 8246242]
    Fibroblast CC50
    > 200 μM
    Compound: Rib
    Cytotoxicity against chicken embryo fibroblasts assessed as reduction in cell viability after 48 hrs by CCK-8 assay
    Cytotoxicity against chicken embryo fibroblasts assessed as reduction in cell viability after 48 hrs by CCK-8 assay
    		[PMID: 30365885]
    Fibroblast CC50
    > 200 μM
    Compound: Rib
    Cytotoxicity against chicken embryo fibroblast assessed as reduction in cell viability after 48 hrs by CCK8 assay
    Cytotoxicity against chicken embryo fibroblast assessed as reduction in cell viability after 48 hrs by CCK8 assay
    		[PMID: 32092589]
    HCT-116 EC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against human HCT-116 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells incubated for 48 hrs by MTT assay
    		[PMID: 36518704]
    HCT-116 EC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against human HCT-116 cells overexpressing human BCRP incubated for 48 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells overexpressing human BCRP incubated for 48 hrs by MTT assay
    		[PMID: 36518704]
    HCT-116 EC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against human HCT-116 cells overexpressing human MDR1 incubated for 48 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells overexpressing human MDR1 incubated for 48 hrs by MTT assay
    		[PMID: 36518704]
    HEK-293T CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 24 hrs by CellTiter-Glo luminescent assay
    Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 24 hrs by CellTiter-Glo luminescent assay
    		[PMID: 28350454]
    HEK-293T CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 48 hrs by CCK8 assay
    Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 48 hrs by CCK8 assay
    		[PMID: 31734025]
    HEK-293T CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against human HEK293T cells assessed as reduction in cell viability after 48 hrs by CCK8 assay
    Cytotoxicity against human HEK293T cells assessed as reduction in cell viability after 48 hrs by CCK8 assay
    		[PMID: 32805550]
    HEK-293T CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against human HEK293T cells assessed as cell viability after 48 hrs by CCK-8 assay
    Cytotoxicity against human HEK293T cells assessed as cell viability after 48 hrs by CCK-8 assay
    		[PMID: 35304224]
    HEK-293T CC50
    > 200 μM
    Compound: ribavirin
    Cytotoxicity against HEK293T cells assessed as cell viability measured at 24 hrs by MTS assay
    Cytotoxicity against HEK293T cells assessed as cell viability measured at 24 hrs by MTS assay
    		[PMID: 26288686]
    HEK-293T CC50
    > 205 μM
    Compound: Ribavirin
    Cytotoxicity against human 293T cells expressing Gluc assessed as inhibition of cell proliferation after 24 hrs by CCK8 assay
    Cytotoxicity against human 293T cells expressing Gluc assessed as inhibition of cell proliferation after 24 hrs by CCK8 assay
    		[PMID: 28314599]
    HEK-293T CC50
    > 250 μM
    Compound: RBV
    Cytotoxicity against human HEK293T cells after 24 hrs by MTT assay
    Cytotoxicity against human HEK293T cells after 24 hrs by MTT assay
    		[PMID: 24785979]
    HEK-293T CC50
    > 250 μM
    Compound: RBV
    Cytotoxicity against HEK293T cells assessed as decrease in cell viability after 24 hrs by MTT assay
    Cytotoxicity against HEK293T cells assessed as decrease in cell viability after 24 hrs by MTT assay
    		[PMID: 30142611]
    HEK-293T CC50
    > 250 μM
    Compound: RBV, Ribavirin
    Cytotoxicity against human HEK293T cells assessed as decrease in cell viability by MTT assay
    Cytotoxicity against human HEK293T cells assessed as decrease in cell viability by MTT assay
    		[PMID: 25856229]
    HEK-293T CC50
    > 250 μM
    Compound: RBV; Ribavirin
    Cytotoxicity against HEK293T cells assessed as decrease in cell viability after 24 hrs by MTT assay
    Cytotoxicity against HEK293T cells assessed as decrease in cell viability after 24 hrs by MTT assay
    		[PMID: 26924568]
    HEK-293T CC50
    > 50 μM
    Compound: RBV
    Cytotoxicity against HEK293T cells incubated for 48 hrs by MTT assay
    Cytotoxicity against HEK293T cells incubated for 48 hrs by MTT assay
    		[PMID: 39153334]
    HEK-293T EC50
    13.1 μM
    Compound: ribavirin
    Antiviral activity against Chikungunya virus infected in HEK293T cells assessed as reduction of infectivity measured at 24 hrs postinfection by gaussia luciferase reporter gene assay
    Antiviral activity against Chikungunya virus infected in HEK293T cells assessed as reduction of infectivity measured at 24 hrs postinfection by gaussia luciferase reporter gene assay
    		[PMID: 26540338]
    HEK-293T EC50
    18 μM
    Compound: RBV, Ribavirin
    Inhibition of Influenza A virus (A/PR/8/34) RNA-dependent-RNA polymerase transfected in HEK293T cells after 24 hrs by renilla luciferase activity/minireplicon assay
    Inhibition of Influenza A virus (A/PR/8/34) RNA-dependent-RNA polymerase transfected in HEK293T cells after 24 hrs by renilla luciferase activity/minireplicon assay
    		[PMID: 25856229]
    HEK-293T EC50
    18.4 μM
    Compound: ribavirin
    Antiviral activity against O'nyong-nyong virus infected in HEK293T cells assessed as inhibition of infectivity measured at 24 hrs postinfection by FITC/DAPI staining based array scan VTI HCS reader analysis
    Antiviral activity against O'nyong-nyong virus infected in HEK293T cells assessed as inhibition of infectivity measured at 24 hrs postinfection by FITC/DAPI staining based array scan VTI HCS reader analysis
    		[PMID: 26540338]
    HEK-293T EC50
    20 μM
    Compound: ribavirin
    Antiviral activity against wild type Chikungunya virus IMT infected in HEK293T cells assessed as inhibition of infectivity measured at 24 hrs postinfection by FITC/DAPI staining based array scan VTI HCS reader analysis
    Antiviral activity against wild type Chikungunya virus IMT infected in HEK293T cells assessed as inhibition of infectivity measured at 24 hrs postinfection by FITC/DAPI staining based array scan VTI HCS reader analysis
    		[PMID: 26540338]
    HEK-293T EC50
    23.8 μM
    Compound: RBV; Ribavirin
    Inhibition of Influenza A virus RdRp transfected in HEK293T cells at 24 hrs by dual luciferase reporter gene-based minireplicon assay
    Inhibition of Influenza A virus RdRp transfected in HEK293T cells at 24 hrs by dual luciferase reporter gene-based minireplicon assay
    		[PMID: 26924568]
    HEK-293T EC50
    24.9 μM
    Compound: RBV
    Inhibition of Influenza A virus RdRP infected in human HEK293T cells after 24 hrs by dual luciferase reporter gene assay
    Inhibition of Influenza A virus RdRP infected in human HEK293T cells after 24 hrs by dual luciferase reporter gene assay
    		[PMID: 24785979]
    HEK-293T EC50
    5.12 μM
    Compound: ribavirin
    Antiviral activity against wild type Sindbis virus infected in HEK293T cells assessed as inhibition of infectivity measured at 24 hrs postinfection by FITC/DAPI staining based array scan VTI HCS reader analysis
    Antiviral activity against wild type Sindbis virus infected in HEK293T cells assessed as inhibition of infectivity measured at 24 hrs postinfection by FITC/DAPI staining based array scan VTI HCS reader analysis
    		[PMID: 26540338]
    HEK-293T EC50
    8.4 μM
    Compound: ribavirin
    Antiviral activity against Influenza A virus (A/PR/8/1934(H1N1)) infected in HEK293T cells assessed as reduction in viral RNP reconstitution measured at 24 hrs by luciferase reporter gene assay
    Antiviral activity against Influenza A virus (A/PR/8/1934(H1N1)) infected in HEK293T cells assessed as reduction in viral RNP reconstitution measured at 24 hrs by luciferase reporter gene assay
    		[PMID: 26288686]
    HEK-293T IC50
    15.36 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in human 293T cells pretreated for 2 hrs followed by viral infection and measured after 24 hrs by Gaussia luciferase reporter gene assay
    Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in human 293T cells pretreated for 2 hrs followed by viral infection and measured after 24 hrs by Gaussia luciferase reporter gene assay
    		[PMID: 32273213]
    HEK-293T IC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against human HEK-293T cells assessed as reduction in cell viability after 48 hrs by CCK-8 assay
    Cytotoxicity against human HEK-293T cells assessed as reduction in cell viability after 48 hrs by CCK-8 assay
    		[PMID: 33571829]
    HEK293 CC50
    > 250 μM
    Compound: RBV
    Cytotoxicity against HEK293 cells assessed as cell viability after 24 hrs by MTT assay
    Cytotoxicity against HEK293 cells assessed as cell viability after 24 hrs by MTT assay
    		[PMID: 24313730]
    HEK293 EC50
    15 μM
    Compound: RBV
    Inhibition of influenza A virus RNA-dependent RNA polymerase expressed in HEK293 cells after 24 hrs by dual luciferase reporter gene assay
    Inhibition of influenza A virus RNA-dependent RNA polymerase expressed in HEK293 cells after 24 hrs by dual luciferase reporter gene assay
    		[PMID: 24313730]
    HEK293 EC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against human HEK293 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human HEK293 cells incubated for 48 hrs by MTT assay
    		[PMID: 36518704]
    HEL CC50
    > 250 μM
    Compound: Ribavirin
    Cytotoxicity against Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method
    Cytotoxicity against Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method
    		[PMID: 20034711]
    HEL CC50
    > 250 μM
    Compound: Ribavirin
    Cytotoxicity against Herpes simplex virus 2 G infected HEL cells by trypan blue exclusion method
    Cytotoxicity against Herpes simplex virus 2 G infected HEL cells by trypan blue exclusion method
    		[PMID: 20034711]
    HEL CC50
    > 250 μM
    Compound: Ribavirin
    Cytotoxicity against VSV infected HEL cells by trypan blue exclusion method
    Cytotoxicity against VSV infected HEL cells by trypan blue exclusion method
    		[PMID: 20034711]
    HEL CC50
    > 250 μM
    Compound: Ribavirin
    Cytotoxicity against Vaccinia virus infected HEL cells by trypan blue exclusion method
    Cytotoxicity against Vaccinia virus infected HEL cells by trypan blue exclusion method
    		[PMID: 20034711]
    HEL CC50
    > 250 μM
    Compound: Ribavirin
    Cytotoxicity against acyclovir-sensitive Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method
    Cytotoxicity against acyclovir-sensitive Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method
    		[PMID: 20034711]
    HEL CC50
    > 250 μM
    Compound: Ribavirin
    Cytotoxicity against HEL cells after 3 days by coulter counter analysis
    Cytotoxicity against HEL cells after 3 days by coulter counter analysis
    		[PMID: 21232828]
    HEL CC50
    > 500 μM
    Compound: Ribavirin
    Cytotoxicity against HEL cells
    Cytotoxicity against HEL cells
    		[PMID: 17181162]
    HEL EC50
    10 μM
    Compound: Ribavirin
    Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay
    Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay
    		[PMID: 20034711]
    HEL EC50
    100 μM
    Compound: Ribavirin
    Antiviral activity against vaccinia virus in HEL cells
    Antiviral activity against vaccinia virus in HEL cells
    		[PMID: 17181162]
    HEL EC50
    10 μg/mL
    Compound: Ribavirin
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    		[PMID: 20971531]
    HEL EC50
    112 μM
    Compound: 1
    Antiviral activity against Vaccinia virus lederle infected in human HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Vaccinia virus lederle infected in human HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 20207546]
    HEL EC50
    112 μM
    Compound: ribavirin
    Antiviral activity against Vaccinia virus Lederle in human HEL cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against Vaccinia virus Lederle in human HEL cells assessed as protection against virus-induced cytopathicity
    		[PMID: 19281225]
    HEL EC50
    120 μg/mL
    Compound: ribavirin
    Antiviral activity against VSV in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against VSV in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17948980]
    HEL EC50
    125 μM
    Compound: Ribavirin
    Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay
    Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay
    		[PMID: 20034711]
    HEL EC50
    125 μM
    Compound: ribavirin
    Antiviral activity against VSV in human HEL cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against VSV in human HEL cells assessed as protection against virus-induced cytopathicity
    		[PMID: 19281225]
    HEL EC50
    146 μM
    Compound: Ribavirin
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    		10.1007/s00044-009-9248-y
    HEL EC50
    146 μM
    Compound: Ribavirin
    Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity
    Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity
    		[PMID: 22464686]
    HEL EC50
    146 μM
    Compound: Ribavirin
    Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 24312722]
    HEL EC50
    146 μg/mL
    Compound: Ribavirin
    Antiviral activity against VSV infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    Antiviral activity against VSV infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    		[PMID: 18851889]
    HEL EC50
    146 μg/mL
    Compound: Ribavirin
    Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
    Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
    		[PMID: 20724039]
    HEL EC50
    146 μg/mL
    Compound: ribavirin
    Antiviral activity against Vaccinia virus infected in in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
    Antiviral activity against Vaccinia virus infected in in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
    		[PMID: 19419804]
    HEL EC50
    1 μg/mL
    Compound: Ribavirin
    Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    		[PMID: 20971531]
    HEL EC50
    250 μM
    Compound: ribavirin
    Antiviral activity against HSV2 G in human HEL cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against HSV2 G in human HEL cells assessed as protection against virus-induced cytopathicity
    		[PMID: 19281225]
    HEL EC50
    2 μg/mL
    Compound: Ribavirin
    Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    		[PMID: 20971531]
    HEL EC50
    2 μg/mL
    Compound: Ribavirin
    Antiviral activity against thymidine kinase deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    Antiviral activity against thymidine kinase deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    		[PMID: 20971531]
    HEL EC50
    300 μM
    Compound: Ribavirin
    Antiviral activity against HSV1 KOS in HEL cells
    Antiviral activity against HSV1 KOS in HEL cells
    		[PMID: 17181162]
    HEL EC50
    50 μM
    Compound: Ribavirin
    Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay
    Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay
    		[PMID: 20034711]
    HEL EC50
    85 μM
    Compound: Ribavirin
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay
    		[PMID: 20034711]
    HEL EC50
    > 100 μM
    Compound: Ribavirin
    Antiviral activity against HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 21232828]
    HEL EC50
    > 100 μM
    Compound: Ribavirin
    Antiviral activity against HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 21232828]
    HEL EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Human herpesvirus 1 strain KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    Antiviral activity against Human herpesvirus 1 strain KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    		10.1007/s00044-009-9248-y
    HEL EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Human herpesvirus 2 strain G infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    Antiviral activity against Human herpesvirus 2 strain G infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    		10.1007/s00044-009-9248-y
    HEL EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Vesicular stomatitis virus infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    Antiviral activity against Vesicular stomatitis virus infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    		10.1007/s00044-009-9248-y
    HEL EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against acyclovir-resistant TK-deficient Hepres simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    Antiviral activity against acyclovir-resistant TK-deficient Hepres simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    		10.1007/s00044-009-9248-y
    HEL EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against VSV infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay
    Antiviral activity against VSV infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay
    		[PMID: 20034711]
    HEL EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 21232828]
    HEL EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 21232828]
    HEL EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 21232828]
    HEL EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 21232828]
    HEL EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity
    Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity
    		[PMID: 22464686]
    HEL EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity
    Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity
    		[PMID: 22464686]
    HEL EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity
    		[PMID: 22464686]
    HEL EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against thymidine kinase-deficient Herpes simplex virus 1 infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity
    Antiviral activity against thymidine kinase-deficient Herpes simplex virus 1 infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity
    		[PMID: 22464686]
    HEL EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Herpes simplex virus type 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Herpes simplex virus type 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 24312722]
    HEL EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Herpes simplex virus type 2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Herpes simplex virus type 2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 24312722]
    HEL EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 24312722]
    HEL EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against thymidine kinase-deficient Herpes simplex virus type 1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against thymidine kinase-deficient Herpes simplex virus type 1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 24312722]
    HEL EC50
    > 250 μM
    Compound: ribavirin
    Antiviral activity against HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity
    		[PMID: 19281225]
    HEL EC50
    > 250 μM
    Compound: ribavirin
    Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity
    		[PMID: 19281225]
    HEL EC50
    > 250 μg/mL
    Compound: Ribavirin
    Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    		[PMID: 18851889]
    HEL EC50
    > 250 μg/mL
    Compound: Ribavirin
    Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    		[PMID: 18851889]
    HEL EC50
    > 250 μg/mL
    Compound: Ribavirin
    Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    		[PMID: 18851889]
    HEL EC50
    > 250 μg/mL
    Compound: Ribavirin
    Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    		[PMID: 18851889]
    HEL EC50
    > 250 μg/mL
    Compound: Ribavirin
    Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
    Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
    		[PMID: 20724039]
    HEL EC50
    > 250 μg/mL
    Compound: Ribavirin
    Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
    Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
    		[PMID: 20724039]
    HEL EC50
    > 250 μg/mL
    Compound: Ribavirin
    Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
    Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
    		[PMID: 20724039]
    HEL EC50
    > 250 μg/mL
    Compound: Ribavirin
    Antiviral activity against acyclovir-resistant TK deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
    Antiviral activity against acyclovir-resistant TK deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
    		[PMID: 20724039]
    HEL EC50
    > 250 μg/mL
    Compound: Ribavirin
    Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    		[PMID: 20971531]
    HEL EC50
    > 250 μg/mL
    Compound: ribavirin
    Antiviral activity against HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
    Antiviral activity against HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
    		[PMID: 19419804]
    HEL EC50
    > 250 μg/mL
    Compound: ribavirin
    Antiviral activity against HSV2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
    Antiviral activity against HSV2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
    		[PMID: 19419804]
    HEL EC50
    > 250 μg/mL
    Compound: ribavirin
    Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
    Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
    		[PMID: 19419804]
    HEL EC50
    > 250 μg/mL
    Compound: ribavirin
    Antiviral activity against thymidine kinase-deficient ACV-resistant HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
    Antiviral activity against thymidine kinase-deficient ACV-resistant HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
    		[PMID: 19419804]
    HEL EC50
    > 500 μM
    Compound: Ribavirin
    Antiviral activity against HSV1 KOS in HEL cells
    Antiviral activity against HSV1 KOS in HEL cells
    		[PMID: 17181162]
    HEL EC50
    > 500 μM
    Compound: Ribavirin
    Antiviral activity against HSV2 in HEL cells
    Antiviral activity against HSV2 in HEL cells
    		[PMID: 17181162]
    HEL EC50
    > 500 μM
    Compound: Ribavirin
    Antiviral activity against vesicular somatitis virus in HEL cells
    Antiviral activity against vesicular somatitis virus in HEL cells
    		[PMID: 17181162]
    HEL 299 CC50
    > 250 μM
    Compound: Ribavirin
    Cytotoxicity against human HEL 299 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
    Cytotoxicity against human HEL 299 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
    		[PMID: 37252100]
    HEL 299 IC50
    45 μM
    Compound: Ribavirin
    Compound was tested for its effect on the proliferation of HELL-299 human diploid embryonal lung cell line.
    Compound was tested for its effect on the proliferation of HELL-299 human diploid embryonal lung cell line.
    		10.1016/0960-894X(96)00216-8
    HEp-2 CC50
    113.9 μM
    Compound: 1
    Cytotoxicity against human Hep2 cells by Cell Titer-Glo assay
    Cytotoxicity against human Hep2 cells by Cell Titer-Glo assay
    		[PMID: 23043370]
    HEp-2 CC50
    250 μM
    Compound: Ribavirin
    Cytotoxicity in human Hep2 cells assessed as reduction in cell viability measured after 3 days by beckman coulter counting method
    Cytotoxicity in human Hep2 cells assessed as reduction in cell viability measured after 3 days by beckman coulter counting method
    		[PMID: 33894564]
    HEp-2 CC50
    273.8 μM
    Compound: Ribavirin
    Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay
    Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay
    		[PMID: 31734025]
    HEp-2 CC50
    3039.67 μM
    Compound: Ribavirin
    Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability after 48 hrs by MTS assay
    Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability after 48 hrs by MTS assay
    		[PMID: 33571829]
    HEp-2 CC50
    386.3 μM
    Compound: Ribavirin
    Cytotoxicity against Coxsackievirus B3 infected human Hep-2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Cytotoxicity against Coxsackievirus B3 infected human Hep-2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    		[PMID: 38976838]
    HEp-2 CC50
    418.21 μM
    Compound: Ribavirin
    Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability measured after 60 hrs by MTT assay
    Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability measured after 60 hrs by MTT assay
    		[PMID: 34256126]
    HEp-2 CC50
    571.6 μg/mL
    Compound: Ribavirin
    Cytotoxicity against human Hep2 cells assessed as reduction in cell viability after 3 days by MTT assay
    Cytotoxicity against human Hep2 cells assessed as reduction in cell viability after 3 days by MTT assay
    		[PMID: 28858766]
    HEp-2 CC50
    62.5 μg/mL
    Compound: ribavirin
    Cytotoxicity against human Hep2 cells after 3 days by MTT reduction assay
    Cytotoxicity against human Hep2 cells after 3 days by MTT reduction assay
    		[PMID: 16724853]
    HEp-2 CC50
    653.33 μM
    Compound: Ribavirin
    Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 37859725]
    HEp-2 CC50
    95 μM
    Compound: Ribavirin
    Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability incubated for 6 days by CellTiter-Glo assay
    Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability incubated for 6 days by CellTiter-Glo assay
    		[PMID: 36596229]
    HEp-2 CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against HEp-2 cells
    Cytotoxicity against HEp-2 cells
    		[PMID: 38447084]
    HEp-2 CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against human HEp-2 cells measured after 3 days by CellTiter 96 aqueous one solution assay (Rvb >100 microM)
    Cytotoxicity against human HEp-2 cells measured after 3 days by CellTiter 96 aqueous one solution assay (Rvb >100 microM)
    		[PMID: 38579352]
    HEp-2 CC50
    > 1000 μM
    Compound: Ribavirin
    Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability
    Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability
    		[PMID: 35729787]
    HEp-2 EC50
    1.8 μg/mL
    Compound: Ribavirin
    Antiviral activity against RSV long infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days
    Antiviral activity against RSV long infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days
    		[PMID: 9599250]
    HEp-2 EC50
    1.8 μg/mL
    Compound: ribavirin
    Antiviral activity against respiratory syncytial virus A2 in human Hep2 cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against respiratory syncytial virus A2 in human Hep2 cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 9784173]
    HEp-2 EC50
    11.5 μM
    Compound: Ribavirin
    Antiviral activity against RSV RSS infected human Hep2 cells assessed as inhibition of virus-induced cell death after 6 days by XTT assay
    Antiviral activity against RSV RSS infected human Hep2 cells assessed as inhibition of virus-induced cell death after 6 days by XTT assay
    		[PMID: 17576833]
    HEp-2 EC50
    13.3 μM
    Compound: Ribavirin
    Antiviral activity against RSV RSS infected human Hep2 cells after 5 days by plaque reduction assay
    Antiviral activity against RSV RSS infected human Hep2 cells after 5 days by plaque reduction assay
    		[PMID: 17576833]
    HEp-2 EC50
    15.83 μM
    Compound: Ribavirin
    Antiviral activity against GFP-fused wild-type RSV subgroup A Long infected in human HEp-2 cells measured 24 to 72 hrs post infection by fluorescence assay
    Antiviral activity against GFP-fused wild-type RSV subgroup A Long infected in human HEp-2 cells measured 24 to 72 hrs post infection by fluorescence assay
    		[PMID: 31734025]
    HEp-2 EC50
    16.8 μM
    Compound: Ribavirin
    Antiviral activity against RSV Long infected human Hep2 cells after 5 days by plaque reduction assay
    Antiviral activity against RSV Long infected human Hep2 cells after 5 days by plaque reduction assay
    		[PMID: 17576833]
    HEp-2 EC50
    17.6 μM
    Compound: Ribavirin
    Antiviral activity against plaque picked RSV604-resistant RSV RSS from passage 2 in human Hep2 cells by plaque reduction assay
    Antiviral activity against plaque picked RSV604-resistant RSV RSS from passage 2 in human Hep2 cells by plaque reduction assay
    		[PMID: 17576833]
    HEp-2 EC50
    18.53 μM
    Compound: Ribavirin
    Antiviral activity against Respiratory syncytial virus infected in human HEp-2 cells incubated for 60 hrs by MTT assay
    Antiviral activity against Respiratory syncytial virus infected in human HEp-2 cells incubated for 60 hrs by MTT assay
    		[PMID: 34256126]
    HEp-2 EC50
    19 μM
    Compound: Ribavirin
    Antiviral activity against RSV A2 infected human Hep2 cells after 5 days by plaque reduction assay
    Antiviral activity against RSV A2 infected human Hep2 cells after 5 days by plaque reduction assay
    		[PMID: 17576833]
    HEp-2 EC50
    2.2 μg/mL
    Compound: Ribavirin
    Antiviral activity against RSV A-2 infected in human Hep2 cells after 3 days by plaque neutralization assay
    Antiviral activity against RSV A-2 infected in human Hep2 cells after 3 days by plaque neutralization assay
    		[PMID: 9599250]
    HEp-2 EC50
    2.3 μg/mL
    Compound: Ribavirin
    Antiviral activity against RSV infected in human Hep2 cells assessed as virus-induced cytopathic effect administered 3 hrs postinfection
    Antiviral activity against RSV infected in human Hep2 cells assessed as virus-induced cytopathic effect administered 3 hrs postinfection
    		[PMID: 9599250]
    HEp-2 EC50
    20.12 μM
    Compound: Ribavirin
    Antiviral activity against Respiratory syncytial virus infected in human HEp-2 cells assessed as inhibition of virus-induced cytopathic effect measured after 6 days by CellTiter-Glo assay
    Antiviral activity against Respiratory syncytial virus infected in human HEp-2 cells assessed as inhibition of virus-induced cytopathic effect measured after 6 days by CellTiter-Glo assay
    		[PMID: 37859725]
    HEp-2 EC50
    20.7 μM
    Compound: Ribavirin
    Antiviral activity against DMSO-passaged wild type RSV RSS infected human Hep2 cells by plaque reduction assay
    Antiviral activity against DMSO-passaged wild type RSV RSS infected human Hep2 cells by plaque reduction assay
    		[PMID: 17576833]
    HEp-2 EC50
    25.3 μM
    Compound: Ribavirin
    Antiviral activity against RSV RSS infected human Hep2 cells assessed as reduction of viral antigen synthesis after 3 days by ELISA
    Antiviral activity against RSV RSS infected human Hep2 cells assessed as reduction of viral antigen synthesis after 3 days by ELISA
    		[PMID: 17576833]
    HEp-2 EC50
    28.4 μM
    Compound: 1
    Antiviral activity against Respiratory syncytial virus Long infected in human Hep2 cells assessed as reduction in virus-induced cytopathogenicity by Cell Titer-Glo assay
    Antiviral activity against Respiratory syncytial virus Long infected in human Hep2 cells assessed as reduction in virus-induced cytopathogenicity by Cell Titer-Glo assay
    		[PMID: 23043370]
    HEp-2 EC50
    29 μM
    Compound: Ribavirin
    Antiviral activity against RSV B infected human Hep2 cells after 5 days by plaque reduction assay
    Antiviral activity against RSV B infected human Hep2 cells after 5 days by plaque reduction assay
    		[PMID: 17576833]
    HEp-2 EC50
    5.4 μM
    Compound: Ribavirin
    Antiviral activity against Respiratory syncytial virus infected in human HEp-2 cells assessed as inhibition of virus-induced cytopathic effect measured after 6 days by CellTiter-Glo assay
    Antiviral activity against Respiratory syncytial virus infected in human HEp-2 cells assessed as inhibition of virus-induced cytopathic effect measured after 6 days by CellTiter-Glo assay
    		[PMID: 36596229]
    HEp-2 IC50
    0.08 μM
    Compound: Ribavirin
    Antiviral activity against RSV infected in human HEp-2 cells assessed as inhibition of viral induced cytopathic effect by CPE assay
    Antiviral activity against RSV infected in human HEp-2 cells assessed as inhibition of viral induced cytopathic effect by CPE assay
    		[PMID: 32937282]
    HEp-2 IC50
    10.6 μM
    Compound: Ribavirin
    Antiviral activity against Human respiratory syncytial virus infected in human HEp-2 cells assessed as plaque reduction preincubated with cells 15 mins followed by viral infection for 2.5 hrs and measured after 3 days by crystal violet staining based microscopic analysis (Rvb >100 microM)
    Antiviral activity against Human respiratory syncytial virus infected in human HEp-2 cells assessed as plaque reduction preincubated with cells 15 mins followed by viral infection for 2.5 hrs and measured after 3 days by crystal violet staining based microscopic analysis (Rvb >100 microM)
    		[PMID: 38579352]
    HEp-2 IC50
    10.7 μM
    Compound: ribavirin
    Antiviral activity against Parainfluenza virus type 3 infected in human Hep2 cells assessed as inhibition of virus-induced cytopathogenic effect by plaque reduction assay
    Antiviral activity against Parainfluenza virus type 3 infected in human Hep2 cells assessed as inhibition of virus-induced cytopathogenic effect by plaque reduction assay
    		[PMID: 19267453]
    HEp-2 IC50
    10.7 μM
    Compound: ribavirin
    Antiviral activity against Respiratory syncytial virus infected in human Hep2 cells assessed as inhibition of virus-induced cytopathogenic effect by plaque reduction assay
    Antiviral activity against Respiratory syncytial virus infected in human Hep2 cells assessed as inhibition of virus-induced cytopathogenic effect by plaque reduction assay
    		[PMID: 19267453]
    HEp-2 IC50
    17.33 μM
    Compound: Ribavirin
    Antiviral activity against RSV Long expressing mGFP infected in HEp-2 cells assessed as reduction in viral replication after 48 hrs by MTS assay
    Antiviral activity against RSV Long expressing mGFP infected in HEp-2 cells assessed as reduction in viral replication after 48 hrs by MTS assay
    		[PMID: 33571829]
    HEp-2 IC50
    19 μM
    Compound: Ribavirin
    Antiviral activity against Respiratory syncytial virus infected in human HEp-2 cells assessed as inhibition of virus-induced cytopathic effect by CPE inhibition assay
    Antiviral activity against Respiratory syncytial virus infected in human HEp-2 cells assessed as inhibition of virus-induced cytopathic effect by CPE inhibition assay
    		[PMID: 35729787]
    HEp-2 IC50
    2.6 μg/mL
    Compound: ribavirin
    Antiviral activity against Parainfluenza virus type 3 infected in human Hep2 cells assessed as inhibition of virus-induced cytopathogenic effect
    Antiviral activity against Parainfluenza virus type 3 infected in human Hep2 cells assessed as inhibition of virus-induced cytopathogenic effect
    		[PMID: 11678648]
    HEp-2 IC50
    20 μM
    Compound: ribavirin
    Antiviral activity against Respiratory syncytial virus infected in human Hep2 cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by XTT assay
    Antiviral activity against Respiratory syncytial virus infected in human Hep2 cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by XTT assay
    		[PMID: 25420212]
    HEp-2 IC50
    20.4 μM
    Compound: ribavirin
    Antiviral activity against Respiratory syncytial virus infected in human Hep2 cells assessed as virus-induced cytopathicity by XTT assay
    Antiviral activity against Respiratory syncytial virus infected in human Hep2 cells assessed as virus-induced cytopathicity by XTT assay
    		[PMID: 24882250]
    HEp-2 IC50
    25 μg/mL
    Compound: Ribavirin
    Cytotoxicity against RSV A-2 infected human Hep2 cells after 3 days
    Cytotoxicity against RSV A-2 infected human Hep2 cells after 3 days
    		[PMID: 9599250]
    HEp-2 IC50
    25 μg/mL
    Compound: Ribavirin
    Cytotoxicity against human Hep2 cells administered 3 hrs postinfection
    Cytotoxicity against human Hep2 cells administered 3 hrs postinfection
    		[PMID: 9599250]
    HEp-2 IC50
    35 μg/mL
    Compound: Ribavirin
    Cytotoxicity against RSV long infected human Hep2 cells after 3 days
    Cytotoxicity against RSV long infected human Hep2 cells after 3 days
    		[PMID: 9599250]
    HEp-2 IC50
    3 μg/mL
    Compound: ribavirin
    Antiviral activity against RSV Long in human Hep2 cells assessed as reduction of virus induced cytopathic effect
    Antiviral activity against RSV Long in human Hep2 cells assessed as reduction of virus induced cytopathic effect
    		[PMID: 16724853]
    HUVEC CC50
    > 150 μM
    Compound: RBV
    Cytotoxicity against HUVECs assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
    Cytotoxicity against HUVECs assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
    		[PMID: 38493729]
    HeLa CC50
    300 μg/mL
    Compound: Rib
    Cytotoxicity against human HeLa cells after 2 days by MTT assay
    Cytotoxicity against human HeLa cells after 2 days by MTT assay
    		[PMID: 12444692]
    HeLa CC50
    300 μg/mL
    Compound: Rib (Ribavirin)
    Cytotoxicity against HeLa cells
    Cytotoxicity against HeLa cells
    		[PMID: 14505657]
    HeLa CC50
    426 μg/mL
    Compound: Ribovirin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 19374435]
    HeLa CC50
    > 200 μg/mL
    Compound: ribavirin
    Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of HeLa cells
    Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of HeLa cells
    		[PMID: 8709116]
    HeLa CC50
    > 250 μM
    Compound: Ribavirin
    Cytotoxicity against Human coxsackievirus B4 infected human HeLa cells by trypan blue exclusion method
    Cytotoxicity against Human coxsackievirus B4 infected human HeLa cells by trypan blue exclusion method
    		[PMID: 20034711]
    HeLa CC50
    > 250 μM
    Compound: Ribavirin
    Cytotoxicity against Respiratory syncytial virus infected human HeLa cells by trypan blue exclusion method
    Cytotoxicity against Respiratory syncytial virus infected human HeLa cells by trypan blue exclusion method
    		[PMID: 20034711]
    HeLa CC50
    > 250 μM
    Compound: Ribavirin
    Cytotoxicity against VSV infected human HeLa cells by trypan blue exclusion method
    Cytotoxicity against VSV infected human HeLa cells by trypan blue exclusion method
    		[PMID: 20034711]
    HeLa CC50
    > 250 μM
    Compound: Ribavirin
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 3 days by coulter counting analysis
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 3 days by coulter counting analysis
    		[PMID: 21565516]
    HeLa CC50
    > 250 μM
    Compound: Ribavirin
    Cytotoxicity against Homo sapiens (human) HeLa cells assessed as change in cellular morphology
    Cytotoxicity against Homo sapiens (human) HeLa cells assessed as change in cellular morphology
    		[PMID: 32214762]
    HeLa CC50
    > 250 μg/mL
    Compound: Ribavirin
    Cytotoxicity against human HeLa cells assessed as cell viability by MTS assay
    Cytotoxicity against human HeLa cells assessed as cell viability by MTS assay
    		[PMID: 20971531]
    HeLa CC50
    > 250 μg/mL
    Compound: ribavirin
    Cytotoxicity against human HeLa cells after 3 days by MTS assay
    Cytotoxicity against human HeLa cells after 3 days by MTS assay
    		[PMID: 20347509]
    HeLa CC50
    > 300 μg/mL
    Compound: ribavirin
    Cytotoxicity against human HeLa cells
    Cytotoxicity against human HeLa cells
    		[PMID: 17046264]
    HeLa CC50
    > 500 μM
    Compound: Ribavirin
    Cytotoxicity against HeLa cells
    Cytotoxicity against HeLa cells
    		[PMID: 17181162]
    HeLa CC50
    > 500 μg/mL
    Compound: Ribavirin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 23920438]
    HeLa EC50
    1.5 μM
    Compound: Ribavirin
    Effective concentration required to inhibit respiratory synaptial(RSV) virus-induced cytopathicity by 50% in HeLa cell lines
    Effective concentration required to inhibit respiratory synaptial(RSV) virus-induced cytopathicity by 50% in HeLa cell lines
    		[PMID: 11495586]
    HeLa EC50
    10 μM
    Compound: Ribavirin
    Antiviral activity against Respiratory syncytial virus infected HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    Antiviral activity against Respiratory syncytial virus infected HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    		10.1007/s00044-009-9248-y
    HeLa EC50
    10 μM
    Compound: Ribavirin
    Antiviral activity against VSV infected in human HeLa cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay
    Antiviral activity against VSV infected in human HeLa cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay
    		[PMID: 20034711]
    HeLa EC50
    10 μM
    Compound: Ribavirin
    Antiviral activity against Respiratory syncytial virus infected in HeLa cells
    Antiviral activity against Respiratory syncytial virus infected in HeLa cells
    		[PMID: 22464686]
    HeLa EC50
    10 μM
    Compound: Ribavirin
    Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 24312722]
    HeLa EC50
    10 μM
    Compound: Ribavirin
    Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis
    Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis
    		[PMID: 26114811]
    HeLa EC50
    10 μM
    Compound: ribavirin
    Antiviral activity against RSV Long in human HeLa cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against RSV Long in human HeLa cells assessed as protection against virus-induced cytopathicity
    		[PMID: 19281225]
    HeLa EC50
    1000 μM
    Compound: Ribavirin
    Effective concentration required to inhibit vesicular stomatitis virus (VSV)-induced cytopathicity by 50% in HeLa cell lines
    Effective concentration required to inhibit vesicular stomatitis virus (VSV)-induced cytopathicity by 50% in HeLa cell lines
    		[PMID: 11495586]
    HeLa EC50
    10 μg/mL
    Compound: Ribavirin
    Antiviral activity against RSV infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    Antiviral activity against RSV infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    		[PMID: 18851889]
    HeLa EC50
    10 μg/mL
    Compound: Ribavirin
    Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE
    Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE
    		[PMID: 20971531]
    HeLa EC50
    10 μg/mL
    Compound: ribavirin
    Antiviral activity against RSV infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity after 3 days
    Antiviral activity against RSV infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity after 3 days
    		[PMID: 19419804]
    HeLa EC50
    112 μM
    Compound: Ribavirin
    Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis
    Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis
    		[PMID: 26114811]
    HeLa EC50
    112 μM
    Compound: ribavirin
    Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 23811093]
    HeLa EC50
    12 μM
    Compound: Ribavirin
    Antiviral activity against RSV in HeLa cells
    Antiviral activity against RSV in HeLa cells
    		[PMID: 17181162]
    HeLa EC50
    12.1 μM
    Compound: Ribavirin
    Antiviral activity against Vesicular stomatitis virus infected human HeLa cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    Antiviral activity against Vesicular stomatitis virus infected human HeLa cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    		[PMID: 32214762]
    HeLa EC50
    14.41 μg/mL
    Compound: Rib (Ribavirin)
    Compound was evaluated for its inhibitory effect on the replication of vesicular stomatitis virus (VSV) in HeLa cells
    Compound was evaluated for its inhibitory effect on the replication of vesicular stomatitis virus (VSV) in HeLa cells
    		[PMID: 14505657]
    HeLa EC50
    14.8 μM
    Compound: Ribavirin
    Antiviral activity against VSV infected in HeLa cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against VSV infected in HeLa cells assessed as protection against virus-induced cytopathicity
    		[PMID: 21565516]
    HeLa EC50
    146 μM
    Compound: Ribavirin
    Antiviral activity against Human coxsackievirus B4 infected HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    Antiviral activity against Human coxsackievirus B4 infected HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    		10.1007/s00044-009-9248-y
    HeLa EC50
    146 μM
    Compound: Ribavirin
    Antiviral activity against Coxsackie virus B4 infected in HeLa cells
    Antiviral activity against Coxsackie virus B4 infected in HeLa cells
    		[PMID: 22464686]
    HeLa EC50
    146 μM
    Compound: Ribavirin
    Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 24312722]
    HeLa EC50
    146 μg/mL
    Compound: Ribavirin
    Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    		[PMID: 18851889]
    HeLa EC50
    146 μg/mL
    Compound: Ribavirin
    Antiviral activity against Coxsackie virus B4 infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity after 2 days
    Antiviral activity against Coxsackie virus B4 infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity after 2 days
    		[PMID: 20724039]
    HeLa EC50
    146 μg/mL
    Compound: ribavirin
    Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity after 3 days
    Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity after 3 days
    		[PMID: 19419804]
    HeLa EC50
    14 μg/mL
    Compound: Ribavirin
    Antiviral activity against coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    Antiviral activity against coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    		[PMID: 20971531]
    HeLa EC50
    150 μM
    Compound: ribavirin
    Antiviral activity against coxsackie B4 virus in HeLa cells assessed as reduction of virus plaque formation after 7 days
    Antiviral activity against coxsackie B4 virus in HeLa cells assessed as reduction of virus plaque formation after 7 days
    		[PMID: 17539622]
    HeLa EC50
    16 μg/mL
    Compound: Ribavirin
    Antiviral activity against RSV infected in human HeLa cell assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against RSV infected in human HeLa cell assessed as inhibition of virus-induced cytopathicity
    		[PMID: 20377249]
    HeLa EC50
    16 μg/mL
    Compound: ribavirin
    Antiviral activity against RSV Long in HeLa cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against RSV Long in HeLa cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 17298047]
    HeLa EC50
    17 μM
    Compound: Ribavirin
    Antiviral activity against Vesicular stomatitis virus infected in HeLa cells assessed as inhibition of virus-induced cytopathogenicity
    Antiviral activity against Vesicular stomatitis virus infected in HeLa cells assessed as inhibition of virus-induced cytopathogenicity
    		[PMID: 24906510]
    HeLa EC50
    17.2 μM
    Compound: ribavirin
    Antiviral activity against VSV infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS assay
    Antiviral activity against VSV infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS assay
    		[PMID: 20347509]
    HeLa EC50
    181.36 μg/mL
    Compound: Rib (Ribavirin)
    Compound was evaluated for its inhibitory effect on the replication of Coxsackie virus B3 (Cox. B3) in HeLa cells
    Compound was evaluated for its inhibitory effect on the replication of Coxsackie virus B3 (Cox. B3) in HeLa cells
    		[PMID: 14505657]
    HeLa EC50
    19 μM
    Compound: 1
    Antiviral activity against Respiratory syncytial virus Long infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Respiratory syncytial virus Long infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 20207546]
    HeLa EC50
    192 μM
    Compound: d
    concentration required to inhibit VSV-induced cytopathicity by 50% in HeLa cells
    concentration required to inhibit VSV-induced cytopathicity by 50% in HeLa cells
    		[PMID: 9748360]
    HeLa EC50
    2.8 μg/mL
    Compound: Ribavirin
    Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    		[PMID: 20971531]
    HeLa EC50
    20.94 μg/mL
    Compound: Rib (Ribavirin)
    Compound was evaluated for its inhibitory effect on the replication of encephalomyocarditis virus (EMCV) in HeLa cells
    Compound was evaluated for its inhibitory effect on the replication of encephalomyocarditis virus (EMCV) in HeLa cells
    		[PMID: 14505657]
    HeLa EC50
    22 μM
    Compound: 1
    Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 20207546]
    HeLa EC50
    22 μM
    Compound: Ribavirin
    Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity
    Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity
    		[PMID: 23911856]
    HeLa EC50
    22 μM
    Compound: Ribavirin
    Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis
    Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis
    		[PMID: 26114811]
    HeLa EC50
    22 μM
    Compound: ribavirin
    Antiviral activity against VSV in human HeLa cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against VSV in human HeLa cells assessed as protection against virus-induced cytopathicity
    		[PMID: 19281225]
    HeLa EC50
    22 μg/mL
    Compound: Ribavirin
    Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity after 2 days
    Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity after 2 days
    		[PMID: 20724039]
    HeLa EC50
    22 μg/mL
    Compound: Ribavirin
    Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity after 2 days
    Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity after 2 days
    		[PMID: 20724039]
    HeLa EC50
    24 μg/mL
    Compound: ribavirin
    Antiviral activity against RSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against RSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17948980]
    HeLa EC50
    24 μg/mL
    Compound: ribavirin
    Antiviral activity against VSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against VSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17948980]
    HeLa EC50
    27.8 μg/mL
    Compound: Ribavirin
    Antiviral activity against Adenovirus type 7 infected in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity after 48 hrs by crystal violet staining method
    Antiviral activity against Adenovirus type 7 infected in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity after 48 hrs by crystal violet staining method
    		[PMID: 23920438]
    HeLa EC50
    28.5 μM
    Compound: Ribavirin
    Antiviral activity against Human coxsackievirus B4 infected human HeLa cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    Antiviral activity against Human coxsackievirus B4 infected human HeLa cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    		[PMID: 32214762]
    HeLa EC50
    29 μM
    Compound: Ribavirin
    Antiviral activity against Vesicular stomatitis virus infected HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    Antiviral activity against Vesicular stomatitis virus infected HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    		10.1007/s00044-009-9248-y
    HeLa EC50
    29 μM
    Compound: Ribavirin
    Antiviral activity against Vesicular stomatitis virus infected in HeLa cells
    Antiviral activity against Vesicular stomatitis virus infected in HeLa cells
    		[PMID: 22464686]
    HeLa EC50
    29 μM
    Compound: Ribavirin
    Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 24312722]
    HeLa EC50
    29 μM
    Compound: ribavirin
    Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 23811093]
    HeLa EC50
    29 μg/mL
    Compound: Ribavirin
    Antiviral activity against VSV infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    Antiviral activity against VSV infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    		[PMID: 18851889]
    HeLa EC50
    29 μg/mL
    Compound: ribavirin
    Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity after 3 days
    Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity after 3 days
    		[PMID: 19419804]
    HeLa EC50
    3 μM
    Compound: Ribavirin
    Antiviral activity against RSV infected in HeLa cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against RSV infected in HeLa cells assessed as protection against virus-induced cytopathicity
    		[PMID: 21565516]
    HeLa EC50
    3.6 μg/mL
    Compound: Ribavirin
    Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    		[PMID: 20971531]
    HeLa EC50
    30 μM
    Compound: Ribavirin
    Antiviral activity against Human coxsackievirus B4 infected in human HeLa cells assessed as protection from virus-induced cytopathogenicity after 2 days by MTT assay
    Antiviral activity against Human coxsackievirus B4 infected in human HeLa cells assessed as protection from virus-induced cytopathogenicity after 2 days by MTT assay
    		[PMID: 20034711]
    HeLa EC50
    30 μM
    Compound: Ribavirin
    Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 20034711]
    HeLa EC50
    320 μM
    Compound: d
    concentration required to inhibit Coxsackie virus B4-induced cytopathicity by 50% in HeLa cells
    concentration required to inhibit Coxsackie virus B4-induced cytopathicity by 50% in HeLa cells
    		[PMID: 9748360]
    HeLa EC50
    4.6 μM
    Compound: Ribavirin
    Antiviral activity against Respiratory syncytial virus infected human HeLa cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    Antiviral activity against Respiratory syncytial virus infected human HeLa cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    		[PMID: 32214762]
    HeLa EC50
    48 μg/mL
    Compound: Ribavirin
    Antiviral activity against VSV infected in human HeLa cell assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against VSV infected in human HeLa cell assessed as inhibition of virus-induced cytopathicity
    		[PMID: 20377249]
    HeLa EC50
    48 μg/mL
    Compound: ribavirin
    Antiviral activity against coxsackie B4 virus in HeLa cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against coxsackie B4 virus in HeLa cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 17298047]
    HeLa EC50
    5 μM
    Compound: Ribavirin
    Antiviral activity against Respiratory syncytial virus Long infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity
    Antiviral activity against Respiratory syncytial virus Long infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity
    		[PMID: 23911856]
    HeLa EC50
    5 μM
    Compound: Ribavirin
    Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity
    Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity
    		[PMID: 23911856]
    HeLa EC50
    5 μM
    Compound: ribavirin
    Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 23811093]
    HeLa EC50
    5.8 μM
    Compound: Ribavirin
    Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis
    Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis
    		[PMID: 28477572]
    HeLa EC50
    50 μM
    Compound: Ribavirin
    Antiviral activity against vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis
    Antiviral activity against vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis
    		[PMID: 28477572]
    HeLa EC50
    50 μM
    Compound: ribavirin
    Antiviral activity against Coxsackievirus B4 in human HeLa cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against Coxsackievirus B4 in human HeLa cells assessed as protection against virus-induced cytopathicity
    		[PMID: 19281225]
    HeLa EC50
    50 μg/mL
    Compound: Ribavirin
    Antiviral activity against coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE
    Antiviral activity against coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE
    		[PMID: 20971531]
    HeLa EC50
    6.6 μM
    Compound: ribavirin
    Antiviral activity against RSV infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS assay
    Antiviral activity against RSV infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS assay
    		[PMID: 20347509]
    HeLa EC50
    69 μM
    Compound: Ribavirin
    Antiviral activity against Coxsackievirus B4 infected in HeLa cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against Coxsackievirus B4 infected in HeLa cells assessed as protection against virus-induced cytopathicity
    		[PMID: 21565516]
    HeLa EC50
    6 μg/mL
    Compound: Ribavirin
    Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE
    Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE
    		[PMID: 20971531]
    HeLa EC50
    73.1 μM
    Compound: ribavirin
    Antiviral activity against Coxsackie virus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS assay
    Antiviral activity against Coxsackie virus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS assay
    		[PMID: 20347509]
    HeLa EC50
    80 μg/mL
    Compound: ribavirin
    Antiviral activity against VSV in HeLa cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against VSV in HeLa cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 17298047]
    HeLa EC50
    85 μM
    Compound: Ribavirin
    Antiviral activity against coxsackie B4 virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis
    Antiviral activity against coxsackie B4 virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis
    		[PMID: 28477572]
    HeLa EC50
    90 μg/mL
    Compound: ribavirin
    Antiviral activity against Coxsackie virus B4 in HeLa cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Coxsackie virus B4 in HeLa cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17948980]
    HeLa EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Coxsackie virus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    Antiviral activity against Coxsackie virus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    		[PMID: 22459876]
    HeLa EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    		[PMID: 22459876]
    HeLa EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Vesicular stomatitis virus infected in HeLa cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    Antiviral activity against Vesicular stomatitis virus infected in HeLa cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    		[PMID: 22459876]
    HeLa EC50
    > 320 μM
    Compound: Ribavirin
    Effective concentration required to inhibit Coxsackie virus B4-induced cytopathicity by 50% in HeLa cell lines
    Effective concentration required to inhibit Coxsackie virus B4-induced cytopathicity by 50% in HeLa cell lines
    		[PMID: 11495586]
    HeLa EC50
    > 500 μM
    Compound: Ribavirin
    Antiviral activity against Coxsackie B4 virus in HeLa cells
    Antiviral activity against Coxsackie B4 virus in HeLa cells
    		[PMID: 17181162]
    HeLa IC50
    11.4 μM
    Compound: Ribavirin
    Inhibitory concentration against respiratory syncytial virus in HeLa cells
    Inhibitory concentration against respiratory syncytial virus in HeLa cells
    		[PMID: 7658442]
    HeLa IC50
    14 μg/mL
    Compound: ribavirin
    Tested for inhibitory effect on RNA virus VSV in HeLa cell line
    Tested for inhibitory effect on RNA virus VSV in HeLa cell line
    		[PMID: 8246242]
    HeLa IC50
    20.3 μg/mL
    Compound: Ribovirin
    Antiviral activity against Coxsackie virus B3 Nacy infected in human HeLa cells assessed as reduction of virus-induced cytopathic effect by MTT assay
    Antiviral activity against Coxsackie virus B3 Nacy infected in human HeLa cells assessed as reduction of virus-induced cytopathic effect by MTT assay
    		[PMID: 19374435]
    HeLa IC50
    20 μg/mL
    Compound: ribavirin
    Antiviral activity against Coxsackie virus B4 in HeLa cells
    Antiviral activity against Coxsackie virus B4 in HeLa cells
    		[PMID: 17518459]
    HeLa IC50
    20 μg/mL
    Compound: ribavirin
    Antiviral activity against VSV in HeLa cells
    Antiviral activity against VSV in HeLa cells
    		[PMID: 17518459]
    HeLa IC50
    2 μg/mL
    Compound: ribavirin
    Antiviral activity against Respiratory syncytial virus in HeLa cells
    Antiviral activity against Respiratory syncytial virus in HeLa cells
    		[PMID: 17518459]
    HeLa IC50
    4 μg/mL
    Compound: ribavirin
    Tested for inhibitory effect on RNA virus RSV in HeLa cell line
    Tested for inhibitory effect on RNA virus RSV in HeLa cell line
    		[PMID: 8246242]
    HeLa IC50
    70 μg/mL
    Compound: ribavirin
    Tested for inhibitory effect on RNA virus Polio-1 in HeLa cell line
    Tested for inhibitory effect on RNA virus Polio-1 in HeLa cell line
    		[PMID: 8246242]
    HeLa IC50
    >= 400 μg/mL
    Compound: ribavirin
    Tested for inhibitory effect on RNA virus cell morphology in HeLa cell line
    Tested for inhibitory effect on RNA virus cell morphology in HeLa cell line
    		[PMID: 8246242]
    HepG2 CC50
    246.27 μM
    Compound: RBV
    Cytotoxicity against human HepG2 cells measured after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells measured after 24 hrs by MTT assay
    		[PMID: 37722289]
    HepG2 CC50
    > 500 μg/mL
    Compound: Ribavirin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 23920438]
    HepG2 EC50
    22.3 μg/mL
    Compound: Ribavirin
    Antiviral activity against Coxsackievirus B5 infected in human HepG2 cells assessed as inhibition of virus-induced cytopathogenicity after 48 hrs by crystal violet staining method
    Antiviral activity against Coxsackievirus B5 infected in human HepG2 cells assessed as inhibition of virus-induced cytopathogenicity after 48 hrs by crystal violet staining method
    		[PMID: 23920438]
    Huh-5-2 CC50
    21 μg/mL
    Compound: Ribavirin
    Cytotoxicity against human Huh-5-2 cells
    Cytotoxicity against human Huh-5-2 cells
    		[PMID: 18445526]
    Huh-5-2 CC50
    86 μM
    Compound: ribavirin
    Cytotoxicity against human HuH5.2 cells
    Cytotoxicity against human HuH5.2 cells
    		[PMID: 19170598]
    Huh-5-2 EC50
    7 μg/mL
    Compound: Ribavirin
    Antiviral activity against Hepatitis C virus infected human Huh-5-2 cells assessed as inhibition of luciferase activity after 4 days by RNA replicon assay
    Antiviral activity against Hepatitis C virus infected human Huh-5-2 cells assessed as inhibition of luciferase activity after 4 days by RNA replicon assay
    		[PMID: 18445526]
    Huh-7 CC50
    100 μM
    Compound: Ribavirin
    Cytotoxicity against human HuH7 cells assessed as reduction in cell viability by measuring ATP level measured after 72 hrs by CellTiter-Glo luminescent assay
    Cytotoxicity against human HuH7 cells assessed as reduction in cell viability by measuring ATP level measured after 72 hrs by CellTiter-Glo luminescent assay
    		[PMID: 32435411]
    Huh-7 CC50
    1060 μM
    Compound: Ribavirin
    Cytotoxicity against human HuH7 cells after3 days by MTT assay
    Cytotoxicity against human HuH7 cells after3 days by MTT assay
    		[PMID: 20337460]
    Huh-7 CC50
    177.94 μM
    Compound: Ribavirin
    Cytotoxicity against human HuH7 cells
    Cytotoxicity against human HuH7 cells
    		[PMID: 20579888]
    Huh-7 CC50
    200 μM
    Compound: Ribavirin
    Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability by Celltiter-Glo luminescent cell viability assay
    Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability by Celltiter-Glo luminescent cell viability assay
    		[PMID: 34273661]
    Huh-7 CC50
    30.5 μM
    Compound: Ribavirin
    Cytotoxicity against human HuH7-J20 cells expressing secreted alkaline phosphatase reporter gene assessed as cell viability preincubated for 1 hr followed by fresh drug administration every 24 hrs at 1/10th of initial concentration for 48 hrs by WST-1 assay
    Cytotoxicity against human HuH7-J20 cells expressing secreted alkaline phosphatase reporter gene assessed as cell viability preincubated for 1 hr followed by fresh drug administration every 24 hrs at 1/10th of initial concentration for 48 hrs by WST-1 assay
    		[PMID: 26428870]
    Huh-7 CC50
    32 μM
    Compound: RBV
    Cytotoxicity against human HuH7 cells infected with HCV1b after 3 days by MTS assay
    Cytotoxicity against human HuH7 cells infected with HCV1b after 3 days by MTS assay
    		[PMID: 22100256]
    Huh-7 CC50
    512.8 μM
    Compound: Ribavirin
    Cytotoxicity against human Huh-7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    Cytotoxicity against human Huh-7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    		[PMID: 35306290]
    Huh-7 CC50
    56 μM
    Compound: Ribavirin
    Cytotoxicity against human HuH7 cells after 72 hrs by MTS assay
    Cytotoxicity against human HuH7 cells after 72 hrs by MTS assay
    		[PMID: 25330401]
    Huh-7 CC50
    56.31 μM
    Compound: Ribavirin
    Cytotoxicity against human HuH7 cells assessed as cell viability after 3 days by XTT assay
    Cytotoxicity against human HuH7 cells assessed as cell viability after 3 days by XTT assay
    		[PMID: 24727241]
    Huh-7 CC50
    56.31 μM
    Compound: Ribavirin
    Cytotoxicity against human HuH7 cells assessed as growth inhibition after 3 days by XTT method
    Cytotoxicity against human HuH7 cells assessed as growth inhibition after 3 days by XTT method
    		[PMID: 29031073]
    Huh-7 CC50
    8.9 μM
    Compound: Ribavirin
    Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
    Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
    		[PMID: 37252100]
    Huh-7 CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against human Huh-7 cells incubated for 3 days by MTT assay
    Cytotoxicity against human Huh-7 cells incubated for 3 days by MTT assay
    		[PMID: 32787106]
    Huh-7 CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against human Huh-7 cells incubated for 72 hrs by Cell Titer-Glo luminescence assay
    Cytotoxicity against human Huh-7 cells incubated for 72 hrs by Cell Titer-Glo luminescence assay
    		[PMID: 32787106]
    Huh-7 CC50
    > 100 μM
    Compound: ribavirin
    Cytotoxicity against mock-infected human Huh7.5 cells assessed as reduction in cell viability incubated for 5 hrs by MTT assay
    Cytotoxicity against mock-infected human Huh7.5 cells assessed as reduction in cell viability incubated for 5 hrs by MTT assay
    		[PMID: 26613291]
    Huh-7 CC50
    > 200 μM
    Compound: Ribavirin
    Cytotoxicity against Huh7 cells by XTT assay
    Cytotoxicity against Huh7 cells by XTT assay
    		[PMID: 17766124]
    Huh-7 CC50
    > 30 μM
    Compound: Ribavirin
    Cytotoxicity against human HuH7-J20 cells expressing secreted alkaline phosphatase reporter gene assessed as cell viability incubated for 1 hr by WST-1 assay
    Cytotoxicity against human HuH7-J20 cells expressing secreted alkaline phosphatase reporter gene assessed as cell viability incubated for 1 hr by WST-1 assay
    		[PMID: 26428870]
    Huh-7 EC50
    12.6 μM
    Compound: Ribavirin
    Antiviral activity against dengue virus 2 infected in human HuH7 cells after 72 hrs by Western blot and ECL detection based assay
    Antiviral activity against dengue virus 2 infected in human HuH7 cells after 72 hrs by Western blot and ECL detection based assay
    		[PMID: 25330401]
    Huh-7 EC50
    14 μM
    Compound: RBV
    Antiviral activity against HCV genotype 1b infected in human HuH7 cells after 3 days by renilla luciferase reporter assay
    Antiviral activity against HCV genotype 1b infected in human HuH7 cells after 3 days by renilla luciferase reporter assay
    		[PMID: 22100256]
    Huh-7 EC50
    16.3 μM
    Compound: ribavirin
    Antiviral activity against recombinant HCV genotype 2a JFH1 infected in human Huh7 cells incubated for 5 hrs measured on day 3 post infection by luciferase reporter gene assay
    Antiviral activity against recombinant HCV genotype 2a JFH1 infected in human Huh7 cells incubated for 5 hrs measured on day 3 post infection by luciferase reporter gene assay
    		[PMID: 26613291]
    Huh-7 EC50
    17.6 μM
    Compound: Ribavirin
    Antiviral activity against HCV 1b infected in human HuH7 cells assessed as inhibition of viral RNA replication after 4 days by replicon assay
    Antiviral activity against HCV 1b infected in human HuH7 cells assessed as inhibition of viral RNA replication after 4 days by replicon assay
    		[PMID: 20337460]
    Huh-7 EC50
    20 μg/mL
    Compound: Ribavirin
    Antiviral activity against Hepatitis C virus subtype 1a infected in human HuH7 cells after 2 days by q-PCR analysis
    Antiviral activity against Hepatitis C virus subtype 1a infected in human HuH7 cells after 2 days by q-PCR analysis
    		[PMID: 22985854]
    Huh-7 EC50
    22 μM
    Compound: ribavirin
    Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease T54A double mutation in human HuH7 cells after 48 hrs by RNA replicon assay
    Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease T54A double mutation in human HuH7 cells after 48 hrs by RNA replicon assay
    		[PMID: 17938182]
    Huh-7 EC50
    30.4 μM
    Compound: Ribavirin
    Antiviral activity against HCV JFH1 infected in human HuH7-J20 cells assessed as inhibition of viral life cycle by measuring secreted alkaline phosphatase level preincubated with cells for 1 hr followed by viral inoculation for 3 hrs measured at 72 hrs
    Antiviral activity against HCV JFH1 infected in human HuH7-J20 cells assessed as inhibition of viral life cycle by measuring secreted alkaline phosphatase level preincubated with cells for 1 hr followed by viral inoculation for 3 hrs measured at 72 hrs
    		[PMID: 26428870]
    Huh-7 EC50
    33 μM
    Compound: ribavirin
    Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M mutation in human HuH7 cells after 48 hrs by RNA replicon assay
    Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M mutation in human HuH7 cells after 48 hrs by RNA replicon assay
    		[PMID: 17938182]
    Huh-7 EC50
    33.5 μM
    Compound: Ribavirin
    Antiviral activity against HCV JFH1 infected in human HuH7-J20 cells assessed as inhibition of viral life cycle by measuring secreted alkaline phosphatase level preincubated with cells for 1 hr followed by viral inoculation for 3 hrs and fresh drug administration every 24 hrs at 1/10th of initial concentration for 48 hrs measured at 72 hrs
    Antiviral activity against HCV JFH1 infected in human HuH7-J20 cells assessed as inhibition of viral life cycle by measuring secreted alkaline phosphatase level preincubated with cells for 1 hr followed by viral inoculation for 3 hrs and fresh drug administration every 24 hrs at 1/10th of initial concentration for 48 hrs measured at 72 hrs
    		[PMID: 26428870]
    Huh-7 EC50
    36 μM
    Compound: ribavirin
    Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36A/R155K double mutation in human HuH7 cells after 48 hrs by RNA replicon assay
    Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36A/R155K double mutation in human HuH7 cells after 48 hrs by RNA replicon assay
    		[PMID: 17938182]
    Huh-7 EC50
    36 μM
    Compound: ribavirin
    Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M/R155T double mutation in human HuH7 cells after 48 hrs by RNA replicon assay
    Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M/R155T double mutation in human HuH7 cells after 48 hrs by RNA replicon assay
    		[PMID: 17938182]
    Huh-7 EC50
    41 μM
    Compound: ribavirin
    Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M/R155K double mutation in human HuH7 cells after 48 hrs by RNA replicon assay
    Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M/R155K double mutation in human HuH7 cells after 48 hrs by RNA replicon assay
    		[PMID: 17938182]
    Huh-7 EC50
    42 μM
    Compound: ribavirin
    Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36A/R155T double mutation in human HuH7 cells after 48 hrs by RNA replicon assay
    Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36A/R155T double mutation in human HuH7 cells after 48 hrs by RNA replicon assay
    		[PMID: 17938182]
    Huh-7 EC50
    43 μM
    Compound: ribavirin
    Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36A mutation in human HuH7 cells after 48 hrs by RNA replicon assay
    Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36A mutation in human HuH7 cells after 48 hrs by RNA replicon assay
    		[PMID: 17938182]
    Huh-7 EC50
    54.8 μM
    Compound: Ribavirin
    Inhibition of HCV replication in Huh7 cells after 48 hrs by luciferase assay
    Inhibition of HCV replication in Huh7 cells after 48 hrs by luciferase assay
    		[PMID: 17766124]
    Huh-7 EC50
    58 μM
    Compound: ribavirin
    Antiviral activity against wild type Con1-mADE HCV replicon in human HuH7 cells after 48 hrs by RNA replicon assay
    Antiviral activity against wild type Con1-mADE HCV replicon in human HuH7 cells after 48 hrs by RNA replicon assay
    		[PMID: 17938182]
    Huh-7 EC50
    81.9 μM
    Compound: Ribavirin
    Antiviral activity against HCV subtype 1a infected in Huh-7 cells assessed as reduction in viral RNA level after 8 to 10 days by quantitative PCR analysis
    Antiviral activity against HCV subtype 1a infected in Huh-7 cells assessed as reduction in viral RNA level after 8 to 10 days by quantitative PCR analysis
    		[PMID: 24485784]
    Huh-7 IC50
    12.61 μM
    Compound: Ribavirin
    Antiviral activity against DENV2 16681 infected in human Huh-7 cells after 3 days by luciferase reporter gene assay
    Antiviral activity against DENV2 16681 infected in human Huh-7 cells after 3 days by luciferase reporter gene assay
    		[PMID: 24727241]
    Huh-7 IC50
    32 μM
    Compound: ribavirin
    Antiviral activity against HCV 1b with NS3-4A R155T mutation in human Huh7 cells after 48 hrs by replicon cell assay
    Antiviral activity against HCV 1b with NS3-4A R155T mutation in human Huh7 cells after 48 hrs by replicon cell assay
    		[PMID: 17556358]
    Huh-7 IC50
    37 μM
    Compound: ribavirin
    Antiviral activity against HCV 1b Con1 with NS3-4A R155K mutation in human Huh7 cells after 48 hrs by replicon cell assay
    Antiviral activity against HCV 1b Con1 with NS3-4A R155K mutation in human Huh7 cells after 48 hrs by replicon cell assay
    		[PMID: 17556358]
    Huh-7 IC50
    39 μM
    Compound: ribavirin
    Antiviral activity against HCV 1b with NS3-4A R155M mutation in human Huh7 cells after 48 hrs by replicon cell assay
    Antiviral activity against HCV 1b with NS3-4A R155M mutation in human Huh7 cells after 48 hrs by replicon cell assay
    		[PMID: 17556358]
    Huh-7 IC50
    4 μM
    Compound: Ribavirin
    Antiviral activity against Dengue virus serotype 2 New Guinea C infected at 50 TCID50 in human HuH7 cells assessed as inhibition of viral replication and 72 hrs later re-infected pre-seeded HuH7 cells with viral supernatant collected from previous infected and measured after 72 hrs by immunodetection assay
    Antiviral activity against Dengue virus serotype 2 New Guinea C infected at 50 TCID50 in human HuH7 cells assessed as inhibition of viral replication and 72 hrs later re-infected pre-seeded HuH7 cells with viral supernatant collected from previous infected and measured after 72 hrs by immunodetection assay
    		[PMID: 32435411]
    Huh-7 IC50
    53.7 μM
    Compound: RBV
    Antiproliferative activity against human HuH-7 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HuH-7 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 31883488]
    Huh-7 IC50
    58 μM
    Compound: ribavirin
    Antiviral activity against wild type HCV 1b Con1 in human Huh7 cells after 48 hrs by replicon cell assay
    Antiviral activity against wild type HCV 1b Con1 in human Huh7 cells after 48 hrs by replicon cell assay
    		[PMID: 17556358]
    Huh-7 IC50
    > 200 μM
    Compound: Ribavirin
    Cytotoxicity against human HuH7 cells after 3 days by MTT assay
    Cytotoxicity against human HuH7 cells after 3 days by MTT assay
    		[PMID: 30721061]
    Huh-7.5 CC50
    1654 μM
    Compound: RBV
    Cytotoxicity against human Huh7.5 cells assessed as reduction in cell viability by MTS assay
    Cytotoxicity against human Huh7.5 cells assessed as reduction in cell viability by MTS assay
    		[PMID: 35661850]
    IGROV-1 IC50
    16 μg/mL
    Compound: RBV
    Antiproliferative activity against human IGROV-1 cells assessed as reduction in cell growth incubated for 7 days by trypan blue exclusion assay
    Antiproliferative activity against human IGROV-1 cells assessed as reduction in cell growth incubated for 7 days by trypan blue exclusion assay
    		[PMID: 31883488]
    IGROV-1 IC50
    21 μg/mL
    Compound: RBV
    Antiproliferative activity against human IGROV-1 cells assessed as reduction in cell growth incubated for 4 days by trypan blue exclusion assay
    Antiproliferative activity against human IGROV-1 cells assessed as reduction in cell growth incubated for 4 days by trypan blue exclusion assay
    		[PMID: 31883488]
    IGROV-1 IC50
    25 μg/mL
    Compound: RBV
    Antiproliferative activity against human IGROV-1 cells assessed as reduction in cell growth incubated for 3 days by trypan blue exclusion assay
    Antiproliferative activity against human IGROV-1 cells assessed as reduction in cell growth incubated for 3 days by trypan blue exclusion assay
    		[PMID: 31883488]
    L1210 IC50
    1 μM
    Compound: Ribavirin
    Inhibition of IMPDH in mouse L1210 cells assessed as formation of [2,8-3H]hypoxanthine from [2,8-3H]IMP after 20 to 60 mins
    Inhibition of IMPDH in mouse L1210 cells assessed as formation of [2,8-3H]hypoxanthine from [2,8-3H]IMP after 20 to 60 mins
    		[PMID: 22555152]
    L1210 IC50
    16.6 μM
    Compound: Ribavirin
    Compound was tested for its effect on the proliferation of L1210 murine leukemia cell line.
    Compound was tested for its effect on the proliferation of L1210 murine leukemia cell line.
    		10.1016/0960-894X(96)00216-8
    L1210 IC50
    7.1 μg/mL
    Compound: ribavirin
    Tested for inhibitory effect on RNA virus cell growth in L1210 cell line
    Tested for inhibitory effect on RNA virus cell growth in L1210 cell line
    		[PMID: 8246242]
    MDA-MB-231 IC50
    > 100 μM
    Compound: RBV
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 31883488]
    MDA-MB-435 IC50
    38.3 μM
    Compound: RBV
    Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 31883488]
    MDCK CC50
    100 μM
    Compound: Ribavirin
    Cytotoxicity against MDCK cells assessed as inhibition of cell viability by colorimetric formazan-based MTS assay
    Cytotoxicity against MDCK cells assessed as inhibition of cell viability by colorimetric formazan-based MTS assay
    		[PMID: 26114811]
    MDCK CC50
    1365.5 μM
    Compound: Ribavirin
    Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by crystal violet staining based method
    Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by crystal violet staining based method
    		[PMID: 30033162]
    MDCK CC50
    20 μM
    Compound: Ribavirin
    Cytotoxicity against MDCK cells by MTT assay
    Cytotoxicity against MDCK cells by MTT assay
    		[PMID: 33705902]
    MDCK CC50
    2336 μM
    Compound: ribavirin
    Cytotoxicity against MDCK cells
    Cytotoxicity against MDCK cells
    		[PMID: 17194832]
    MDCK CC50
    58 μM
    Compound: Ribavirin
    Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    		[PMID: 32220685]
    MDCK CC50
    62.5 μg/mL
    Compound: ribavirin
    Antiviral activity against PIV3 in MDCK cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against PIV3 in MDCK cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 15104496]
    MDCK CC50
    67 μM
    Compound: Ribavirin
    Cytotoxicity against dog MDCK cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
    Cytotoxicity against dog MDCK cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay
    		[PMID: 37252100]
    MDCK CC50
    707.3 μM
    Compound: RIB
    Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 37517205]
    MDCK CC50
    > 1 mM
    Compound: Ribavirin
    Cytotoxicity against dog MDCK cells infected with Influenza A virus H1N1
    Cytotoxicity against dog MDCK cells infected with Influenza A virus H1N1
    		[PMID: 37077387]
    MDCK CC50
    > 1 mM
    Compound: Ribavirin
    Cytotoxicity against dog MDCK cells infected with Influenza A virus H3N2
    Cytotoxicity against dog MDCK cells infected with Influenza A virus H3N2
    		[PMID: 37077387]
    MDCK CC50
    > 1 mM
    Compound: Ribavirin
    Cytotoxicity against dog MDCK cells infected with Influenza B virus
    Cytotoxicity against dog MDCK cells infected with Influenza B virus
    		[PMID: 37077387]
    MDCK CC50
    > 100 μM
    Compound: RBV
    Cytotoxicity against MDCK cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
    Cytotoxicity against MDCK cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
    		[PMID: 36764470]
    MDCK CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against Influenza A virus subtype H1N1 infected MDCK cells by trypan blue exclusion method
    Cytotoxicity against Influenza A virus subtype H1N1 infected MDCK cells by trypan blue exclusion method
    		[PMID: 20034711]
    MDCK CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against Influenza A virus subtype H3N2 infected MDCK cells by trypan blue exclusion method
    Cytotoxicity against Influenza A virus subtype H3N2 infected MDCK cells by trypan blue exclusion method
    		[PMID: 20034711]
    MDCK CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against Influenza B virus infected MDCK cells by trypan blue exclusion method
    Cytotoxicity against Influenza B virus infected MDCK cells by trypan blue exclusion method
    		[PMID: 20034711]
    MDCK CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against MDCK cells assessed as cell viability by colorimetric formazan-based MTS assay
    Cytotoxicity against MDCK cells assessed as cell viability by colorimetric formazan-based MTS assay
    		[PMID: 22459876]
    MDCK CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against dog MDCK cells assessed as cell viability by MTS assay
    Cytotoxicity against dog MDCK cells assessed as cell viability by MTS assay
    		[PMID: 23117173]
    MDCK CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against MDCK cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Cytotoxicity against MDCK cells assessed as reduction in cell viability after 72 hrs by MTS assay
    		[PMID: 24974341]
    MDCK CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against MDCK cells after 72 hrs by MTS assay
    Cytotoxicity against MDCK cells after 72 hrs by MTS assay
    		[PMID: 25752526]
    MDCK CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against MDCK cells assessed as cell viability measured after 4 days by formazan-based MTS assay
    Cytotoxicity against MDCK cells assessed as cell viability measured after 4 days by formazan-based MTS assay
    		[PMID: 27112451]
    MDCK CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 5 to 6 days by MTS assay
    Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 5 to 6 days by MTS assay
    		[PMID: 28477572]
    MDCK CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against MDCK cells assessed as decrease in cell viability after 72 hrs by MTS assay
    Cytotoxicity against MDCK cells assessed as decrease in cell viability after 72 hrs by MTS assay
    		[PMID: 29220568]
    MDCK CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 3 to 6 days by MTS assay
    Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 3 to 6 days by MTS assay
    		[PMID: 29886325]
    MDCK CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay
    Cytotoxicity against HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay
    		[PMID: 29906392]
    MDCK CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay
    Cytotoxicity against MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay
    		[PMID: 29906392]
    MDCK CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against MDCK cells assessed as reduction in cell viability after 3 days by MTS assay
    Cytotoxicity against MDCK cells assessed as reduction in cell viability after 3 days by MTS assay
    		[PMID: 30170320]
    MDCK CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against MDCK cells assessed as reduction in cell viability measured on day 5 by Celltiter-Glo luminescence assay
    Cytotoxicity against MDCK cells assessed as reduction in cell viability measured on day 5 by Celltiter-Glo luminescence assay
    		[PMID: 30852083]
    MDCK CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 72 hrs by alamar blue assay
    Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 72 hrs by alamar blue assay
    		[PMID: 31053507]
    MDCK CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 3 days by coulter counter method
    Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 3 days by coulter counter method
    		[PMID: 31586832]
    MDCK CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against MDCK cells assessed as reduction in cell viability after 4 days by MTS assay
    Cytotoxicity against MDCK cells assessed as reduction in cell viability after 4 days by MTS assay
    		[PMID: 31753804]
    MDCK CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against MDCK cells assessed as change in cellular morphology
    Cytotoxicity against MDCK cells assessed as change in cellular morphology
    		[PMID: 32214762]
    MDCK CC50
    > 100 μM
    Compound: ribavirin
    Cytotoxicity against MDCK cells assessed as decrease in cell viability by MTS assay
    Cytotoxicity against MDCK cells assessed as decrease in cell viability by MTS assay
    		[PMID: 18778942]
    MDCK CC50
    > 100 μM
    Compound: ribavirin
    Cytotoxicity against MDCK cells by MTS assay
    Cytotoxicity against MDCK cells by MTS assay
    		[PMID: 19281225]
    MDCK CC50
    > 100 μM
    Compound: ribavirin
    Cytotoxicity against MDCK cells relative to control
    Cytotoxicity against MDCK cells relative to control
    		[PMID: 26260336]
    MDCK CC50
    > 100 μg/mL
    Compound: Ribavirin
    The compound was evaluated for cytotoxicity by MTT assay in MDCK cells
    The compound was evaluated for cytotoxicity by MTT assay in MDCK cells
    		10.1016/S0960-894X(97)10154-8
    MDCK CC50
    > 100 μg/mL
    Compound: Ribavirin
    Cytotoxicity against MDCK cells by MTS assay
    Cytotoxicity against MDCK cells by MTS assay
    		[PMID: 20724039]
    MDCK CC50
    > 100 μg/mL
    Compound: Ribavirin
    Cytotoxicity against MDCK cells assessed as cell viability by MTS assay
    Cytotoxicity against MDCK cells assessed as cell viability by MTS assay
    		[PMID: 20971531]
    MDCK CC50
    > 125 μg/mL
    Compound: ribavirin
    Antiviral activity against influenza virus type A H1N1 in MDCK cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against influenza virus type A H1N1 in MDCK cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 15104496]
    MDCK CC50
    > 200 μM
    Compound: RBV
    Cytotoxicity against MDCK cells assessed as cell growth after 40 hrs by CellTiter-Glo assay
    Cytotoxicity against MDCK cells assessed as cell growth after 40 hrs by CellTiter-Glo assay
    		[PMID: 25681711]
    MDCK CC50
    > 200 μM
    Compound: RBV
    Cytotoxicity against MDCK cells after 40 hrs by Celltiter-Glo assay
    Cytotoxicity against MDCK cells after 40 hrs by Celltiter-Glo assay
    		[PMID: 26686929]
    MDCK CC50
    > 200 μM
    Compound: Ribavirin
    Cytotoxicity against dog MDCK cells assessed as reduction in cell viability
    Cytotoxicity against dog MDCK cells assessed as reduction in cell viability
    		[PMID: 34126455]
    MDCK CC50
    > 200 μM
    Compound: ribavirin
    Cytotoxicity against MDCK cells assessed as cell viability measured at 24 hrs by MTS assay
    Cytotoxicity against MDCK cells assessed as cell viability measured at 24 hrs by MTS assay
    		[PMID: 26288686]
    MDCK CC50
    > 2000 μM
    Compound: Ribavirin
    Cytotoxicity against MDCK cells after 48 hrs by MTT assay
    Cytotoxicity against MDCK cells after 48 hrs by MTT assay
    		[PMID: 30108810]
    MDCK CC50
    > 2000 μg/mL
    Compound: ribavirin
    Cytotoxicity in MDCK cells infected with influenza A H3N2 virus
    Cytotoxicity in MDCK cells infected with influenza A H3N2 virus
    		[PMID: 16183283]
    MDCK CC50
    > 2130 μM
    Compound: Ribavirin
    Cytotoxicity against MDCK cells after 48 hrs by MTT assay
    Cytotoxicity against MDCK cells after 48 hrs by MTT assay
    		[PMID: 29716780]
    MDCK CC50
    > 2130 μM
    Compound: Ribavirin
    Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 30746065]
    MDCK CC50
    > 2130 μM
    Compound: Ribavirin
    Cytotoxicity against dog MDCK cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against dog MDCK cells assessed as reduction in cell viability by MTT assay
    		[PMID: 33129992]
    MDCK CC50
    > 2130 μM
    Compound: Ribavirin
    Cytotoxicity against MDCK cells assessed as cell death incubated for 48 hrs by MTT assay
    Cytotoxicity against MDCK cells assessed as cell death incubated for 48 hrs by MTT assay
    		[PMID: 33171219]
    MDCK CC50
    > 250 μM
    Compound: RBV
    Cytotoxicity against MDCK cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against MDCK cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 24313730]
    MDCK CC50
    > 250 μM
    Compound: RBV
    Cytotoxicity against MDCK cells after 48 hrs by MTT assay
    Cytotoxicity against MDCK cells after 48 hrs by MTT assay
    		[PMID: 24785979]
    MDCK CC50
    > 250 μM
    Compound: RBV
    Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 28666191]
    MDCK CC50
    > 250 μM
    Compound: RBV
    Cytotoxicity against MDCK cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against MDCK cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 30142611]
    MDCK CC50
    > 250 μM
    Compound: RBV
    Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 33328103]
    MDCK CC50
    > 250 μM
    Compound: RBV
    Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 33962311]
    MDCK CC50
    > 250 μM
    Compound: RBV
    Cytotoxicity against MDCK cells incubated for 48 hrs by MTT assay
    Cytotoxicity against MDCK cells incubated for 48 hrs by MTT assay
    		[PMID: 39153334]
    MDCK CC50
    > 250 μM
    Compound: RBV, Ribavirin
    Cytotoxicity against MDCK cells assessed as decrease in cell viability by MTT assay
    Cytotoxicity against MDCK cells assessed as decrease in cell viability by MTT assay
    		[PMID: 25856229]
    MDCK CC50
    > 250 μM
    Compound: RBV; Ribavirin
    Cytotoxicity against MDCK cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against MDCK cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 26924568]
    MDCK CC50
    > 300 μM
    Compound: Ribavirin
    Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo assay
    Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo assay
    		[PMID: 36596229]
    MDCK CC50
    > 320 μg/mL
    Compound: Ribavirin
    Cytotoxicity against MDCK cells assessed as cell viability by neutral red assay
    Cytotoxicity against MDCK cells assessed as cell viability by neutral red assay
    		[PMID: 26291036]
    MDCK CC50
    > 320 μg/mL
    Compound: Ribavirin
    Cytotoxicity against MDCK cells assessed as cell viability by visual assay
    Cytotoxicity against MDCK cells assessed as cell viability by visual assay
    		[PMID: 26291036]
    MDCK CC50
    > 323.5 μM
    Compound: Ribavirin
    Cytotoxicity against MDCK cells
    Cytotoxicity against MDCK cells
    		[PMID: 23811085]
    MDCK CC50
    > 4095 μM
    Compound: Ribavirin
    Cytotoxicity against MDCK cells infected with influenza A virus California/7/2009(H1N1)
    Cytotoxicity against MDCK cells infected with influenza A virus California/7/2009(H1N1)
    		[PMID: 36898483]
    MDCK CC50
    > 50 μM
    Compound: Ribavirin
    Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    		[PMID: 34273661]
    MDCK CC50
    > 500 mg/mL
    Compound: Ribavirin
    Cytotoxicity against dog MDCK cells
    Cytotoxicity against dog MDCK cells
    		[PMID: 18160286]
    MDCK CC50
    > 512 μM
    Compound: ribavirin
    Cytotoxicity against MDCK cells by MTT assay
    Cytotoxicity against MDCK cells by MTT assay
    		[PMID: 18640042]
    MDCK CC50
    >= 20 μM
    Compound: ribavirin
    Cytotoxicity against dog MDCK cells assessed as cell viability after 72 hrs by MTS assay
    Cytotoxicity against dog MDCK cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 24900429]
    MDCK EC50
    0.094 μM
    Compound: Ribavirin
    Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis
    Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis
    		[PMID: 23117173]
    MDCK EC50
    0.14 μM
    Compound: Ribavirin
    Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay
    Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay
    		[PMID: 23117173]
    MDCK EC50
    1.05 μM
    Compound: RBV
    Antiviral activity against oseltamivir-resistant influenza A virus LN/1109 (H1N1) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay
    Antiviral activity against oseltamivir-resistant influenza A virus LN/1109 (H1N1) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay
    		[PMID: 26686929]
    MDCK EC50
    1.1 μM
    Compound: ribavirin
    Antiviral activity against influenza A virus H3N3 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay
    Antiviral activity against influenza A virus H3N3 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay
    		[PMID: 23811093]
    MDCK EC50
    1.43 μM
    Compound: RBV
    Antiviral activity against amantadine-resistant influenza A virus JX/312 (H3N2) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay
    Antiviral activity against amantadine-resistant influenza A virus JX/312 (H3N2) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay
    		[PMID: 26686929]
    MDCK EC50
    10 μM
    Compound: ribavirin
    Antiviral activity against amantadine-sensitive Influenza A virus (A/FM/1/47 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis
    Antiviral activity against amantadine-sensitive Influenza A virus (A/FM/1/47 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis
    		[PMID: 24900429]
    MDCK EC50
    10.2 μM
    Compound: 3
    Antiviral activity against Influenza B virus Malaysia/2506/2004 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days
    Antiviral activity against Influenza B virus Malaysia/2506/2004 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days
    		[PMID: 20231094]
    MDCK EC50
    11 μM
    Compound: RBV
    Antiviral activity against influenza A virus A/Padova/253/2011(H1N1) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay
    Antiviral activity against influenza A virus A/Padova/253/2011(H1N1) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay
    		[PMID: 24313730]
    MDCK EC50
    11 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay
    Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay
    		[PMID: 24974341]
    MDCK EC50
    11.2 μM
    Compound: 3
    Antiviral activity against Influenza A virus California/07/2009 /H1N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days
    Antiviral activity against Influenza A virus California/07/2009 /H1N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days
    		[PMID: 20231094]
    MDCK EC50
    11.5 μM
    Compound: Ribavirin
    Antiviral activity against Unidentified Influenza A virus (H1N1) infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    Antiviral activity against Unidentified Influenza A virus (H1N1) infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    		[PMID: 32214762]
    MDCK EC50
    11.7 μg/mL
    Compound: Ribavirin
    The compound was evaluated for inhibitory effect on the replication of influenza A subtype H1N1 yamagata/120/86 strain in MDCK cells
    The compound was evaluated for inhibitory effect on the replication of influenza A subtype H1N1 yamagata/120/86 strain in MDCK cells
    		10.1016/S0960-894X(97)10154-8
    MDCK EC50
    12 μM
    Compound: RBV
    Antiviral activity against Influenza A virus (A/Wisconsin/67/2005(H3N2)) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay
    Antiviral activity against Influenza A virus (A/Wisconsin/67/2005(H3N2)) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay
    		[PMID: 24313730]
    MDCK EC50
    12 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy
    Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy
    		[PMID: 24974341]
    MDCK EC50
    12 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay
    Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 25752526]
    MDCK EC50
    12 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis
    Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis
    		[PMID: 25752526]
    MDCK EC50
    12.5 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A H3N2 infected in MDCK cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against Influenza A H3N2 infected in MDCK cells assessed as protection against virus-induced cytopathicity
    		[PMID: 21565516]
    MDCK EC50
    12.8 μM
    Compound: RBV; Ribavirin
    Antiviral activity against Influenza A virus PR/8/34 infected in MDCK cells assessed as inhibition of plaque formation treated for 1 hr measured after 2 days by toluidine blue staining-based assay
    Antiviral activity against Influenza A virus PR/8/34 infected in MDCK cells assessed as inhibition of plaque formation treated for 1 hr measured after 2 days by toluidine blue staining-based assay
    		[PMID: 26924568]
    MDCK EC50
    12.9 μg/mL
    Compound: Ribavirin
    Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as cell viability after 2 days by MTS assay
    Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as cell viability after 2 days by MTS assay
    		[PMID: 20724039]
    MDCK EC50
    12 μg/mL
    Compound: Ribavirin
    Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    		[PMID: 20971531]
    MDCK EC50
    13.9 μM
    Compound: 3
    Antiviral activity against Influenza A virus Vietnam/1203/ 2004H/H5N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay
    Antiviral activity against Influenza A virus Vietnam/1203/ 2004H/H5N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay
    		[PMID: 20231094]
    MDCK EC50
    13.93 μM
    Compound: Ribavirin
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus B/Memphis/20/1996 infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus B/Memphis/20/1996 infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    		[PMID: 20350949]
    MDCK EC50
    14.3 μM
    Compound: ribavirin
    Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay
    Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay
    		[PMID: 17194832]
    MDCK EC50
    15.6 μM
    Compound: RBV
    Inhibition of Influenza A virus A/PR/8/34 infected in MDCK cells after 48 hrs by plaque reduction assay
    Inhibition of Influenza A virus A/PR/8/34 infected in MDCK cells after 48 hrs by plaque reduction assay
    		[PMID: 24785979]
    MDCK EC50
    16.4 μM
    Compound: 3
    Antiviral activity against Influenza A virus Wisconsin/67/2005/H3N2 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days
    Antiviral activity against Influenza A virus Wisconsin/67/2005/H3N2 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days
    		[PMID: 20231094]
    MDCK EC50
    16 μg/mL
    Compound: Ribavirin
    Antiviral activity against Influenza A virus (A/California/07/2009(H1N1)) infected in MDCK cell line assessed as reduction of virus induced cytopathic effect by neutral red assay
    Antiviral activity against Influenza A virus (A/California/07/2009(H1N1)) infected in MDCK cell line assessed as reduction of virus induced cytopathic effect by neutral red assay
    		[PMID: 26291036]
    MDCK EC50
    17 μM
    Compound: RBV
    Antiviral activity against oseltamivir-resistant Influenza A virus (A/Parma/24/2009(H1N1)) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay
    Antiviral activity against oseltamivir-resistant Influenza A virus (A/Parma/24/2009(H1N1)) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay
    		[PMID: 24313730]
    MDCK EC50
    18.43 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus (A/Perth/16/2009(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay
    Antiviral activity against Influenza A virus (A/Perth/16/2009(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay
    		[PMID: 23811085]
    MDCK EC50
    18.43 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus (A/duck/Minnesota/1525/1981(H5N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay
    Antiviral activity against Influenza A virus (A/duck/Minnesota/1525/1981(H5N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay
    		[PMID: 23811085]
    MDCK EC50
    19.4 μM
    Compound: 3
    Antiviral activity against Influenza A virus California/07/2009 /H1N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay
    Antiviral activity against Influenza A virus California/07/2009 /H1N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay
    		[PMID: 20231094]
    MDCK EC50
    19.5 μM
    Compound: 3
    Antiviral activity against Influenza B virus Malaysia/2506/2004 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay
    Antiviral activity against Influenza B virus Malaysia/2506/2004 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay
    		[PMID: 20231094]
    MDCK EC50
    19.67 μM
    Compound: Ribavirin
    Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Georgia/20/2006(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Georgia/20/2006(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    		[PMID: 20350949]
    MDCK EC50
    2 μM
    Compound: RBV
    Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as inhibition of plaque formation after 12 hrs by toluidine blue staining assay
    Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as inhibition of plaque formation after 12 hrs by toluidine blue staining assay
    		[PMID: 24313730]
    MDCK EC50
    2.1 μg/mL
    Compound: Ribavirin
    The compound was evaluated for inhibitory effect on the replication of influenza A subtype H2N2 murakami/4/64 strain in MDCK cells
    The compound was evaluated for inhibitory effect on the replication of influenza A subtype H2N2 murakami/4/64 strain in MDCK cells
    		10.1016/S0960-894X(97)10154-8
    MDCK EC50
    2.2 μg/mL
    Compound: Ribavirin
    The compound was evaluated for inhibitory effect on the replication of influenza A subtype H2N2 Adachi/2/57 in MDCK cells
    The compound was evaluated for inhibitory effect on the replication of influenza A subtype H2N2 Adachi/2/57 in MDCK cells
    		10.1016/S0960-894X(97)10154-8
    MDCK EC50
    2.3 μM
    Compound: Ribavirin
    Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity
    Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity
    		[PMID: 22464686]
    MDCK EC50
    2.5 μM
    Compound: ribavirin
    Antiviral activity against influenza A virus H1N1 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay
    Antiviral activity against influenza A virus H1N1 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay
    		[PMID: 23811093]
    MDCK EC50
    2.8 μM
    Compound: ribavirin
    Antiviral activity against influenza B virus infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay
    Antiviral activity against influenza B virus infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay
    		[PMID: 23811093]
    MDCK EC50
    20.2 μM
    Compound: 3
    Antiviral activity against Influenza A virus Wisconsin/67/2005/H3N2 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay
    Antiviral activity against Influenza A virus Wisconsin/67/2005/H3N2 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay
    		[PMID: 20231094]
    MDCK EC50
    20.92 μM
    Compound: Ribavirin
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Florida/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Florida/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    		[PMID: 20350949]
    MDCK EC50
    21 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay
    Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay
    		[PMID: 24974341]
    MDCK EC50
    23.3 μM
    Compound: 3
    Antiviral activity against Influenza A virus Solomon Islands/03/2006/H1N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days
    Antiviral activity against Influenza A virus Solomon Islands/03/2006/H1N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days
    		[PMID: 20231094]
    MDCK EC50
    23.6 μM
    Compound: 3
    Antiviral activity against Influenza A virus Gull/PA/4175/83/H5N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days
    Antiviral activity against Influenza A virus Gull/PA/4175/83/H5N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days
    		[PMID: 20231094]
    MDCK EC50
    23.75 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus (A/California/07/2009(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay
    Antiviral activity against Influenza A virus (A/California/07/2009(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay
    		[PMID: 23811085]
    MDCK EC50
    24 μg/mL
    Compound: Ribavirin
    Antiviral activity against Influenza A virus (A/California/07/2009(H1N1) infected in MDCK cell line assessed as reduction of virus induced cytopathic effect by visual assay
    Antiviral activity against Influenza A virus (A/California/07/2009(H1N1) infected in MDCK cell line assessed as reduction of virus induced cytopathic effect by visual assay
    		[PMID: 26291036]
    MDCK EC50
    25 μM
    Compound: Ribavirin
    Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus B/Memphis/20/1996 harboring neuraminidase R152K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus B/Memphis/20/1996 harboring neuraminidase R152K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    		[PMID: 20350949]
    MDCK EC50
    25.1 μM
    Compound: 3
    Antiviral activity against Influenza A virus Solomon Islands/03/2006/H1N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay
    Antiviral activity against Influenza A virus Solomon Islands/03/2006/H1N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay
    		[PMID: 20231094]
    MDCK EC50
    27.4 μM
    Compound: 3
    Antiviral activity against Influenza A virus Gull/PA/4175/83/H5N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay
    Antiviral activity against Influenza A virus Gull/PA/4175/83/H5N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay
    		[PMID: 20231094]
    MDCK EC50
    3.4 μM
    Compound: Ribavirin
    Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay
    Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 25752526]
    MDCK EC50
    3.56 μM
    Compound: RBV
    Antiviral activity against amantadine-resistant influenza A virus HN/1222 (H3N2) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay
    Antiviral activity against amantadine-resistant influenza A virus HN/1222 (H3N2) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay
    		[PMID: 26686929]
    MDCK EC50
    3.7 μM
    Compound: Ribavirin
    Antiviral activity against influenza A H2N2(A2 japan/305/57) in MDCK cells
    Antiviral activity against influenza A H2N2(A2 japan/305/57) in MDCK cells
    		[PMID: 12729645]
    MDCK EC50
    3.7 μg/mL
    Compound: Ribavirin
    Antiviral activity against influenza A virus NWS33 in MDCK cells assessed as inhibition of viral cytopathic effect by neutral red assay
    Antiviral activity against influenza A virus NWS33 in MDCK cells assessed as inhibition of viral cytopathic effect by neutral red assay
    		[PMID: 9214738]
    MDCK EC50
    32.5 μM
    Compound: 3
    Antiviral activity against Influenza A virus Duck/MN/1525/81/H5N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay
    Antiviral activity against Influenza A virus Duck/MN/1525/81/H5N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay
    		[PMID: 20231094]
    MDCK EC50
    34.2 μg/mL
    Compound: Ribavirin
    The compound was evaluated for inhibitory effect on the replication of influenza A subtype H1N1 Bangkok/10/83 strain in MDCK cells
    The compound was evaluated for inhibitory effect on the replication of influenza A subtype H1N1 Bangkok/10/83 strain in MDCK cells
    		10.1016/S0960-894X(97)10154-8
    MDCK EC50
    35.4 μM
    Compound: 3
    Antiviral activity against Influenza A virus Duck/MN/1525/81/H5N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days
    Antiviral activity against Influenza A virus Duck/MN/1525/81/H5N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days
    		[PMID: 20231094]
    MDCK EC50
    35.6 μM
    Compound: Ribavirin
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Washington/01/2007(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Washington/01/2007(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    		[PMID: 20350949]
    MDCK EC50
    35.7 μM
    Compound: ribavirin
    Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay
    Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay
    		[PMID: 17194832]
    MDCK EC50
    38.1 μM
    Compound: ribavirin
    Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by neutral red uptake assay
    Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by neutral red uptake assay
    		[PMID: 17194832]
    MDCK EC50
    4 μM
    Compound: ribavirin
    Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method
    Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method
    		[PMID: 19281225]
    MDCK EC50
    4.28 μM
    Compound: RBV
    Antiviral activity against influenza B virus B/SZ/155 infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay
    Antiviral activity against influenza B virus B/SZ/155 infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay
    		[PMID: 26686929]
    MDCK EC50
    4.3 μM
    Compound: 3
    Antiviral activity against Influenza A virus Hong Kong/213/2003/H5N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days
    Antiviral activity against Influenza A virus Hong Kong/213/2003/H5N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days
    		[PMID: 20231094]
    MDCK EC50
    4.3 μg/mL
    Compound: Ribavirin
    Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    		[PMID: 20971531]
    MDCK EC50
    4.5 μM
    Compound: Ribavirin
    Antiviral activity against influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity
    Antiviral activity against influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity
    		[PMID: 22464686]
    MDCK EC50
    4.6 μM
    Compound: Ribavirin
    Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 23099097]
    MDCK EC50
    4.6 μM
    Compound: Ribavirin
    Antiviral activity against IInfluenza A virus H3N2 A/HK/7/87 infected in MDCK cells after 4 days by MTS assay
    Antiviral activity against IInfluenza A virus H3N2 A/HK/7/87 infected in MDCK cells after 4 days by MTS assay
    		[PMID: 31753804]
    MDCK EC50
    4.8 μM
    Compound: Ribavirin
    Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay
    Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay
    		[PMID: 22459876]
    MDCK EC50
    4.8 μM
    Compound: ribavirin
    Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method
    Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method
    		[PMID: 19281225]
    MDCK EC50
    4.92 μM
    Compound: Ribavirin
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Georgia/17/2006(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Georgia/17/2006(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    		[PMID: 20350949]
    MDCK EC50
    43 μM
    Compound: ribavirin
    Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by neutral red uptake assay
    Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by neutral red uptake assay
    		[PMID: 17194832]
    MDCK EC50
    46.7 μM
    Compound: Ribavirin
    Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Texas/12/2007 (clone)(H3N2)) harboring neuraminidase E119I mutant and harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Texas/12/2007 (clone)(H3N2)) harboring neuraminidase E119I mutant and harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain
    		[PMID: 20350949]
    MDCK EC50
    5.1 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity
    Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity
    		[PMID: 22464686]
    MDCK EC50
    5.5 μg/mL
    Compound: Ribavirin
    The compound was evaluated for inhibitory effect on the replication of influenza B norway/1/80 strain in MDCK cells
    The compound was evaluated for inhibitory effect on the replication of influenza B norway/1/80 strain in MDCK cells
    		10.1016/S0960-894X(97)10154-8
    MDCK EC50
    5.6 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay
    Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay
    		[PMID: 22459876]
    MDCK EC50
    5.73 μM
    Compound: Ribavirin
    Antiviral activity against Influenza B virus (B/Florida/4/2006) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay
    Antiviral activity against Influenza B virus (B/Florida/4/2006) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay
    		[PMID: 23811085]
    MDCK EC50
    6 μM
    Compound: RBV
    Antiviral activity against Influenza B virus (B/Lee/1940) clinical isolate infected in MDCK cells assessed as inhibition of viral replication after 2 days by toluidine blue staining assay
    Antiviral activity against Influenza B virus (B/Lee/1940) clinical isolate infected in MDCK cells assessed as inhibition of viral replication after 2 days by toluidine blue staining assay
    		[PMID: 24313730]
    MDCK EC50
    6 μM
    Compound: RBV
    Antiviral activity against influenza A virus A/Padova/72/2011(H1N1) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay
    Antiviral activity against influenza A virus A/Padova/72/2011(H1N1) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay
    		[PMID: 24313730]
    MDCK EC50
    6 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 23099097]
    MDCK EC50
    6.1 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 23099097]
    MDCK EC50
    6.1 μg/mL
    Compound: Ribavirin
    The compound was evaluated for inhibitory effect on the replication of influenza A subtype H3N2 Philippine/2/82 in MDCK cells
    The compound was evaluated for inhibitory effect on the replication of influenza A subtype H3N2 Philippine/2/82 in MDCK cells
    		10.1016/S0960-894X(97)10154-8
    MDCK EC50
    6.7 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay
    Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay
    		[PMID: 22459876]
    MDCK EC50
    6.8 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A/PR/8/34 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay
    Antiviral activity against Influenza A/PR/8/34 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay
    		[PMID: 23149298]
    MDCK EC50
    6.8 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy
    Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy
    		[PMID: 24974341]
    MDCK EC50
    6.8 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy
    Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy
    		[PMID: 24974341]
    MDCK EC50
    6.8 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus H3N2 infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    Antiviral activity against Influenza A virus H3N2 infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    		[PMID: 32214762]
    MDCK EC50
    6.8 μM
    Compound: ribavirin
    Antiviral activity against Influenza A virus (A/PR/8/1934(H1N1)) infected in MDCK cells assessed as 1-log10 reduction in viral RNA copy number after 24 hrs by quantitative RT-PCR analysis
    Antiviral activity against Influenza A virus (A/PR/8/1934(H1N1)) infected in MDCK cells assessed as 1-log10 reduction in viral RNA copy number after 24 hrs by quantitative RT-PCR analysis
    		[PMID: 26288686]
    MDCK EC50
    6 μg/mL
    Compound: Ribavirin
    Antiviral activity against influenza B virus infected in MDCK cells assessed as cell viability after 2 days by MTS assay
    Antiviral activity against influenza B virus infected in MDCK cells assessed as cell viability after 2 days by MTS assay
    		[PMID: 20724039]
    MDCK EC50
    7 μM
    Compound: RBV
    Antiviral activity against influenza A virus A/Padova/30/2011(H1N1) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay
    Antiviral activity against influenza A virus A/Padova/30/2011(H1N1) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay
    		[PMID: 24313730]
    MDCK EC50
    7 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay
    Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay
    		[PMID: 20034711]
    MDCK EC50
    7 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days
    Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days
    		[PMID: 22459876]
    MDCK EC50
    7 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days
    Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days
    		[PMID: 22459876]
    MDCK EC50
    7 μM
    Compound: Ribavirin
    Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days
    Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days
    		[PMID: 22459876]
    MDCK EC50
    7 μM
    Compound: Ribavirin
    Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis
    Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis
    		[PMID: 25752526]
    MDCK EC50
    7 μM
    Compound: ribavirin
    Antiviral activity against Influenza A virus (A/HK/7/87 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect by MTS assay
    Antiviral activity against Influenza A virus (A/HK/7/87 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect by MTS assay
    		[PMID: 24900429]
    MDCK EC50
    7.2 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus H3N3 infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity
    Antiviral activity against Influenza A virus H3N3 infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity
    		[PMID: 23911856]
    MDCK EC50
    7.3 μM
    Compound: Ribavirin
    Antiviral activity against Influenza B virus infected in MDCK cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against Influenza B virus infected in MDCK cells assessed as protection against virus-induced cytopathicity
    		[PMID: 21565516]
    MDCK EC50
    7.3 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay
    Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay
    		[PMID: 24974341]
    MDCK EC50
    7.5 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus A/PR/8/34 infected in MDCK cells assessed as reduction of virus-induced cytopathic effect measured after 4 days by formazan-based MTS assay
    Antiviral activity against Influenza A virus A/PR/8/34 infected in MDCK cells assessed as reduction of virus-induced cytopathic effect measured after 4 days by formazan-based MTS assay
    		[PMID: 27112451]
    MDCK EC50
    7.6 μM
    Compound: ribavirin
    Antiviral activity against amantadine-sensitive Influenza A virus (A/Ned/378/05 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis
    Antiviral activity against amantadine-sensitive Influenza A virus (A/Ned/378/05 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis
    		[PMID: 24900429]
    MDCK EC50
    7.7 μM
    Compound: ribavirin
    Antiviral activity against Influenza A virus (A/HK/7/87 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis
    Antiviral activity against Influenza A virus (A/HK/7/87 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis
    		[PMID: 24900429]
    MDCK EC50
    7.8 μg/mL
    Compound: Ribavirin
    Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as cell viability after 2 days by MTS assay
    Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as cell viability after 2 days by MTS assay
    		[PMID: 20724039]
    MDCK EC50
    7.9 μg/mL
    Compound: Ribavirin
    The compound was evaluated for inhibitory effect on the replication of influenza A subtype H3N2 ishikawa/7/82 in MDCK cells
    The compound was evaluated for inhibitory effect on the replication of influenza A subtype H3N2 ishikawa/7/82 in MDCK cells
    		10.1016/S0960-894X(97)10154-8
    MDCK EC50
    7 μg/mL
    Compound: Ribavirin
    Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE
    Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE
    		[PMID: 20971531]
    MDCK EC50
    8 μM
    Compound: RBV
    Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay
    Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay
    		[PMID: 24313730]
    MDCK EC50
    8 μM
    Compound: RBV, Ribavirin
    Antiviral activity against Influenza A virus (A/PR/8/34) (H1N1) infected in MDCK cells assessed as reduction in plaque formation after 48 hrs by plaque reduction assay
    Antiviral activity against Influenza A virus (A/PR/8/34) (H1N1) infected in MDCK cells assessed as reduction in plaque formation after 48 hrs by plaque reduction assay
    		[PMID: 25856229]
    MDCK EC50
    8 μM
    Compound: ribavirin
    Antiviral activity against amantidine and rimantadine-resistant Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis
    Antiviral activity against amantidine and rimantadine-resistant Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis
    		[PMID: 24900429]
    MDCK EC50
    8.1 μM
    Compound: ribavirin
    Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method
    Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method
    		[PMID: 19281225]
    MDCK EC50
    8.1 μM
    Compound: ribavirin
    Antiviral activity against amantidine and rimantadine-resistant Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect by MTS assay
    Antiviral activity against amantidine and rimantadine-resistant Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect by MTS assay
    		[PMID: 24900429]
    MDCK EC50
    8.2 μM
    Compound: Ribavirin
    Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay
    Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay
    		[PMID: 24974341]
    MDCK EC50
    8.2 μM
    Compound: ribavirin
    Antiviral activity against amantadine-resistant Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect by MTS assay
    Antiviral activity against amantadine-resistant Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect by MTS assay
    		[PMID: 24900429]
    MDCK EC50
    8.3 μM
    Compound: Ribavirin
    Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity
    Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity
    		[PMID: 23911856]
    MDCK EC50
    8.3 μg/mL
    Compound: Ribavirin
    The compound was evaluated for inhibitory effect on the replication of influenza A subtype H1N1 PR8/34 strain in MDCK cells
    The compound was evaluated for inhibitory effect on the replication of influenza A subtype H1N1 PR8/34 strain in MDCK cells
    		10.1016/S0960-894X(97)10154-8
    MDCK EC50
    8.4 μM
    Compound: 3
    Antiviral activity against Influenza A virus Vietnam/1203/ 2004H/H5N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days
    Antiviral activity against Influenza A virus Vietnam/1203/ 2004H/H5N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days
    		[PMID: 20231094]
    MDCK EC50
    8.4 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay
    Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay
    		[PMID: 23117173]
    MDCK EC50
    8.4 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus H3N2 A/HK/7/87 infected in MDCK cells assessed as reduction in virus induced cytopathic effect after 4 days by microscopy based method
    Antiviral activity against Influenza A virus H3N2 A/HK/7/87 infected in MDCK cells assessed as reduction in virus induced cytopathic effect after 4 days by microscopy based method
    		[PMID: 31753804]
    MDCK EC50
    8.4 μM
    Compound: Ribavirin
    Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    		[PMID: 32214762]
    MDCK EC50
    8.4 μg/mL
    Compound: Ribavirin
    Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    		[PMID: 20971531]
    MDCK EC50
    8.5 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay
    Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay
    		[PMID: 23117173]
    MDCK EC50
    8.5 μg/mL
    Compound: Ribavirin
    The compound was evaluated for inhibitory effect on the replication of influenza B Singapore/222/79 strain in MDCK cells
    The compound was evaluated for inhibitory effect on the replication of influenza B Singapore/222/79 strain in MDCK cells
    		10.1016/S0960-894X(97)10154-8
    MDCK EC50
    8.68 μM
    Compound: ribavirin
    Antiviral activity against influenza A/Hong Kong/7/87 (H3N2) in MDCK cells assessed as inhibition of virus-induced cytopathic effect by MTS assay
    Antiviral activity against influenza A/Hong Kong/7/87 (H3N2) in MDCK cells assessed as inhibition of virus-induced cytopathic effect by MTS assay
    		[PMID: 17588747]
    MDCK EC50
    8.7 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity by MTS assay
    Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity by MTS assay
    		[PMID: 20805012]
    MDCK EC50
    8.7 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus A/PR/8/34 infected in MDCK cells assessed as reduction of virus induced cytopathic effect measured by visual scoring of cytopathic effect
    Antiviral activity against Influenza A virus A/PR/8/34 infected in MDCK cells assessed as reduction of virus induced cytopathic effect measured by visual scoring of cytopathic effect
    		[PMID: 27112451]
    MDCK EC50
    8.7 μM
    Compound: ribavirin
    Antiviral activity against amantadine-resistant Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis
    Antiviral activity against amantadine-resistant Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis
    		[PMID: 24900429]
    MDCK EC50
    8.8 μM
    Compound: ribavirin
    Antiviral activity against Influenza A virus (A/Ishikawa/7/82 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis
    Antiviral activity against Influenza A virus (A/Ishikawa/7/82 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis
    		[PMID: 24900429]
    MDCK EC50
    8.8 μM
    Compound: ribavirin
    Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis
    Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis
    		[PMID: 24900429]
    MDCK EC50
    8.9 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis
    Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis
    		[PMID: 23117173]
    MDCK EC50
    8.9 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis
    Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis
    		[PMID: 23117173]
    MDCK EC50
    8.9 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A/HK/7/87 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay
    Antiviral activity against Influenza A/HK/7/87 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay
    		[PMID: 23149298]
    MDCK EC50
    8.9 μM
    Compound: Ribavirin
    Antiviral activity against Influenza B/HK/5/72 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay
    Antiviral activity against Influenza B/HK/5/72 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay
    		[PMID: 23149298]
    MDCK EC50
    8.9 μM
    Compound: Ribavirin
    Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy
    Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy
    		[PMID: 24974341]
    MDCK EC50
    8.9 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay
    Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 25752526]
    MDCK EC50
    8400 μM
    Compound: ribavirin
    Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method
    Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method
    		[PMID: 19281225]
    MDCK EC50
    9 μM
    Compound: 1
    Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 20207546]
    MDCK EC50
    9 μM
    Compound: 1
    Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 20207546]
    MDCK EC50
    9 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay
    Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay
    		[PMID: 20034711]
    MDCK EC50
    9 μM
    Compound: Ribavirin
    Antiviral activity against Influenza B virus infected in MDCK cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay
    Antiviral activity against Influenza B virus infected in MDCK cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay
    		[PMID: 20034711]
    MDCK EC50
    9 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 24312722]
    MDCK EC50
    9 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 24312722]
    MDCK EC50
    9 μM
    Compound: Ribavirin
    Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 24312722]
    MDCK EC50
    9 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis
    Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis
    		[PMID: 25752526]
    MDCK EC50
    9 μM
    Compound: ribavirin
    Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method
    Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method
    		[PMID: 19281225]
    MDCK EC50
    9.4 μM
    Compound: 3
    Antiviral activity against Influenza A virus Hong Kong/213/2003/H5N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay
    Antiviral activity against Influenza A virus Hong Kong/213/2003/H5N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay
    		[PMID: 20231094]
    MDCK EC50
    9.6 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity
    Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity
    		[PMID: 23911856]
    MDCK EC50
    9.8 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as protection against virus-induced cytopathicity
    		[PMID: 21565516]
    MDCK EC50
    900 μM
    Compound: ribavirin
    Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method
    Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method
    		[PMID: 19281225]
    MDCK EC50
    9 μg/mL
    Compound: Ribavirin
    Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days
    Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days
    		[PMID: 20724039]
    MDCK EC50
    9 μg/mL
    Compound: Ribavirin
    Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days
    Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days
    		[PMID: 20724039]
    MDCK EC50
    9 μg/mL
    Compound: Ribavirin
    Antiviral activity against influenza B virus infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days
    Antiviral activity against influenza B virus infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days
    		[PMID: 20724039]
    MDCK EC50
    9 μg/mL
    Compound: Ribavirin
    Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE
    Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE
    		[PMID: 20971531]
    MDCK EC50
    9 μg/mL
    Compound: Ribavirin
    Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE
    Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE
    		[PMID: 20971531]
    MDCK ED50
    24.6 μM
    Compound: Ribavirin
    Antiviral activity against Influenza virus A/California/07/09 (H1N1) pdm09 infected in MDCK cells after 48 hrs followed by incubated in chicken erythrocytes for 1 hr by hemagglutinination based end-point dilution method
    Antiviral activity against Influenza virus A/California/07/09 (H1N1) pdm09 infected in MDCK cells after 48 hrs followed by incubated in chicken erythrocytes for 1 hr by hemagglutinination based end-point dilution method
    		[PMID: 23099095]
    MDCK IC50
    0.41 μM
    Compound: RIBA
    Antiviral activity against Influenza A virus A/Hong Kong/8/68(H3N2) infected in dog MDCK cells after 3 days by CPE assay
    Antiviral activity against Influenza A virus A/Hong Kong/8/68(H3N2) infected in dog MDCK cells after 3 days by CPE assay
    		[PMID: 23806112]
    MDCK IC50
    1.9 μM
    Compound: RBV
    Antiinfluenza activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 36 hrs
    Antiinfluenza activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 36 hrs
    		[PMID: 22341943]
    MDCK IC50
    1.92 μg/mL
    Compound: RBV
    Antiviral activity against Influenza A virus (A/FM/1/1947(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs
    Antiviral activity against Influenza A virus (A/FM/1/1947(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs
    		[PMID: 24583605]
    MDCK IC50
    100.8 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as compound concentration required for inhibiting influenza virus yield at 48 h post-infection by crystal violet staining based CPE inhibition assay
    Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as compound concentration required for inhibiting influenza virus yield at 48 h post-infection by crystal violet staining based CPE inhibition assay
    		[PMID: 21879714]
    MDCK IC50
    101 μM
    Compound: Ribavirin
    Antiviral activity against influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs by crystal violet staining assay
    Antiviral activity against influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs by crystal violet staining assay
    		[PMID: 24967847]
    MDCK IC50
    113.1 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) PR/8 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 48 hrs by crystal-violet staining-based assay
    Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) PR/8 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 48 hrs by crystal-violet staining-based assay
    		[PMID: 23886345]
    MDCK IC50
    114.8 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 48 hrs
    Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 48 hrs
    		[PMID: 22487178]
    MDCK IC50
    115 μM
    Compound: Ribavirin
    Antiviral activity against influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells incubated for 48 hrs assessed as inhibition of virus-induced cytopathic effect by crystal violet staining assay
    Antiviral activity against influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells incubated for 48 hrs assessed as inhibition of virus-induced cytopathic effect by crystal violet staining assay
    		[PMID: 26046820]
    MDCK IC50
    131 μM
    Compound: ribavirin
    Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs by crystal violet staining assay
    Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs by crystal violet staining assay
    		[PMID: 24499327]
    MDCK IC50
    14 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A/PR8/H1N1 virus infected in MDCK cells assessed as inhibition of virus yield after 24 hrs
    Antiviral activity against Influenza A/PR8/H1N1 virus infected in MDCK cells assessed as inhibition of virus yield after 24 hrs
    		[PMID: 24216089]
    MDCK IC50
    14.7 μM
    Compound: RBV
    Antiinfluenza activity against influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 36 hrs
    Antiinfluenza activity against influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 36 hrs
    		[PMID: 22341943]
    MDCK IC50
    15.2 μM
    Compound: ribavirin
    Antiviral activity against influenza B/Jingfang/76/98 in MDCK cells by CPE assay
    Antiviral activity against influenza B/Jingfang/76/98 in MDCK cells by CPE assay
    		[PMID: 17611105]
    MDCK IC50
    16.3 μM
    Compound: Ribavirin
    Inhibitory concentration against influenza virus B in MDCK cells
    Inhibitory concentration against influenza virus B in MDCK cells
    		[PMID: 7658442]
    MDCK IC50
    164 μM
    Compound: ribavirin
    Antiviral activity against influenza B/Sichuan/83/2000 virus in MDCK cells by CPE assay
    Antiviral activity against influenza B/Sichuan/83/2000 virus in MDCK cells by CPE assay
    		[PMID: 17611105]
    MDCK IC50
    176 μM
    Compound: ribavirin
    Antiviral activity against influenza A/Jingfang/262/95(H1N1) virus in MDCK cells by CPE assay
    Antiviral activity against influenza A/Jingfang/262/95(H1N1) virus in MDCK cells by CPE assay
    		[PMID: 17611105]
    MDCK IC50
    185.9 μM
    Compound: ribavirin
    Antiviral activity against influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect incubated for 48 hrs by crystal violet staining based assay
    Antiviral activity against influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect incubated for 48 hrs by crystal violet staining based assay
    		[PMID: 26114936]
    MDCK IC50
    2.06 mg/mL
    Compound: Ribavirin
    Antiviral activity against influenza A virus H3N2 (A3 China/15/90) expressed in dog MDCK cells assessed as reduction of virus-induced cytopathic effect
    Antiviral activity against influenza A virus H3N2 (A3 China/15/90) expressed in dog MDCK cells assessed as reduction of virus-induced cytopathic effect
    		[PMID: 18160286]
    MDCK IC50
    2.6 μg/mL
    Compound: ribavirin
    Antiviral activity against PIV3 in MDCK cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against PIV3 in MDCK cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 15104496]
    MDCK IC50
    2.6 μg/mL
    Compound: ribavirin
    Antiviral activity against RSV Long in MDCK cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against RSV Long in MDCK cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 15104496]
    MDCK IC50
    20.2 μM
    Compound: RIBA
    Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in dog MDCK cells after 3 days by CPE assay
    Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in dog MDCK cells after 3 days by CPE assay
    		[PMID: 23806112]
    MDCK IC50
    24.6 μg/mL
    Compound: Ribavirin
    Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as protection against virus-induced cytopathic effect after 48 hrs by crystal violet staining method
    Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as protection against virus-induced cytopathic effect after 48 hrs by crystal violet staining method
    		[PMID: 23411074]
    MDCK IC50
    3.27 μg/mL
    Compound: RBV
    Antiviral activity against Influenza B virus jifang/13/97 infected in MDCK cells assessed as inhibition of plaque formation after 3 to 4 days by crystal violet staining-based assay
    Antiviral activity against Influenza B virus jifang/13/97 infected in MDCK cells assessed as inhibition of plaque formation after 3 to 4 days by crystal violet staining-based assay
    		[PMID: 24583605]
    MDCK IC50
    3.73 μg/mL
    Compound: ribavirin
    Antiviral activity against influenza A H3N2 virus in MDCK cells
    Antiviral activity against influenza A H3N2 virus in MDCK cells
    		[PMID: 16183283]
    MDCK IC50
    3.9 μM
    Compound: RBV
    Antiinfluenza activity against influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 36 hrs
    Antiinfluenza activity against influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 36 hrs
    		[PMID: 22341943]
    MDCK IC50
    35.3 μM
    Compound: RBV
    Antiviral activity against Influenza A virus (A/Tianjin-Jinnan/15/2009(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against Influenza A virus (A/Tianjin-Jinnan/15/2009(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 22824205]
    MDCK IC50
    4.27 mg/mL
    Compound: Ribavirin
    Antiviral activity against influenza B virus expressed in dog MDCK cells assessed as reduction of virus-induced cytopathic effect
    Antiviral activity against influenza B virus expressed in dog MDCK cells assessed as reduction of virus-induced cytopathic effect
    		[PMID: 18160286]
    MDCK IC50
    4.9 μM
    Compound: Ribavirin
    Inhibitory concentration against influenza virus A in MDCK cells
    Inhibitory concentration against influenza virus A in MDCK cells
    		[PMID: 7658442]
    MDCK IC50
    42.6 μM
    Compound: ribavirin
    Antiviral activity against Influenza A virus infected in MDCK cells assessed as inhibition of virus-induced cytopathogenic effect by plaque reduction assay
    Antiviral activity against Influenza A virus infected in MDCK cells assessed as inhibition of virus-induced cytopathogenic effect by plaque reduction assay
    		[PMID: 19267453]
    MDCK IC50
    45.5 μM
    Compound: RBV
    Antiviral activity against Influenza B virus (strain B/Jifang/13/97) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against Influenza B virus (strain B/Jifang/13/97) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 22824205]
    MDCK IC50
    4 μg/mL
    Compound: ribavirin
    Tested for inhibitory effect on RNA virus Influenza A in MDCK cell line
    Tested for inhibitory effect on RNA virus Influenza A in MDCK cell line
    		[PMID: 8246242]
    MDCK IC50
    4 μg/mL
    Compound: ribavirin
    Tested for inhibitory effect on RNA virus Influenza B in MDCK cell line
    Tested for inhibitory effect on RNA virus Influenza B in MDCK cell line
    		[PMID: 8246242]
    MDCK IC50
    5.04 μM
    Compound: ribavirin
    Antiviral activity against influenza A/Jifang/15/90 (H3N2) virus in MDCK cells by CPE assay
    Antiviral activity against influenza A/Jifang/15/90 (H3N2) virus in MDCK cells by CPE assay
    		[PMID: 17611105]
    MDCK IC50
    5.59 μg/mL
    Compound: RBV
    Antiviral activity against Influenza A virus A/hanfang/359/95(H3N2) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs
    Antiviral activity against Influenza A virus A/hanfang/359/95(H3N2) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs
    		[PMID: 24583605]
    MDCK IC50
    5.85 μM
    Compound: ribavirin
    Antiviral activity against influenza A/Yuefang/243/72 (H3N2) virus in MDCK cells by CPE assay
    Antiviral activity against influenza A/Yuefang/243/72 (H3N2) virus in MDCK cells by CPE assay
    		[PMID: 17611105]
    MDCK IC50
    5.86 μM
    Compound: RBV
    Antiviral activity against influenza A virus (A/Hanfang/359/95(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenic effect dosed 1 hr after viral adsorption
    Antiviral activity against influenza A virus (A/Hanfang/359/95(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenic effect dosed 1 hr after viral adsorption
    		[PMID: 26132528]
    MDCK IC50
    6.5 μg/mL
    Compound: RBV
    Antiviral activity against oseltamivir-resistant Influenza A virus (A/Tianjinjinnan/15/2009/H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs
    Antiviral activity against oseltamivir-resistant Influenza A virus (A/Tianjinjinnan/15/2009/H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs
    		[PMID: 24583605]
    MDCK IC50
    62.5 μg/mL
    Compound: ribavirin
    Antiviral activity against influenza virus type A H1N1 in MDCK cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against influenza virus type A H1N1 in MDCK cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 15104496]
    MDCK IC50
    62.5 μg/mL
    Compound: ribavirin
    Cytotoxicity against MDCK cells
    Cytotoxicity against MDCK cells
    		[PMID: 15104496]
    MDCK IC50
    7.01 μM
    Compound: ribavirin
    Antiviral activity against influenza A/Hanfang/359/95 (H3N2) virus in MDCK cells by CPE assay
    Antiviral activity against influenza A/Hanfang/359/95 (H3N2) virus in MDCK cells by CPE assay
    		[PMID: 17611105]
    MDCK IC50
    7.84 μg/mL
    Compound: RBV
    Antiviral activity against Influenza B virus jifang/13/97 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs
    Antiviral activity against Influenza B virus jifang/13/97 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs
    		[PMID: 24583605]
    MDCK IC50
    8.8 μM
    Compound: RBV
    Antiviral activity against Influenza A virus (A/Guangdong-Luohu/219/2006(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against Influenza A virus (A/Guangdong-Luohu/219/2006(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 22824205]
    MDCK IC50
    84 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs by crystal violet staining technique
    Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs by crystal violet staining technique
    		[PMID: 24495078]
    MDCK IC50
    87 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus H1N1 infected in dog MDCK cells after 48 hrs by CPE inhibition assay
    Antiviral activity against Influenza A virus H1N1 infected in dog MDCK cells after 48 hrs by CPE inhibition assay
    		[PMID: 23758051]
    MDCK IC50
    87.7 μg/mL
    Compound: Ribavirin
    Antiviral activity against Influenza A virus H3N2 A3/JINGKE/30/95 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs
    Antiviral activity against Influenza A virus H3N2 A3/JINGKE/30/95 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs
    		[PMID: 26791013]
    MDCK IC50
    9 μM
    Compound: ribavirin
    Antiviral activity against Influenza B virus infected in MDCK cells after 3 days by neutral red dye-based plaque reduction assay
    Antiviral activity against Influenza B virus infected in MDCK cells after 3 days by neutral red dye-based plaque reduction assay
    		[PMID: 26260336]
    MDCK IC50
    96.2 μM
    Compound: ribavirin
    Antiviral activity against influenza B/Jifang/13/97 virus in MDCK cells by CPE assay
    Antiviral activity against influenza B/Jifang/13/97 virus in MDCK cells by CPE assay
    		[PMID: 17611105]
    MDCK IC50
    98.3 μM
    Compound: Ribavirin
    Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect incubated for 48 hrs by crystal violet staining based assay
    Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect incubated for 48 hrs by crystal violet staining based assay
    		[PMID: 32520560]
    MDCK IC50
    > 1310 μM
    Compound: 3
    Cytotoxicity against MDCK cells after 3 days by neutral red dye uptake assay
    Cytotoxicity against MDCK cells after 3 days by neutral red dye uptake assay
    		[PMID: 20231094]
    MDCK IC50
    > 200 μg/mL
    Compound: Ribavirin
    Cytotoxicity against MDCK cells by neutral red assay
    Cytotoxicity against MDCK cells by neutral red assay
    		[PMID: 9214738]
    MDCK IC50
    > 200 μg/mL
    Compound: ribavirin
    Tested for inhibitory effect on RNA virus cell morphology in MDCK cell line
    Tested for inhibitory effect on RNA virus cell morphology in MDCK cell line
    		[PMID: 8246242]
    MOLT-4 IC50
    5.7 μM
    Compound: Ribavirin
    Compound was tested for its effect on the proliferation of MOLT-4 human lymphoblastic T-leukemia cell line.
    Compound was tested for its effect on the proliferation of MOLT-4 human lymphoblastic T-leukemia cell line.
    		10.1016/0960-894X(96)00216-8
    MT4 CC50
    31 μM
    Compound: Ribavirin
    Cytotoxicity against human MT4 cells after 96 hrs by MTT assay
    Cytotoxicity against human MT4 cells after 96 hrs by MTT assay
    		[PMID: 19482481]
    MT4 CC50
    31 μM
    Compound: Ribavirin
    Cytotoxicity against human MT4 cells after 96 hrs by MTT assay
    Cytotoxicity against human MT4 cells after 96 hrs by MTT assay
    		[PMID: 20359898]
    MT4 CC50
    31 μM
    Compound: Ribavirin
    Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay
    Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay
    		[PMID: 25082514]
    MT4 CC50
    31 μM
    Compound: Ribavirin
    Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay
    Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay
    		[PMID: 26443549]
    MT4 IC50
    23 μM
    Compound: Ribavirin
    Compound was tested for its effect on the proliferation of MT-4 cells expressing the TAT gene of HTLV-1.
    Compound was tested for its effect on the proliferation of MT-4 cells expressing the TAT gene of HTLV-1.
    		10.1016/0960-894X(96)00216-8
    MT4 IC50
    6.5 μg/mL
    Compound: ribavirin
    Tested for inhibitory effect on RNA virus cell growth in MT-4 cell line
    Tested for inhibitory effect on RNA virus cell growth in MT-4 cell line
    		[PMID: 8246242]
    MT4 IC50
    > 5 μg/mL
    Compound: ribavirin
    Tested for inhibitory effect on RNA virus HIV-1 in MT-4 cell line
    Tested for inhibitory effect on RNA virus HIV-1 in MT-4 cell line
    		[PMID: 8246242]
    MT4 IC50
    > 5 μg/mL
    Compound: ribavirin
    Tested for inhibitory effect on RNA virus HIV-2 in MT-4 cell line
    Tested for inhibitory effect on RNA virus HIV-2 in MT-4 cell line
    		[PMID: 8246242]
    RD CC50
    1485 μM
    Compound: Ribavirin
    Cytotoxicity against human RD cells assessed as reduction in cell viability after 12 hrs by CCK8 assay
    Cytotoxicity against human RD cells assessed as reduction in cell viability after 12 hrs by CCK8 assay
    		[PMID: 31063370]
    RD CC50
    485.9 μg/mL
    Compound: Ribavirin
    Cytotoxicity against human RD cells assessed as reduction in cell viability after 3 days by MTT assay
    Cytotoxicity against human RD cells assessed as reduction in cell viability after 3 days by MTT assay
    		[PMID: 28858766]
    RD IC50
    60 μg/mL
    Compound: Ribavirin
    Antiviral activity against C4 type Human enterovirus 71 FY0805 infected in human RD cells assessed as inhibition of viral replication by plaque reduction assay
    Antiviral activity against C4 type Human enterovirus 71 FY0805 infected in human RD cells assessed as inhibition of viral replication by plaque reduction assay
    		[PMID: 22342145]
    Raji IC50
    56 μM
    Compound: Ribavirin
    Compound was tested for its effect on the proliferation of RAJI burkitt lymphoma cell line.
    Compound was tested for its effect on the proliferation of RAJI burkitt lymphoma cell line.
    		10.1016/0960-894X(96)00216-8
    Rhabdomyosarcoma cell CC50
    > 500 μg/mL
    Compound: Ribavirin
    Cytotoxicity against human rhabdomyosarcoma cells after 72 hrs by MTT assay
    Cytotoxicity against human rhabdomyosarcoma cells after 72 hrs by MTT assay
    		[PMID: 23920438]
    SK-OV-3 IC50
    10 μg/mL
    Compound: RBV
    Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 4 days by trypan blue exclusion assay
    Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 4 days by trypan blue exclusion assay
    		[PMID: 31883488]
    SK-OV-3 IC50
    10 μg/mL
    Compound: RBV
    Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 7 days by trypan blue exclusion assay
    Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 7 days by trypan blue exclusion assay
    		[PMID: 31883488]
    SK-OV-3 IC50
    9 μg/mL
    Compound: RBV
    Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 3 days by trypan blue exclusion assay
    Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 3 days by trypan blue exclusion assay
    		[PMID: 31883488]
    SNB-19 CC50
    485.2 μM
    Compound: Ribavirin
    Cytotoxicity against human SNB-19 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    Cytotoxicity against human SNB-19 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    		[PMID: 35306290]
    SNB-75 IC50
    18.53 μM
    Compound: RBV
    Antiproliferative activity against human SNB-75 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human SNB-75 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 31883488]
    Vero CC50
    0.3 μM
    Compound: Ribavirin
    Cytotoxicity against African green monkey Vero E6 cells
    Cytotoxicity against African green monkey Vero E6 cells
    		[PMID: 27262598]
    Vero CC50
    1245 μM
    Compound: RBV
    Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTS assay
    Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTS assay
    		[PMID: 35661850]
    Vero CC50
    156 μM
    Compound: Ribavirin
    Cytotoxicity against african green monkey Vero cells after 7 to 8 days by neutral-red dye uptake assay
    Cytotoxicity against african green monkey Vero cells after 7 to 8 days by neutral-red dye uptake assay
    		[PMID: 17606691]
    Vero CC50
    1622 μM
    Compound: 95
    Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 4 days by MTT assay
    Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 4 days by MTT assay
    		[PMID: 28689975]
    Vero CC50
    297 μM
    Compound: Ribavirin
    Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay
    		[PMID: 31843348]
    Vero CC50
    300 μM
    Compound: Ribavirin
    Cytotoxicity against African green monkey Vero cells by MTT assay
    Cytotoxicity against African green monkey Vero cells by MTT assay
    		[PMID: 33822611]
    Vero CC50
    3931 μM
    Compound: Ribavirin
    Cytotoxicity against African green monkey Vero cells infected with Tacaribe virus TRVL11573 by neutral red dye based analysis
    Cytotoxicity against African green monkey Vero cells infected with Tacaribe virus TRVL11573 by neutral red dye based analysis
    		[PMID: 36898483]
    Vero CC50
    409 μM
    Compound: ribavirin
    Cytotoxicity against african green monkey Vero B cells
    Cytotoxicity against african green monkey Vero B cells
    		[PMID: 26039671]
    Vero CC50
    470.5 μM
    Compound: Ribavirin
    Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    		[PMID: 35306290]
    Vero CC50
    8189.67 μM
    Compound: Ribavirin
    Cytotoxicity against african green monkey Vero cells after 96 hrs by MTT assay
    Cytotoxicity against african green monkey Vero cells after 96 hrs by MTT assay
    		[PMID: 23999140]
    Vero CC50
    > 100 μM
    Compound: 9
    Cytotoxicity against African green monkey Vero cells
    Cytotoxicity against African green monkey Vero cells
    		[PMID: 31549836]
    Vero CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against african green monkey Vero 76 cells by crystal violet staining
    Cytotoxicity against african green monkey Vero 76 cells by crystal violet staining
    		[PMID: 19482481]
    Vero CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against african green monkey Vero cells
    Cytotoxicity against african green monkey Vero cells
    		[PMID: 20359898]
    Vero CC50
    > 1000 μM
    Compound: Ribavirin
    Cytotoxicity against African green monkey Vero cells after 4 days by MTT assay
    Cytotoxicity against African green monkey Vero cells after 4 days by MTT assay
    		[PMID: 24679044]
    Vero CC50
    > 250 μM
    Compound: Ribavirin
    Cytotoxicity against Human coxsackievirus B4 infected african green monkey Vero cells by trypan blue exclusion method
    Cytotoxicity against Human coxsackievirus B4 infected african green monkey Vero cells by trypan blue exclusion method
    		[PMID: 20034711]
    Vero CC50
    > 250 μM
    Compound: Ribavirin
    Cytotoxicity against PIV 3 infected african green monkey Vero cells by trypan blue exclusion method
    Cytotoxicity against PIV 3 infected african green monkey Vero cells by trypan blue exclusion method
    		[PMID: 20034711]
    Vero CC50
    > 250 μM
    Compound: Ribavirin
    Cytotoxicity against Punta Toro virus infected african green monkey Vero cells by trypan blue exclusion method
    Cytotoxicity against Punta Toro virus infected african green monkey Vero cells by trypan blue exclusion method
    		[PMID: 20034711]
    Vero CC50
    > 250 μM
    Compound: Ribavirin
    Cytotoxicity against Reovirus 1 infected african green monkey Vero cells by trypan blue exclusion method
    Cytotoxicity against Reovirus 1 infected african green monkey Vero cells by trypan blue exclusion method
    		[PMID: 20034711]
    Vero CC50
    > 250 μM
    Compound: Ribavirin
    Cytotoxicity against Sindbis virus infected african green monkey Vero cells by trypan blue exclusion method
    Cytotoxicity against Sindbis virus infected african green monkey Vero cells by trypan blue exclusion method
    		[PMID: 20034711]
    Vero CC50
    > 3562 μM
    Compound: Ribavirin
    Cytotoxicity against African green monkey Vero cells infected in Pichinde virus AN 4763 by neutral red dye based analysis
    Cytotoxicity against African green monkey Vero cells infected in Pichinde virus AN 4763 by neutral red dye based analysis
    		[PMID: 36898483]
    Vero CC50
    > 400 μM
    Compound: 73
    Cytotoxicity against African green monkey Vero cells by CCK8 assay method
    Cytotoxicity against African green monkey Vero cells by CCK8 assay method
    		[PMID: 33070079]
    Vero CC50
    > 400 μM
    Compound: Ribavirin
    Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 30612844]
    Vero CC50
    > 400 μg/mL
    Compound: ribavirin
    Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of Vero cells
    Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of Vero cells
    		[PMID: 8709116]
    Vero CC50
    > 4094 μM
    Compound: Ribavirin
    Cytotoxicity against African green monkey Vero cells infected in Pichinde virus AN 4763 by visual analysis
    Cytotoxicity against African green monkey Vero cells infected in Pichinde virus AN 4763 by visual analysis
    		[PMID: 36898483]
    Vero CC50
    > 4094 μM
    Compound: Ribavirin
    Cytotoxicity against African green monkey Vero cells infected with Tacaribe virus TRVL11573 by visual analysis
    Cytotoxicity against African green monkey Vero cells infected with Tacaribe virus TRVL11573 by visual analysis
    		[PMID: 36898483]
    Vero CC50
    > 410 μM
    Compound: Ribavirin
    Cytotoxicity against DENV serotype 2 strain New Guinea C infected african green monkey Vero B cells by virus yield-reduction assay
    Cytotoxicity against DENV serotype 2 strain New Guinea C infected african green monkey Vero B cells by virus yield-reduction assay
    		[PMID: 25791449]
    Vero CC50
    > 4100 μM
    Compound: Ribavirin
    Cytotoxicity against African green monkey Vero cells by luciferase-based cell viability assay
    Cytotoxicity against African green monkey Vero cells by luciferase-based cell viability assay
    		[PMID: 18955536]
    Vero CC50
    > 500 μM
    Compound: Ribavirin
    Cytotoxicity against Vero cells
    Cytotoxicity against Vero cells
    		[PMID: 17181162]
    Vero CC50
    > 850 μM
    Compound: ribavirin
    Cytotoxicity against Vero E6 cells
    Cytotoxicity against Vero E6 cells
    		[PMID: 17336519]
    Vero EC50
    10 μM
    Compound: Ribavirin
    Antiviral activity against Tacaribe virus TRVL11573 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days
    Antiviral activity against Tacaribe virus TRVL11573 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days
    		[PMID: 17606691]
    Vero EC50
    100 μM
    Compound: Ribavirin
    Antiviral activity against Punta Toro virus in Vero cells
    Antiviral activity against Punta Toro virus in Vero cells
    		[PMID: 17181162]
    Vero EC50
    100 μM
    Compound: Ribavirin
    Antiviral activity against reovirus 1 in Vero cells
    Antiviral activity against reovirus 1 in Vero cells
    		[PMID: 17181162]
    Vero EC50
    11 μM
    Compound: Ribavirin
    Antiviral activity against Junin virus Candid-1 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days
    Antiviral activity against Junin virus Candid-1 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days
    		[PMID: 17606691]
    Vero EC50
    111 μM
    Compound: Ribavirin
    Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay
    Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay
    		[PMID: 20034711]
    Vero EC50
    112 μM
    Compound: Ribavirin
    Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity
    Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity
    		[PMID: 23911856]
    Vero EC50
    112 μM
    Compound: Ribavirin
    Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 26001344]
    Vero EC50
    112 μM
    Compound: Ribavirin
    Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis
    Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis
    		[PMID: 26114811]
    Vero EC50
    112 μM
    Compound: Ribavirin
    Antiviral activity against Para-influenza-3 virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis
    Antiviral activity against Para-influenza-3 virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis
    		[PMID: 27979594]
    Vero EC50
    112 μM
    Compound: Ribavirin
    Antiviral activity against Yellow fever virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis
    Antiviral activity against Yellow fever virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis
    		[PMID: 27979594]
    Vero EC50
    112 μM
    Compound: Ribavirin
    Antiviral activity against para influenza 3 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis
    Antiviral activity against para influenza 3 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis
    		[PMID: 28477572]
    Vero EC50
    112 μM
    Compound: Ribavirin
    Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    		[PMID: 32214762]
    Vero EC50
    112 μg/mL
    Compound: Ribavirin
    Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    		[PMID: 20971531]
    Vero EC50
    112 μg/mL
    Compound: Ribavirin
    Antiviral activity against Reovirus 1 virus infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    Antiviral activity against Reovirus 1 virus infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    		[PMID: 20971531]
    Vero EC50
    119 μM
    Compound: Ribavirin
    Inhibition of West Nile viral Rluc-Neo-Rep in Vero cells
    Inhibition of West Nile viral Rluc-Neo-Rep in Vero cells
    		[PMID: 16539402]
    Vero EC50
    120 μg/mL
    Compound: ribavirin
    Antiviral activity against Parainfluenza 3 in Vero cells reduction of virus-induced cytopathogenicity after 4 days
    Antiviral activity against Parainfluenza 3 in Vero cells reduction of virus-induced cytopathogenicity after 4 days
    		[PMID: 17948980]
    Vero EC50
    120 μg/mL
    Compound: ribavirin
    Antiviral activity against Sindbis virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days
    Antiviral activity against Sindbis virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days
    		[PMID: 17948980]
    Vero EC50
    121 μM
    Compound: Ribavirin
    Antiviral activity against Parainfluenza virus 3 infected in Vero cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against Parainfluenza virus 3 infected in Vero cells assessed as protection against virus-induced cytopathicity
    		[PMID: 21565516]
    Vero EC50
    125 μM
    Compound: Ribavirin
    Antiviral activity against Punta Toro virus infected in Vero cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against Punta Toro virus infected in Vero cells assessed as protection against virus-induced cytopathicity
    		[PMID: 21565516]
    Vero EC50
    126 μM
    Compound: Ribavirin
    Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity
    Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity
    		[PMID: 22464686]
    Vero EC50
    126 μM
    Compound: Ribavirin
    Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 24312722]
    Vero EC50
    126 μM
    Compound: ribavirin
    Antiviral activity against Punts virus B4 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Punts virus B4 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 23811093]
    Vero EC50
    12 μg/mL
    Compound: Ribavirin
    Antiviral activity against Pichinde virus infected in African green monkey Vero cells assessed as reduction in virus induced cytopathic effect
    Antiviral activity against Pichinde virus infected in African green monkey Vero cells assessed as reduction in virus induced cytopathic effect
    		[PMID: 31431358]
    Vero EC50
    13 μM
    Compound: Ribavirin
    Antiviral activity against Pichinde virus An 4763 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days
    Antiviral activity against Pichinde virus An 4763 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days
    		[PMID: 17606691]
    Vero EC50
    13.5 μM
    Compound: RIBA
    Antiviral activity against DENV-2 New guinea infected in African green monkey Vero cells assessed as reduction in plaque formation administered post viral infection after 8 days by crystal violet staining technique
    Antiviral activity against DENV-2 New guinea infected in African green monkey Vero cells assessed as reduction in plaque formation administered post viral infection after 8 days by crystal violet staining technique
    		[PMID: 26638041]
    Vero EC50
    146 μM
    Compound: Ribavirin
    Antiviral activity against Punta Toro virus infected Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    Antiviral activity against Punta Toro virus infected Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    		10.1007/s00044-009-9248-y
    Vero EC50
    146 μM
    Compound: Ribavirin
    Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    		[PMID: 22459876]
    Vero EC50
    146 μM
    Compound: ribavirin
    Antiviral activity against Reovirus 1 in african green monkey Vero cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against Reovirus 1 in african green monkey Vero cells assessed as protection against virus-induced cytopathicity
    		[PMID: 19281225]
    Vero EC50
    146 μM
    Compound: ribavirin
    Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 23811093]
    Vero EC50
    146 μg/mL
    Compound: Ribavirin
    Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    		[PMID: 18851889]
    Vero EC50
    146 μg/mL
    Compound: Ribavirin
    Antiviral activity against Para influenza-3 virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days
    Antiviral activity against Para influenza-3 virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days
    		[PMID: 20724039]
    Vero EC50
    146 μg/mL
    Compound: Ribavirin
    Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days
    Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days
    		[PMID: 20724039]
    Vero EC50
    146 μg/mL
    Compound: ribavirin
    Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days
    Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days
    		[PMID: 19419804]
    Vero EC50
    150 μM
    Compound: Ribavirin
    Antiviral activity against Punta Toro virus expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity
    Antiviral activity against Punta Toro virus expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity
    		[PMID: 26291038]
    Vero EC50
    150 μM
    Compound: ribavirin
    Antiviral activity against Punta Toro virus in Vero cells assessed as reduction of virus plaque formation after 7 days
    Antiviral activity against Punta Toro virus in Vero cells assessed as reduction of virus plaque formation after 7 days
    		[PMID: 17539622]
    Vero EC50
    150 μM
    Compound: ribavirin
    Antiviral activity against parainfluenza 3 virus in Vero cells assessed as reduction of virus plaque formation after 7 days
    Antiviral activity against parainfluenza 3 virus in Vero cells assessed as reduction of virus plaque formation after 7 days
    		[PMID: 17539622]
    Vero EC50
    18.5 μM
    Compound: Ribavirin
    Antiviral activity against Junin virus IV4454 infected in african green monkey Vero cells assessed as reduction in virus yield after 48 hrs by plaque assay
    Antiviral activity against Junin virus IV4454 infected in african green monkey Vero cells assessed as reduction in virus yield after 48 hrs by plaque assay
    		[PMID: 21115214]
    Vero EC50
    18.5 μM
    Compound: Ribavirin
    Antiviral activity against Junin virus IV4454 infected in African green monkey Vero cells assessed as reduction in vrius yield after 48 hrs by plaque assay
    Antiviral activity against Junin virus IV4454 infected in African green monkey Vero cells assessed as reduction in vrius yield after 48 hrs by plaque assay
    		[PMID: 30612844]
    Vero EC50
    183 μM
    Compound: 1
    Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 20207546]
    Vero EC50
    196 μM
    Compound: Ribavirin
    Effective concentration required to inhibit parainfluenza-3 virus-induced cytopathicity by 50% in Vero cell lines
    Effective concentration required to inhibit parainfluenza-3 virus-induced cytopathicity by 50% in Vero cell lines
    		[PMID: 11495586]
    Vero EC50
    2.42 μM
    Compound: Ribavirin
    Antiviral activity against Chikungunya virus infected in African green monkey Vero cells assessed as reduction in viral replication treated with compound at 1 hr post-viral infection
    Antiviral activity against Chikungunya virus infected in African green monkey Vero cells assessed as reduction in viral replication treated with compound at 1 hr post-viral infection
    		[PMID: 31843348]
    Vero EC50
    20.8 μM
    Compound: 9
    Inhibition of RNA-dependent RNA polymerase in Zika virus MR766 infected in African green monkey Vero cells assessed as antiviral activity after 72 hrs by DAPI staining based assay
    Inhibition of RNA-dependent RNA polymerase in Zika virus MR766 infected in African green monkey Vero cells assessed as antiviral activity after 72 hrs by DAPI staining based assay
    		[PMID: 31549836]
    Vero EC50
    200 μg/mL
    Compound: ribavirin
    Antiviral activity against Reovirus 1 in Vero cells reduction of virus-induced cytopathogenicity after 4 days
    Antiviral activity against Reovirus 1 in Vero cells reduction of virus-induced cytopathogenicity after 4 days
    		[PMID: 17948980]
    Vero EC50
    240 μg/mL
    Compound: ribavirin
    Antiviral activity against coxsackie B4 virus in Vero cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against coxsackie B4 virus in Vero cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 17298047]
    Vero EC50
    240 μg/mL
    Compound: ribavirin
    Antiviral activity against sindbis virus in Vero cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against sindbis virus in Vero cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 17298047]
    Vero EC50
    250 μM
    Compound: Ribavirin
    Antiviral activity against Reovirus 1 infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay
    Antiviral activity against Reovirus 1 infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay
    		[PMID: 20034711]
    Vero EC50
    250 μM
    Compound: Ribavirin
    Antiviral activity against Coxsackievirus B4 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis
    Antiviral activity against Coxsackievirus B4 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis
    		[PMID: 26114811]
    Vero EC50
    250 μM
    Compound: ribavirin
    Antiviral activity against reovirus1 virus in Vero cells assessed as reduction of virus plaque formation after 7 days
    Antiviral activity against reovirus1 virus in Vero cells assessed as reduction of virus plaque formation after 7 days
    		[PMID: 17539622]
    Vero EC50
    250 μM
    Compound: ribavirin
    Antiviral activity against Sindbis virus in african green monkey Vero cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against Sindbis virus in african green monkey Vero cells assessed as protection against virus-induced cytopathicity
    		[PMID: 19281225]
    Vero EC50
    250 μg/mL
    Compound: Ribavirin
    Antiviral activity against Coxsackie virus B4 infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    Antiviral activity against Coxsackie virus B4 infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    		[PMID: 20971531]
    Vero EC50
    28 μM
    Compound: Ribavirin
    Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect by microscopic analysis
    Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect by microscopic analysis
    		[PMID: 18955536]
    Vero EC50
    29 μM
    Compound: Ribavirin
    Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    		[PMID: 22459876]
    Vero EC50
    29 μM
    Compound: Ribavirin
    Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis
    Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis
    		[PMID: 28477572]
    Vero EC50
    3.95 μM
    Compound: Ribavirin
    Antiviral activity against Zika virus infected in African green monkey Vero cells assessed as reduction in viral replication treated with compound at 1 hr post-viral infection
    Antiviral activity against Zika virus infected in African green monkey Vero cells assessed as reduction in viral replication treated with compound at 1 hr post-viral infection
    		[PMID: 31843348]
    Vero EC50
    30 μM
    Compound: Ribavirin
    Inhibition of Rluc-FL-WNV replicon in Vero cells
    Inhibition of Rluc-FL-WNV replicon in Vero cells
    		[PMID: 16539402]
    Vero EC50
    300 μM
    Compound: Ribavirin
    Antiviral activity against para influenza 3 virus in Vero cells
    Antiviral activity against para influenza 3 virus in Vero cells
    		[PMID: 17181162]
    Vero EC50
    35 μM
    Compound: Ribavirin
    Antiviral activity against RSV infected in African green monkey Vero 76 cells after 5 days by plaque reduction assay
    Antiviral activity against RSV infected in African green monkey Vero 76 cells after 5 days by plaque reduction assay
    		[PMID: 25913116]
    Vero EC50
    40 μM
    Compound: Ribavirin
    Effective concentration required to inhibit PuntaToro virus-induced cytopathicity by 50% in Vero cell lines
    Effective concentration required to inhibit PuntaToro virus-induced cytopathicity by 50% in Vero cell lines
    		[PMID: 11495586]
    Vero EC50
    40 μM
    Compound: Ribavirin
    Effective concentration required to inhibit reovirus-induced cytopathicity by 50% in Vero cell lines
    Effective concentration required to inhibit reovirus-induced cytopathicity by 50% in Vero cell lines
    		[PMID: 11495586]
    Vero EC50
    40 μg/mL
    Compound: ribavirin
    Antiviral activity against Punta Toro virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days
    Antiviral activity against Punta Toro virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days
    		[PMID: 17948980]
    Vero EC50
    42 μM
    Compound: ribavirin
    Antiviral activity against DENV serotype 2 strain New Guinea V infected in African green monkey Vero B cells assessed as inhibition of virus replication after 4 days by qRT-PCR analysis
    Antiviral activity against DENV serotype 2 strain New Guinea V infected in African green monkey Vero B cells assessed as inhibition of virus replication after 4 days by qRT-PCR analysis
    		[PMID: 26039671]
    Vero EC50
    45 μM
    Compound: Ribavirin
    Antiviral activity against Human parainfluenza virus 3 infected Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    Antiviral activity against Human parainfluenza virus 3 infected Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    		10.1007/s00044-009-9248-y
    Vero EC50
    45 μg/mL
    Compound: Ribavirin
    Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    		[PMID: 18851889]
    Vero EC50
    45 μg/mL
    Compound: ribavirin
    Antiviral activity against Parainfluenza virus type 3 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days
    Antiviral activity against Parainfluenza virus type 3 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days
    		[PMID: 19419804]
    Vero EC50
    47.9 μM
    Compound: Ribavirin
    Antiviral activity against DENV serotype 2 strain New Guinea C infected in african green monkey Vero cells assessed as reduction in production and release of infectious progeny virions after 2 hrs by virus yield-reduction assay
    Antiviral activity against DENV serotype 2 strain New Guinea C infected in african green monkey Vero cells assessed as reduction in production and release of infectious progeny virions after 2 hrs by virus yield-reduction assay
    		[PMID: 25791449]
    Vero EC50
    48 μg/mL
    Compound: Ribavirin
    Antiviral activity against Parainfluenza virus 3 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Parainfluenza virus 3 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 20377249]
    Vero EC50
    48 μg/mL
    Compound: Ribavirin
    Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 20377249]
    Vero EC50
    48 μg/mL
    Compound: ribavirin
    Antiviral activity against parainfluenza3 virus in Vero cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against parainfluenza3 virus in Vero cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 17298047]
    Vero EC50
    48 μg/mL
    Compound: ribavirin
    Antiviral activity against punta toro virus in Vero cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against punta toro virus in Vero cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 17298047]
    Vero EC50
    48 μg/mL
    Compound: ribavirin
    Antiviral activity against reovirus1 in Vero cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against reovirus1 in Vero cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 17298047]
    Vero EC50
    50 μM
    Compound: Ribavirin
    Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity by MTT assay
    Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity by MTT assay
    		[PMID: 20034711]
    Vero EC50
    50 μM
    Compound: Ribavirin
    Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    		[PMID: 22459876]
    Vero EC50
    50 μM
    Compound: Ribavirin
    Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis
    Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis
    		[PMID: 27979594]
    Vero EC50
    50 μM
    Compound: Ribavirin
    Antiviral activity against Human parainfluenza virus 3 infected African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    Antiviral activity against Human parainfluenza virus 3 infected African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    		[PMID: 32214762]
    Vero EC50
    50 μM
    Compound: ribavirin
    Antiviral activity against sindbis virus in Vero cells assessed as reduction of virus plaque formation after 7 days
    Antiviral activity against sindbis virus in Vero cells assessed as reduction of virus plaque formation after 7 days
    		[PMID: 17539622]
    Vero EC50
    50 μM
    Compound: ribavirin
    Antiviral activity against Punta Toro virus in african green monkey Vero cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against Punta Toro virus in african green monkey Vero cells assessed as protection against virus-induced cytopathicity
    		[PMID: 19281225]
    Vero EC50
    64 μM
    Compound: d
    concentration required to inhibit Punta Toro virus-induced cytopathicity by 50% in Vero cells
    concentration required to inhibit Punta Toro virus-induced cytopathicity by 50% in Vero cells
    		[PMID: 9748360]
    Vero EC50
    64 μM
    Compound: d
    concentration required to inhibit Sindbis virus -induced cytopathicity by 50% in Vero cells
    concentration required to inhibit Sindbis virus -induced cytopathicity by 50% in Vero cells
    		[PMID: 9748360]
    Vero EC50
    64 μM
    Compound: d
    concentration required to inhibit parainfluenza-3 virus-induced cytopathicity by 50% in Vero cells
    concentration required to inhibit parainfluenza-3 virus-induced cytopathicity by 50% in Vero cells
    		[PMID: 9748360]
    Vero EC50
    64 μM
    Compound: d
    concentration required to inhibit reovirus-1-induced cytopathicity by 50% in Vero cells
    concentration required to inhibit reovirus-1-induced cytopathicity by 50% in Vero cells
    		[PMID: 9748360]
    Vero EC50
    7 μM
    Compound: Ribavirin
    Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay
    Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay
    		[PMID: 20359898]
    Vero EC50
    7 μM
    Compound: Ribavirin
    Antiviral activity against Respiratory syncytial virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 5 days by plaque reduction assay
    Antiviral activity against Respiratory syncytial virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 5 days by plaque reduction assay
    		[PMID: 25082514]
    Vero EC50
    73.5 μM
    Compound: Ribavirin
    Antiviral activity against Parainfluenza virus 3 expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity
    Antiviral activity against Parainfluenza virus 3 expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity
    		[PMID: 26291038]
    Vero EC50
    80 μg/mL
    Compound: Ribavirin
    Antiviral activity against Reovirus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Reovirus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 20377249]
    Vero EC50
    85 μM
    Compound: Ribavirin
    Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity
    Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity
    		[PMID: 22464686]
    Vero EC50
    85 μM
    Compound: Ribavirin
    Antiviral activity against Parainfluenza virus 3 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity
    Antiviral activity against Parainfluenza virus 3 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity
    		[PMID: 23911856]
    Vero EC50
    85 μM
    Compound: Ribavirin
    Antiviral activity against Parainfluenza virus 3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Parainfluenza virus 3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 24312722]
    Vero EC50
    85 μM
    Compound: Ribavirin
    Antiviral activity against Parainfluenza virus 3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis
    Antiviral activity against Parainfluenza virus 3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis
    		[PMID: 26114811]
    Vero EC50
    9.3 μg/mL
    Compound: Ribavirin
    Antiviral activity against Tacaribe virus infected in African green monkey Vero cells assessed as reduction in virus induced cytopathic effect
    Antiviral activity against Tacaribe virus infected in African green monkey Vero cells assessed as reduction in virus induced cytopathic effect
    		[PMID: 31431358]
    Vero EC50
    95 μM
    Compound: Ribavirin
    Antiviral activity against PIV 3 infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay
    Antiviral activity against PIV 3 infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay
    		[PMID: 20034711]
    Vero EC50
    95 μM
    Compound: Ribavirin
    Antiviral activity against West Nile virus infected in African green monkey Vero cells incubated for 4 days by crystal violet staining based plaque reduction assay
    Antiviral activity against West Nile virus infected in African green monkey Vero cells incubated for 4 days by crystal violet staining based plaque reduction assay
    		[PMID: 30721061]
    Vero EC50
    95 μg/mL
    Compound: Ribavirin
    Antiviral activity against parainfluenza-3 virus infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    Antiviral activity against parainfluenza-3 virus infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    		[PMID: 20971531]
    Vero EC50
    > 100 μM
    Compound: Ribavirin
    Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay
    Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay
    		[PMID: 20359898]
    Vero EC50
    > 100 μM
    Compound: Ribavirin
    Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay
    Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay
    		[PMID: 20359898]
    Vero EC50
    > 100 μM
    Compound: Ribavirin
    Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay
    Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay
    		[PMID: 20359898]
    Vero EC50
    > 100 μM
    Compound: Ribavirin
    Antiviral activity against Vaccinia virus Elstree-Lister infected in african green monkey Vero cells after 3 days by plaque reduction assay
    Antiviral activity against Vaccinia virus Elstree-Lister infected in african green monkey Vero cells after 3 days by plaque reduction assay
    		[PMID: 20359898]
    Vero EC50
    > 100 μM
    Compound: Ribavirin
    Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay
    Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay
    		[PMID: 25082514]
    Vero EC50
    > 100 μM
    Compound: Ribavirin
    Antiviral activity against HSV1 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay
    Antiviral activity against HSV1 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay
    		[PMID: 25082514]
    Vero EC50
    > 100 μM
    Compound: Ribavirin
    Antiviral activity against Poliovirus type 1 Sabin strain infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay
    Antiviral activity against Poliovirus type 1 Sabin strain infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay
    		[PMID: 25082514]
    Vero EC50
    > 100 μM
    Compound: Ribavirin
    Antiviral activity against Vaccinia Virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay
    Antiviral activity against Vaccinia Virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay
    		[PMID: 25082514]
    Vero EC50
    > 100 μM
    Compound: Ribavirin
    Antiviral activity against Vesicular stomatitis virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay
    Antiviral activity against Vesicular stomatitis virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay
    		[PMID: 25082514]
    Vero EC50
    > 1600 μM
    Compound: Ribavirin
    Effective concentration required to inhibit respiratory synaptial (RSV) virus-induced cytopathicity by 50% in Vero cell lines
    Effective concentration required to inhibit respiratory synaptial (RSV) virus-induced cytopathicity by 50% in Vero cell lines
    		[PMID: 11495586]
    Vero EC50
    > 1600 μM
    Compound: d
    concentration required to inhibit Coxsackie virus B4-induced cytopathicity by 50% in Vero cells
    concentration required to inhibit Coxsackie virus B4-induced cytopathicity by 50% in Vero cells
    		[PMID: 9748360]
    Vero EC50
    > 200 μg/mL
    Compound: ribavirin
    Antiviral activity against Coxsackie virus B4 in Vero cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Coxsackie virus B4 in Vero cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17948980]
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Human coxsackievirus B4 infected Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    Antiviral activity against Human coxsackievirus B4 infected Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    		10.1007/s00044-009-9248-y
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Mammalian orthoreovirus 1 virus infected Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    Antiviral activity against Mammalian orthoreovirus 1 virus infected Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    		10.1007/s00044-009-9248-y
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Sindbis virus infected Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    Antiviral activity against Sindbis virus infected Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    		10.1007/s00044-009-9248-y
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Human coxsackievirus B4 infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 2 days by MTT assay
    Antiviral activity against Human coxsackievirus B4 infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 2 days by MTT assay
    		[PMID: 20034711]
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Coxsackievirus B4 infected in Vero cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against Coxsackievirus B4 infected in Vero cells assessed as protection against virus-induced cytopathicity
    		[PMID: 21565516]
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Sindbis virus infected in Vero cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against Sindbis virus infected in Vero cells assessed as protection against virus-induced cytopathicity
    		[PMID: 21565516]
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Coxsackie virus B4 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    Antiviral activity against Coxsackie virus B4 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    		[PMID: 22459876]
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    		[PMID: 22459876]
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Coxsackie virus B4 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity
    Antiviral activity against Coxsackie virus B4 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity
    		[PMID: 22464686]
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity
    Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity
    		[PMID: 22464686]
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity
    Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity
    		[PMID: 22464686]
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity
    Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity
    		[PMID: 23911856]
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity
    Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity
    		[PMID: 23911856]
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity
    Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity
    		[PMID: 23911856]
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Coxsackievirus B4 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Coxsackievirus B4 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 24312722]
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Reovirus 1 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Reovirus 1 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 24312722]
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 24312722]
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Coxsackievirus B4 infected in African green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Coxsackievirus B4 infected in African green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 26001344]
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Reovirus-1 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis
    Antiviral activity against Reovirus-1 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis
    		[PMID: 26114811]
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis
    Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis
    		[PMID: 26114811]
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Coxsackievirus B4 expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity
    Antiviral activity against Coxsackievirus B4 expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity
    		[PMID: 26291038]
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Reovirus 1 expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity
    Antiviral activity against Reovirus 1 expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity
    		[PMID: 26291038]
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Sindbis virus expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity
    Antiviral activity against Sindbis virus expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity
    		[PMID: 26291038]
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Coxsackie virus B4 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis
    Antiviral activity against Coxsackie virus B4 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis
    		[PMID: 27979594]
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Reovirus-1 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis
    Antiviral activity against Reovirus-1 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis
    		[PMID: 27979594]
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis
    Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis
    		[PMID: 27979594]
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Coxsackie B4 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis
    Antiviral activity against Coxsackie B4 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis
    		[PMID: 28477572]
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Reovirus 1 infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis
    Antiviral activity against Reovirus 1 infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis
    		[PMID: 28477572]
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis
    Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis
    		[PMID: 28477572]
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Yellow fever virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis
    Antiviral activity against Yellow fever virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis
    		[PMID: 28477572]
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Human coxsackievirus B4 infected African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    Antiviral activity against Human coxsackievirus B4 infected African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    		[PMID: 32214762]
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Mammalian orthoreovirus 1 infected African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    Antiviral activity against Mammalian orthoreovirus 1 infected African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    		[PMID: 32214762]
    Vero EC50
    > 250 μM
    Compound: Ribavirin
    Antiviral activity against Sendai virus infected African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    Antiviral activity against Sendai virus infected African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    		[PMID: 32214762]
    Vero EC50
    > 250 μM
    Compound: ribavirin
    Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 23811093]
    Vero EC50
    > 250 μM
    Compound: ribavirin
    Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 23811093]
    Vero EC50
    > 250 μM
    Compound: ribavirin
    Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 23811093]
    Vero EC50
    > 250 μg/mL
    Compound: Ribavirin
    Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    		[PMID: 18851889]
    Vero EC50
    > 250 μg/mL
    Compound: Ribavirin
    Antiviral activity against Reovirus 1 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    Antiviral activity against Reovirus 1 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    		[PMID: 18851889]
    Vero EC50
    > 250 μg/mL
    Compound: Ribavirin
    Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    		[PMID: 18851889]
    Vero EC50
    > 250 μg/mL
    Compound: Ribavirin
    Antiviral activity against Coxsackie virus B4 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days
    Antiviral activity against Coxsackie virus B4 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days
    		[PMID: 20724039]
    Vero EC50
    > 250 μg/mL
    Compound: Ribavirin
    Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days
    Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days
    		[PMID: 20724039]
    Vero EC50
    > 250 μg/mL
    Compound: Ribavirin
    Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days
    Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days
    		[PMID: 20724039]
    Vero EC50
    > 250 μg/mL
    Compound: Ribavirin
    Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    		[PMID: 20971531]
    Vero EC50
    > 250 μg/mL
    Compound: ribavirin
    Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days
    Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days
    		[PMID: 19419804]
    Vero EC50
    > 250 μg/mL
    Compound: ribavirin
    Antiviral activity against Reovirus 1 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days
    Antiviral activity against Reovirus 1 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days
    		[PMID: 19419804]
    Vero EC50
    > 250 μg/mL
    Compound: ribavirin
    Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days postinfection
    Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days postinfection
    		[PMID: 19419804]
    Vero EC50
    > 400 μg/mL
    Compound: Ribavirin
    Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 20377249]
    Vero EC50
    > 50 μM
    Compound: ribavirin
    Antiviral activity against Parainfluenza virus type 3 in african green monkey Vero cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against Parainfluenza virus type 3 in african green monkey Vero cells assessed as protection against virus-induced cytopathicity
    		[PMID: 19281225]
    Vero EC50
    > 500 μM
    Compound: Ribavirin
    Antiviral activity against Sindbis virus in Vero cells
    Antiviral activity against Sindbis virus in Vero cells
    		[PMID: 17181162]
    Vero EC50
    >= 174 μM
    Compound: Ribavirin
    Antiviral activity against Mammalian orthoreovirus 1 infected in Vero cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against Mammalian orthoreovirus 1 infected in Vero cells assessed as protection against virus-induced cytopathicity
    		[PMID: 21565516]
    Vero EC50
    >= 250 μM
    Compound: ribavirin
    Antiviral activity against Coxsackievirus B4 in african green monkey Vero cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against Coxsackievirus B4 in african green monkey Vero cells assessed as protection against virus-induced cytopathicity
    		[PMID: 19281225]
    Vero ED50
    0.00016 M
    Compound: 3
    In vitro antiviral activity against parainfluenza type 3 virus in Vero cells.
    In vitro antiviral activity against parainfluenza type 3 virus in Vero cells.
    		[PMID: 3950908]
    Vero ED50
    0.00016 M
    Compound: Ribavirin
    In vitro antiviral activity against Parainfluenza type 3 was evaluated.
    In vitro antiviral activity against Parainfluenza type 3 was evaluated.
    		[PMID: 4020823]
    Vero ED50
    0.00019 M
    Compound: 3
    In vitro antiviral activity against herpes simplex virus type 2 (HSV-2) in Vero cells.
    In vitro antiviral activity against herpes simplex virus type 2 (HSV-2) in Vero cells.
    		[PMID: 3950908]
    Vero ED50
    0.00019 M
    Compound: Ribavirin
    In vitro antiviral activity against herpes simplex virus type 2 virus was evaluated.
    In vitro antiviral activity against herpes simplex virus type 2 virus was evaluated.
    		[PMID: 4020823]
    Vero ED50
    9.9 x 10-5 M
    Compound: 3
    In vitro antiviral activity against measles virus in Vero cells
    In vitro antiviral activity against measles virus in Vero cells
    		[PMID: 3950908]
    Vero ED50
    9.0 x 10-5 M
    Compound: 3
    In vitro antiviral activity against vaccinia virus in Vero cells.
    In vitro antiviral activity against vaccinia virus in Vero cells.
    		[PMID: 3950908]
    Vero ED50
    3.3 x 10-5 M
    Compound: Ribavirin
    In vitro antiviral activity against measles virus was evaluated.
    In vitro antiviral activity against measles virus was evaluated.
    		[PMID: 4020823]
    Vero ED50
    8.5 x 10-5 M
    Compound: Ribavirin
    In vitro antiviral activity against vaccinia virus was evaluated.
    In vitro antiviral activity against vaccinia virus was evaluated.
    		[PMID: 4020823]
    Vero IC50
    0.04 μM
    Compound: Ribavirin
    Antiviral activity against Hepatitis C virus infected in African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect
    Antiviral activity against Hepatitis C virus infected in African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect
    		[PMID: 27262598]
    Vero IC50
    0.7 μg/mL
    Compound: ribavirin
    Antiviral activity against Reovirus1 in vero cells
    Antiviral activity against Reovirus1 in vero cells
    		[PMID: 17518459]
    Vero IC50
    0.9 mM
    Compound: RBV
    Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 48 hrs by Reed-Muench analysis
    Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 48 hrs by Reed-Muench analysis
    		[PMID: 24070022]
    Vero IC50
    10 μM
    Compound: Ribavirin
    Antiviral activity against Herpes simplex virus type 1 L2 infected in African green monkey Vero E6 cells assessed as reduction of virus-induced cytopathic effect
    Antiviral activity against Herpes simplex virus type 1 L2 infected in African green monkey Vero E6 cells assessed as reduction of virus-induced cytopathic effect
    		[PMID: 27262598]
    Vero IC50
    1197.58 μM
    Compound: RBV
    Antiviral activity against coxsackievirus B3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenic effect dosed 1 hr after viral adsorption
    Antiviral activity against coxsackievirus B3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenic effect dosed 1 hr after viral adsorption
    		[PMID: 26132528]
    Vero IC50
    1200 μM
    Compound: ribavirin
    Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 26110443]
    Vero IC50
    13.3 μM
    Compound: Ribavirin
    Antiviral activity against human EV71 infected in African green monkey Vero cells assessed as reduction in cytopathic effect by CCK-8 assay
    Antiviral activity against human EV71 infected in African green monkey Vero cells assessed as reduction in cytopathic effect by CCK-8 assay
    		[PMID: 32937282]
    Vero IC50
    13.3 μM
    Compound: Ribavirin
    Antiviral activity against human EV71 infected in African green monkey Vero cells assessed as reduction in cytopathic effect incubated for 72 to 96 hrs by CCK-8 assay
    Antiviral activity against human EV71 infected in African green monkey Vero cells assessed as reduction in cytopathic effect incubated for 72 to 96 hrs by CCK-8 assay
    		[PMID: 32937282]
    Vero IC50
    1576.11 μM
    Compound: Ribavirin
    Antiviral activity against Coxsackie B3 virus Nancy in african green monkey Vero cells assessed as inhibition virus-induced cytopathic effect after 48 hrs
    Antiviral activity against Coxsackie B3 virus Nancy in african green monkey Vero cells assessed as inhibition virus-induced cytopathic effect after 48 hrs
    		[PMID: 23999140]
    Vero IC50
    160 μg/mL
    Compound: ribavirin
    Tested for inhibitory effect on RNA virus Reo-1 in Vero cell line
    Tested for inhibitory effect on RNA virus Reo-1 in Vero cell line
    		[PMID: 8246242]
    Vero IC50
    1690 μM
    Compound: RBV
    Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as inhibition of viral growth after 24 hrs by Reed-Muench method
    Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as inhibition of viral growth after 24 hrs by Reed-Muench method
    		[PMID: 21441033]
    Vero IC50
    1708 μM
    Compound: RBV
    Antiviral activity against Coxsackievirus B6 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect
    Antiviral activity against Coxsackievirus B6 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect
    		[PMID: 25699158]
    Vero IC50
    1951 μM
    Compound: RBV
    Antiviral activity against Coxsackievirus B1 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect
    Antiviral activity against Coxsackievirus B1 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect
    		[PMID: 25699158]
    Vero IC50
    2088 μM
    Compound: RBV
    Antiviral activity against Coxsackievirus B6 Schmitt infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against Coxsackievirus B6 Schmitt infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 27750147]
    Vero IC50
    2088 μM
    Compound: Ribavirin
    Antiviral activity against Coxsackievirus B6 (strain Schmitt) infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis
    Antiviral activity against Coxsackievirus B6 (strain Schmitt) infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis
    		[PMID: 28109785]
    Vero IC50
    20 μg/mL
    Compound: ribavirin
    Antiviral activity against Punta Toro virus in vero cells
    Antiviral activity against Punta Toro virus in vero cells
    		[PMID: 17518459]
    Vero IC50
    20 μg/mL
    Compound: ribavirin
    Tested for inhibitory effect on RNA virus Coxsackie B4 in Vero cell line
    Tested for inhibitory effect on RNA virus Coxsackie B4 in Vero cell line
    		[PMID: 8246242]
    Vero IC50
    20 μg/mL
    Compound: ribavirin
    Tested for inhibitory effect on RNA virus PV-3 in Vero cell line
    Tested for inhibitory effect on RNA virus PV-3 in Vero cell line
    		[PMID: 8246242]
    Vero IC50
    2101 μM
    Compound: RBV
    Antiviral activity against Coxsackievirus B2 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect
    Antiviral activity against Coxsackievirus B2 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect
    		[PMID: 25699158]
    Vero IC50
    2119 μM
    Compound: RBV
    Antiviral activity against Enterovirus 71 infected in african green monkey vero cells assessed as inhibition of viral replication by Reed-Muench analysis
    Antiviral activity against Enterovirus 71 infected in african green monkey vero cells assessed as inhibition of viral replication by Reed-Muench analysis
    		[PMID: 21880491]
    Vero IC50
    222.2 μM
    Compound: RBV
    Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 23734721]
    Vero IC50
    2340 μM
    Compound: RBV
    Antiviral activity against Human enterovirus 71 infected in african green monkey Vero cells assessed as inhibition of viral growth after 24 hrs by Reed-Muench method
    Antiviral activity against Human enterovirus 71 infected in african green monkey Vero cells assessed as inhibition of viral growth after 24 hrs by Reed-Muench method
    		[PMID: 21441033]
    Vero IC50
    2375 μM
    Compound: RBV
    Antiviral activity against Coxsackievirus B1 Conn 5 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against Coxsackievirus B1 Conn 5 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 27750147]
    Vero IC50
    2375 μM
    Compound: Ribavirin
    Antiviral activity against Coxsackievirus B1 Conn-5 infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis
    Antiviral activity against Coxsackievirus B1 Conn-5 infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis
    		[PMID: 28109785]
    Vero IC50
    253.1 μM
    Compound: Ribavirin
    Antiviral activity against Enterovirus 71 BrCr infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
    Antiviral activity against Enterovirus 71 BrCr infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
    		[PMID: 24679044]
    Vero IC50
    26.7 μM
    Compound: ribavirin
    Antiviral activity against Tacaribe virus infected in African green monkey Vero 76 cells after 3 days by neutral red dye-based plaque reduction assay
    Antiviral activity against Tacaribe virus infected in African green monkey Vero 76 cells after 3 days by neutral red dye-based plaque reduction assay
    		[PMID: 26260336]
    Vero IC50
    286.8 μM
    Compound: Ribavirin
    Inhibitory concentration against parainfluenza-3 virus in vero cells
    Inhibitory concentration against parainfluenza-3 virus in vero cells
    		[PMID: 7658442]
    Vero IC50
    292 μM
    Compound: Ribavirin
    Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 27792321]
    Vero IC50
    3316 μM
    Compound: RBV
    Antiviral activity against Coxsackievirus B5 Faulkner infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against Coxsackievirus B5 Faulkner infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 27750147]
    Vero IC50
    3316 μM
    Compound: Ribavirin
    Antiviral activity against Coxsackievirus B5 Faulkner infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis
    Antiviral activity against Coxsackievirus B5 Faulkner infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis
    		[PMID: 28109785]
    Vero IC50
    37.3 μM
    Compound: ribavirin
    Antiviral activity against Rift Valley fever virus infected in African green monkey Vero 76 cells after 3 days by neutral red dye-based plaque reduction assay
    Antiviral activity against Rift Valley fever virus infected in African green monkey Vero 76 cells after 3 days by neutral red dye-based plaque reduction assay
    		[PMID: 26260336]
    Vero IC50
    379.1 μM
    Compound: RBV
    Antiviral activity against Coxsackievirus B3 Nancy infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against Coxsackievirus B3 Nancy infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 27750147]
    Vero IC50
    379.12 μM
    Compound: Ribavirin
    Antiviral activity against Coxsackievirus B3 (strain Nancy) infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis
    Antiviral activity against Coxsackievirus B3 (strain Nancy) infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis
    		[PMID: 28109785]
    Vero IC50
    38.49 μg/mL
    Compound: RBV
    Antiviral activity against Herpes simplex virus 1 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenic effect by microscopic analysis
    Antiviral activity against Herpes simplex virus 1 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenic effect by microscopic analysis
    		[PMID: 30578076]
    Vero IC50
    4090 μM
    Compound: RBV
    Antiviral activity against Coxsackievirus A16 infected in african green monkey Vero cells assessed as inhibition of viral growth after 24 hrs by Reed-Muench method
    Antiviral activity against Coxsackievirus A16 infected in african green monkey Vero cells assessed as inhibition of viral growth after 24 hrs by Reed-Muench method
    		[PMID: 21441033]
    Vero IC50
    447.8 μg/mL
    Compound: RVB
    Antiviral activity against Coxsackie virus B3 growth by 50% in Vero cells
    Antiviral activity against Coxsackie virus B3 growth by 50% in Vero cells
    		[PMID: 15603937]
    Vero IC50
    5.2 μg/mL
    Compound: ribavirin
    Tested for inhibitory effect on RNA virus JV in Vero cell line
    Tested for inhibitory effect on RNA virus JV in Vero cell line
    		[PMID: 8246242]
    Vero IC50
    6.4 μg/mL
    Compound: ribavirin
    Tested for inhibitory effect on RNA virus TV in Vero cell line
    Tested for inhibitory effect on RNA virus TV in Vero cell line
    		[PMID: 8246242]
    Vero IC50
    694.6 μM
    Compound: RBV
    Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect
    Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect
    		[PMID: 25699158]
    Vero IC50
    82 μM
    Compound: ribavirin
    Antiviral activity against SARS-CoV Frankfurt1 in Vero E6 cells by plaque reduction assay
    Antiviral activity against SARS-CoV Frankfurt1 in Vero E6 cells by plaque reduction assay
    		[PMID: 17336519]
    Vero IC50
    884.9 μM
    Compound: Ribavirin
    Antiviral activity against CVB3 infected in African green monkey Vero cells by MTT assay
    Antiviral activity against CVB3 infected in African green monkey Vero cells by MTT assay
    		[PMID: 31735601]
    Vero IC50
    909.96 μM
    Compound: Ribavirin
    Antiviral activity against Coxsackie B6 virus Schmitt in african green monkey Vero cells assessed as inhibition virus-induced cytopathic effect after 48 hrs
    Antiviral activity against Coxsackie B6 virus Schmitt in african green monkey Vero cells assessed as inhibition virus-induced cytopathic effect after 48 hrs
    		[PMID: 23999140]
    Vero IC50
    910 μM
    Compound: RBV
    Antiviral activity against Coxsackievirus B6 infected in african green monkey Vero cells assessed as inhibition of viral growth after 24 hrs by Reed-Muench method
    Antiviral activity against Coxsackievirus B6 infected in african green monkey Vero cells assessed as inhibition of viral growth after 24 hrs by Reed-Muench method
    		[PMID: 21441033]
    Vero IC50
    910 μM
    Compound: RBV
    Antiviral activity against Coxsackievirus B3 infected in african green monkey vero cells assessed as inhibition of viral replication by Reed-Muench analysis
    Antiviral activity against Coxsackievirus B3 infected in african green monkey vero cells assessed as inhibition of viral replication by Reed-Muench analysis
    		[PMID: 21880491]
    Vero IC50
    910.8 μM
    Compound: RBV
    Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect
    Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect
    		[PMID: 25699158]
    Vero IC50
    9622 μM
    Compound: Ribavirin
    Antiviral activity against Coxsackievirus A16 shzh05-1 infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis
    Antiviral activity against Coxsackievirus A16 shzh05-1 infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis
    		[PMID: 28109785]
    Vero IC50
    > 400 μM
    Compound: Ribavirin
    Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay
    Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay
    		[PMID: 21115214]
    Vero IC50
    > 400 μg/mL
    Compound: ribavirin
    Tested for inhibitory effect on RNA virus cell morphology in Vero cell line
    Tested for inhibitory effect on RNA virus cell morphology in Vero cell line
    		[PMID: 8246242]
    Vero IC50
    > 40948 μM
    Compound: Ribavirin
    Antiviral activity against Coxsackievirus B2 (strain Ohio-1) infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis
    Antiviral activity against Coxsackievirus B2 (strain Ohio-1) infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis
    		[PMID: 28109785]
    Vero IC50
    > 40948 μM
    Compound: Ribavirin
    Antiviral activity against Coxsackievirus B4 J.V.B infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis
    Antiviral activity against Coxsackievirus B4 J.V.B infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis
    		[PMID: 28109785]
    Vero IC50
    > 500 μM
    Compound: RBV
    Antiviral activity against Coxsackievirus B2 Ohio-1 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against Coxsackievirus B2 Ohio-1 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 27750147]
    Vero IC50
    > 500 μM
    Compound: RBV
    Antiviral activity against Coxsackievirus B4 JVB infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against Coxsackievirus B4 JVB infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 27750147]
    Vero IC50
    >= 235 μg/mL
    Compound: ribavirin
    Tested for inhibitory effect on RNA virus SFV in Vero cell line
    Tested for inhibitory effect on RNA virus SFV in Vero cell line
    		[PMID: 8246242]
    Vero IC50
    >= 250 μg/mL
    Compound: ribavirin
    Tested for inhibitory effect on RNA virus SV in Vero cell line
    Tested for inhibitory effect on RNA virus SV in Vero cell line
    		[PMID: 8246242]
    Vero 76 CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against mock-infected african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay
    Cytotoxicity against mock-infected african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay
    		[PMID: 25082514]
    Vero 76 CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method
    Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method
    		[PMID: 25913116]
    Vero 76 CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method
    Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method
    		[PMID: 26443549]
    Vero 76 CC50
    > 100 μM
    Compound: Ribavirin
    Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay
    Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay
    		[PMID: 29028528]
    Vero 76 CC50
    > 1000 μM
    Compound: ribavirin
    Cytotoxicity against African green monkey Vero 76 cells
    Cytotoxicity against African green monkey Vero 76 cells
    		[PMID: 26260336]
    Vero 76 CC50
    > 1000 μM
    Compound: ribavirin
    Cytotoxicity against African green monkey Vero 76 cells relative to control
    Cytotoxicity against African green monkey Vero 76 cells relative to control
    		[PMID: 26260336]
    Vero 76 CC50
    > 4094 μM
    Compound: Ribavirin
    Cytotoxicity against African green monkey Vero 76 cells infected with Rift Valley fever virus MP-12 by neutral red dye based analysis
    Cytotoxicity against African green monkey Vero 76 cells infected with Rift Valley fever virus MP-12 by neutral red dye based analysis
    		[PMID: 36898483]
    Vero 76 CC50
    > 4094 μM
    Compound: Ribavirin
    Cytotoxicity against African green monkey Vero 76 cells infected with Rift Valley fever virus MP-12 by visual analysis
    Cytotoxicity against African green monkey Vero 76 cells infected with Rift Valley fever virus MP-12 by visual analysis
    		[PMID: 36898483]
    Vero 76 EC50
    1.2 μM
    Compound: Ribavirin
    Antiviral activity against Human respiratory syncytial virus A2 ATCC VR 1540 infected in African green monkey Vero 76 cells assessed as protection against virus-induced cytopathic effect after 5 days by crystal violet staining-based plaque reduction assay
    Antiviral activity against Human respiratory syncytial virus A2 ATCC VR 1540 infected in African green monkey Vero 76 cells assessed as protection against virus-induced cytopathic effect after 5 days by crystal violet staining-based plaque reduction assay
    		[PMID: 29028528]
    Vero 76 EC50
    7 μM
    Compound: Ribavirin
    Antiviral activity against Respiratory syncytial virus A2 infected in Vero-76 cells after 5 days by plaque reduction assay
    Antiviral activity against Respiratory syncytial virus A2 infected in Vero-76 cells after 5 days by plaque reduction assay
    		[PMID: 19482481]
    Vero 76 EC50
    7 μM
    Compound: Ribavirin
    Antiviral activity against human RSV infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by plaque reduction assay
    Antiviral activity against human RSV infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by plaque reduction assay
    		[PMID: 26443549]
    Vero 76 EC50
    > 100 μM
    Compound: Ribavirin
    Antiviral activity against Coxsackie virus type B2 virus infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay
    Antiviral activity against Coxsackie virus type B2 virus infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay
    		[PMID: 19482481]
    Vero 76 EC50
    > 100 μM
    Compound: Ribavirin
    Antiviral activity against HSV1 infected in Vero-76 cells after 3 days by plaque reduction assay
    Antiviral activity against HSV1 infected in Vero-76 cells after 3 days by plaque reduction assay
    		[PMID: 19482481]
    Vero 76 EC50
    > 100 μM
    Compound: Ribavirin
    Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay
    Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay
    		[PMID: 26443549]
    Vero 76 EC50
    > 100 μM
    Compound: Ribavirin
    Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay
    Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay
    		[PMID: 26443549]
    Vero C1008 CC50
    > 100 μM
    Compound: RBV
    Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability
    Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability
    		[PMID: 31902708]
    Vero C1008 CC50
    > 160 μM
    Compound: R
    Cytotoxicity against African green monkey Vero E6 cells infected with ZIKV COL345Si measured after 6 days by MTT assay
    Cytotoxicity against African green monkey Vero E6 cells infected with ZIKV COL345Si measured after 6 days by MTT assay
    		[PMID: 35969814]
    Vero C1008 CC50
    > 160 μM
    Compound: R
    Cytotoxicity against African green monkey Vero E6 cells infected with Zika 459148 measured after 72 hrs by MTT assay
    Cytotoxicity against African green monkey Vero E6 cells infected with Zika 459148 measured after 72 hrs by MTT assay
    		[PMID: 35969814]
    Vero C1008 CC50
    > 200 μM
    Compound: Ribavirin
    Cytotoxicity in African green monkey Vero E6 cells assessed as reduction in cell viability
    Cytotoxicity in African green monkey Vero E6 cells assessed as reduction in cell viability
    		[PMID: 32378892]
    Vero C1008 CC50
    > 400 μM
    Compound: 5
    Cytotoxicity against African green monkey Vero E6 cells by the CCK8 assay
    Cytotoxicity against African green monkey Vero E6 cells by the CCK8 assay
    		[PMID: 32845145]
    Vero C1008 CC50
    > 400 μM
    Compound: 53
    Cytotoxicity against African green monkey Vero E6 cells by CCK-8 assay
    Cytotoxicity against African green monkey Vero E6 cells by CCK-8 assay
    		[PMID: 33486200]
    Vero C1008 CC50
    > 400 μM
    Compound: Ribavirin
    Cytotoxicity against African green monkey Vero E6 cells by CCK8 assay
    Cytotoxicity against African green monkey Vero E6 cells by CCK8 assay
    		[PMID: 32511912]
    Vero C1008 CC50
    > 400 μM
    Compound: Ribavirin
    Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 48 hrs by CCK-8 assay
    Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 48 hrs by CCK-8 assay
    		[PMID: 32563814]
    Vero C1008 CC50
    > 400 μM
    Compound: Ribavirin
    Cytotoxicity against African green monkey Vero E6 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 assay
    Cytotoxicity against African green monkey Vero E6 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 assay
    		[PMID: 32992245]
    Vero C1008 CC50
    > 400 μM
    Compound: Ribavirin
    Cytotoxicity against African green monkey Vero E6 cells infected with SARS-COV-2 by celltiter-glo luminescent cell viability assay
    Cytotoxicity against African green monkey Vero E6 cells infected with SARS-COV-2 by celltiter-glo luminescent cell viability assay
    		[PMID: 34273661]
    Vero C1008 EC50
    109.5 μM
    Compound: 53
    Antiviral activity against SARS-CoV infected in Vero E6 cells assessed as reduction in viral replication measured after 48 hrs by qRT-PCR assay
    Antiviral activity against SARS-CoV infected in Vero E6 cells assessed as reduction in viral replication measured after 48 hrs by qRT-PCR assay
    		[PMID: 33486200]
    Vero C1008 EC50
    33 μM
    Compound: RBV
    Antiviral activity against Zika virus infected in African green monkey Vero E6 cells assessed as reduction in viral induced cytopathic effect
    Antiviral activity against Zika virus infected in African green monkey Vero E6 cells assessed as reduction in viral induced cytopathic effect
    		[PMID: 31902708]
    Vero C1008 EC50
    33 μM
    Compound: Ribavirin
    Antiviral activity against Zika virus infected in Vero E6 cells assessed as reduction in virus-induced cytopathic effect incubated for 96 hrs by CCK8 assay
    Antiviral activity against Zika virus infected in Vero E6 cells assessed as reduction in virus-induced cytopathic effect incubated for 96 hrs by CCK8 assay
    		[PMID: 32378892]
    Vero C1008 IC50
    1024 μM
    Compound: Ribavirin
    Antiviral activity against HSV-1 L2/Rp-ACV/2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect
    Antiviral activity against HSV-1 L2/Rp-ACV/2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect
    		[PMID: 28408228]
    Vero C1008 IC50
    1024 μM
    Compound: Ribavirin
    Antiviral activity against acyclovir and cidofovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect
    Antiviral activity against acyclovir and cidofovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect
    		[PMID: 28408228]
    Vero C1008 IC50
    1024 μM
    Compound: Ribavirin
    Antiviral activity against acyclovir and foscarnet-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect
    Antiviral activity against acyclovir and foscarnet-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect
    		[PMID: 28408228]
    Vero C1008 IC50
    1024 μM
    Compound: Ribavirin
    Antiviral activity against acyclovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect
    Antiviral activity against acyclovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect
    		[PMID: 28408228]
    Vero C1008 IC50
    1024 μM
    Compound: Ribavirin
    Antiviral activity against foscarnet-resistant HSV-1 F+ infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect
    Antiviral activity against foscarnet-resistant HSV-1 F+ infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect
    		[PMID: 28408228]
    Vero C1008 IC50
    125 μg/mL
    Compound: Ribavirin
    Antiviral activity against Human herpesvirus 1 L2 infected in African green monkey Vero E6 cells assessed as protection against virus-induced cytopathic effect
    Antiviral activity against Human herpesvirus 1 L2 infected in African green monkey Vero E6 cells assessed as protection against virus-induced cytopathic effect
    		[PMID: 29173944]
    Vero C1008 IC50
    512 μM
    Compound: Ribavirin
    Antiviral activity against HSV1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect
    Antiviral activity against HSV1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect
    		[PMID: 28408228]
    WIL2-NS IC50
    > 100 μM
    Compound: Ribavirin
    Compound was tested for its effect on the proliferation of WIL-2-NS cell line.
    Compound was tested for its effect on the proliferation of WIL-2-NS cell line.
    		10.1016/0960-894X(96)00216-8
    In Vitro

    Treatment of LPS-stimulated microglia with 5, 10 and 20 μM Ribavirin (ICN-1229) induces reduction of NO2 levels for 43% (p<0.05), 53% (p<0.05) and 59% (p<0.05), respectively. Ribavirin (ICN-1229) (10 mM) insignificantly decreases the cell surface area in non-stimulated culture, but significantly reduces cell surface area (by 32%, p<0.05) in LPS-stimulated microglia[3]. Ribavirin (ICN-1229) is active against DENV, with an EC50 of 3 μM in A549 cells, and combination of CM-10-18 with Ribavirin (ICN-1229) demonstrates a clear enhancement in the reduction of virus replication[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Ribavirin Related Antibodies
    In Vivo

    ALT, AST activities and bilirubin levels are significantly loared by administration of JAT in combination with interferon and Ribavirin (ICN-1229) (p<0.01). JAT, interferon or ribavirin alone with CCl4, livers appear to exhibit some liver protection against CCl4 as evident by the presence of normal hepatic cords, absence of necrosis and lesser fatty infiltration. Groups treated with JAT, Peg-interferon and Ribavirin (ICN-1229) separately or in combination shows reduction in the expression of TGF- β and Bax. In the group treated by triple combination of interferon, Ribavirin (ICN-1229), and JAT, the expression level of p53 is markedly reduced[1].
    Ribavirin (ICN-1229) capsules (400 mg of ribavirin)-treated Wistar rats show a significant decrease in activin-A and significant increase in follistatin at the serum and liver levels. Ribavirin (ICN-1229) has strong antiviral activity only when ribavirin is combined with either IFN-α or Peg-IFN-α[2].
    Ribavirin (40 mg/kg, p.o.) significantly improves the antiviral efficacy of CM-10-18 in mice. Ribavirin (ICN-1229) inhibits DENV virus infection in cultured cells, but it is ineffective in reducing viremia in monotherapy[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    Molecular Weight

    244.20

    Formula

    C8H12N4O5
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O[C@H]1[C@@H](O)[C@H](N2N=C(C(N)=O)N=C2)O[C@@H]1CO
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    Solvent & Solubility
    In Vitro: 

    H2O : 100 mg/mL (409.50 mM; Need ultrasonic)

    DMSO : 100 mg/mL (409.50 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 4.0950 mL 20.4750 mL 40.9500 mL
    5 mM 0.8190 mL 4.0950 mL 8.1900 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (10.24 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (10.24 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 110 mg/mL (450.45 mM); Clear solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    Purity & Documentation

    Purity: 99.96%

    SDS (418 KB)

    COA (254 KB) HNMR (131 KB) RP-HPLC (87 KB) MS (69 KB)

    Handling Instructions (2659 KB)
    References
    Cell Assay
    [3]

    The effect of Ribavirin (ICN-1229) on microglial cell viability is evaluated by the sulforhodamine B (SRB) chemosensitivity assay. Briefly, LPS-stimulated microglial cells are incubated for 48 h in the presence or absence of Ribavirin (ICN-1229). Afterward, the cells are fixed in 10% (w/v) trichloroacetic acid for 1 h at 4°C, rinsed in tap water and stained with 0.4% (w/v) SRB in 1% acetic acid (100 μL/well) for 30 min at room temperature (RT). The cells are then rinsed three times in 1% acetic acid to remove the unbound stain. The protein bound stain is extracted with 200 μL 10 mM Tris base (pH 10.5) per well. The optical density is read at 540 nm, with correction at 670 nm. The results are presented as percentage of the control (non-stimulated/untreated microglial cells), that is arbitrarily set to 100%.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [4]

    The in vivo efficacy experiments are largely performed, using a dengue viremia model in AG129 mouse (defective of both type I and type II interferon receptors). Each experiment contains 6 mice (7 to 8 week-old) per dosing group. The mice are challenged with DENV (serotype 2, TSV01 strain), at 5×106 pfu/mouse via i.p. injection. Imino sugars are dosed twice daily at 12 hr intervals, and ribavirin is dosed once daily, for 3 consecutive days post-infection. Blood samples are drawn 3 days post-infection for determination of plasma virus titer by plaque assay.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    H2O / DMSO 1 mM 4.0950 mL 20.4750 mL 40.9500 mL 102.3751 mL
    5 mM 0.8190 mL 4.0950 mL 8.1900 mL 20.4750 mL
    10 mM 0.4095 mL 2.0475 mL 4.0950 mL 10.2375 mL
    15 mM 0.2730 mL 1.3650 mL 2.7300 mL 6.8250 mL
    20 mM 0.2048 mL 1.0238 mL 2.0475 mL 5.1188 mL
    25 mM 0.1638 mL 0.8190 mL 1.6380 mL 4.0950 mL
    30 mM 0.1365 mL 0.6825 mL 1.3650 mL 3.4125 mL
    40 mM 0.1024 mL 0.5119 mL 1.0238 mL 2.5594 mL
    50 mM 0.0819 mL 0.4095 mL 0.8190 mL 2.0475 mL
    60 mM 0.0683 mL 0.3413 mL 0.6825 mL 1.7063 mL
    80 mM 0.0512 mL 0.2559 mL 0.5119 mL 1.2797 mL
    100 mM 0.0410 mL 0.2048 mL 0.4095 mL 1.0238 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Ribavirin Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Ribavirin36791-04-5RibasphereHCVRSVOrthopoxvirusAntibioticHepatitis C virusRespiratory syncytial virusInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Ribavirin
    Cat. No.:
    HY-B0434
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (418 KB) Français - FR (418 KB) Deutsch - DE (418 KB) Norwegian - NO (418 KB) Español - ES (418 KB) Swedish - SV (418 KB) Italian - IT (418 KB) Korean - KR (418 KB) Portuguese - PT (418 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.